

=> fil reg; d ide l20 1-2; d ide l21 1-2
FILE 'REGISTRY' ENTERED AT 15:59:28 ON 13 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAY 2004 HIGHEST RN 681425-81-0
DICTIONARY FILE UPDATES: 12 MAY 2004 HIGHEST RN 681425-81-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L20 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 61941-56-8 REGISTRY
CN Benzeneacetic acid, 2-amino-3-benzoyl-, monosodium salt (9CI) (CA INDEX NAME)
OTHER NAMES:
CN AHR 5850
CN AHR 5850D
CN **Amfenac sodium**
CN Phenazox
CN Sodium (2-amino-3-benzoylphenyl)acetate
CN Sodium 2-amino-3-benzoylbenzeneacetate
MF C15 H13 N O3 . Na
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS,
CASREACT, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, PROMT, PS, RTECS*,
TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
CRN (51579-82-9)

*Registry
search of compound
in claim 1 yielded
157 compounds. If
they are in
Registry, they are
These 5 are "known".
appears to
be the most
widely known.*




anti-inflammatory

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

39 REFERENCES IN FILE CA (1907 TO DATE)
39 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L20 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 51579-82-9 REGISTRY
CN Benzeneacetic acid, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (2-Amino-3-benzoylphenyl)acetic acid
CN **Amfenac**
CN NSC 309467
FS 3D CONCORD
MF C15 H13 N O3
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CIN, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO




anti-inflammatory

****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

77 REFERENCES IN FILE CA (1907 TO DATE)
15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
77 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L21 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 91714-94-2 REGISTRY
CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN AHR 10282
CN **Bromfenac**
FS 3D CONCORD
MF C15 H12 Br N O3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CIN, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

84 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
84 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L21 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 91714-93-1 REGISTRY
CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt (9CI)
(CA INDEX NAME)
OTHER NAMES:
CN AHR 10282B
CN **Bromfenac sodium**
MF C15 H12 Br N O3 . Na
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS,
BIOSIS, CA, CAPLUS, CASREACT, CBNB, CIN, DIOGENES, IMSPATENTS,
IMSRESEARCH, MRCK*, MSDS-OHS, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE,
TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
CRN (91714-94-2)




● Na

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

21 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
21 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d ide

L80 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **78281-72-8** REGISTRY
CN Benzeneacetamide, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN AHR 9434
CN AL 6515
CN Nepafenac
FS 3D CONCORD
MF C15 H14 N2 O2
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMINFORMRX, DDFU,
DRUGU, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

20 REFERENCES IN FILE CA (1907 TO DATE)

20 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil reg; d ide l29

FILE 'REGISTRY' ENTERED AT 16:08:27 ON 13 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAY 2004 HIGHEST RN 681425-81-0
DICTIONARY FILE UPDATES: 12 MAY 2004 HIGHEST RN 681425-81-0


TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L29 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 22071-22-3 REGISTRY
CN **Benzeneacetic acid, 3-benzoyl-** (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetic acid, (m-benzoylphenyl)- (8CI)
OTHER NAMES:
CN (3-Benzoylphenyl)acetic acid
CN 2-(3-Benzoylphenyl)acetic acid
CN m-Benzoylphenylacetic acid
CN RU 4462
FS 3D CONCORD
MF C15 H12 O3
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST,
CSCHEM, IFICDB, IFIPAT, IFIUDB, RTECS*, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



notice there's no nitrogen at this position (claim 1 structure has nitrogen)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

33 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
33 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil capl; d que l32; fil uspatf; d que l43; fil biosis toxcenter; d que l53
FILE 'CAPLUS' ENTERED AT 16:30:09 ON 13 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 May 2004 VOL 140 ISS 20
FILE LAST UPDATED: 12 May 2004 (20040512/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L6	24651	SEA	FILE=CAPLUS	ABB=ON	?ANGIOGEN?/BI
L7	97920	SEA	FILE=CAPLUS	ABB=ON	ANTITUMOR AGENTS/CT
L8	322151	SEA	FILE=CAPLUS	ABB=ON	NEOPLAS?/CW
L9	4426	SEA	FILE=CAPLUS	ABB=ON	GLAUCOMA/OBI
L10	1662	SEA	FILE=CAPLUS	ABB=ON	ANTIGLAUCOMA?/OBI
L11	3181	SEA	FILE=CAPLUS	ABB=ON	NEOVASCULAR?/OBI
L29	1	SEA	FILE=REGISTRY	ABB=ON	"BENZENEACETIC ACID, 3-BENZOYL-"/CN
L30	33	SEA	FILE=CAPLUS	ABB=ON	L29
L32	3	SEA	FILE=CAPLUS	ABB=ON	L30 AND (L6 OR L7 OR L8 OR L9 OR L10 OR L11)

FILE 'USPATFULL' ENTERED AT 16:30:09 ON 13 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 13 May 2004 (20040513/PD)
FILE LAST UPDATED: 13 May 2004 (20040513/ED)
HIGHEST GRANTED PATENT NUMBER: US6735778
HIGHEST APPLICATION PUBLICATION NUMBER: US2004093652
CA INDEXING IS CURRENT THROUGH 13 May 2004 (20040513/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 13 May 2004 (20040513/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2004
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2004

>>>	USPAT2 is now available. USPATFULL contains full text of the	<<<
>>>	original, i.e., the earliest published granted patents or	<<<
>>>	applications. USPAT2 contains full text of the latest US	<<<
>>>	publications, starting in 2001, for the inventions covered in	<<<
>>>	USPATFULL. A USPATFULL record contains not only the original	<<<
>>>	published document but also a list of any subsequent	<<<
>>>	publications. The publication number, patent kind code, and	<<<
>>>	publication date for all the US publications for an invention	<<<

```
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L29      1 SEA FILE=REGISTRY ABB=ON "BENZENEACETIC ACID, 3-BENZOYL-"/CN
L34      8 SEA FILE=USPATFULL ABB=ON L29
L35      4225 SEA FILE=USPATFULL ABB=ON ?ANGIOGEN?/AB, TI, CLM OR (ANGIOGEN?
        OR ANTIANGIOGEN?)/IT
L36      3120 SEA FILE=USPATFULL ABB=ON ANGIOGEN?/IT
L37      24055 SEA FILE=USPATFULL ABB=ON NEOPLAS?/IT
L38      1747 SEA FILE=USPATFULL ABB=ON GLAUCOMA?/IT OR ANTIGLAUCOMA?/IT
L39      658 SEA FILE=USPATFULL ABB=ON NEOVASCULAR?/IT
L40      15235 SEA FILE=USPATFULL ABB=ON ANTITUMOR AGENTS/CT
L43      2 SEA FILE=USPATFULL ABB=ON L34 AND (L35 OR L36 OR L37 OR L38
        OR L39 OR L40)
```

FILE 'BIOSIS' ENTERED AT 16:30:10 ON 13 MAY 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'TOXCENTER' ENTERED AT 16:30:10 ON 13 MAY 2004
COPYRIGHT (C) 2004 ACS

```
L29      1 SEA FILE=REGISTRY ABB=ON "BENZENEACETIC ACID, 3-BENZOYL-"/CN
L45      4 SEA L29
L46      41628 SEA ?ANGIOGEN?
L47      14920 SEA ?NEOVASCULAR?
L48      1103931 SEA ?NEOPLAS?
L49      842201 SEA ?CANCER?
L50      1429591 SEA ?TUMOR? OR ?TUMOUR?
L51      30737 SEA ?GLAUCOMA?
L53      3 SEA L45 AND (L46 OR L47 OR L48 OR L49 OR L50 OR L51)
```

=> dup rem 132,143,153

FILE 'CAPLUS' ENTERED AT 16:30:15 ON 13 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:30:15 ON 13 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:30:15 ON 13 MAY 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'TOXCENTER' ENTERED AT 16:30:15 ON 13 MAY 2004
COPYRIGHT (C) 2004 ACS

PROCESSING COMPLETED FOR L32

PROCESSING COMPLETED FOR L43

PROCESSING COMPLETED FOR L53

L81 7 DUP REM L32 L43 L53 (1 DUPLICATE REMOVED)

ANSWERS '1-3' FROM FILE CAPLUS

ANSWERS '4-5' FROM FILE USPATFULL

ANSWER '6' FROM FILE BIOSIS

ANSWER '7' FROM FILE TOXCENTER

=> d ibib ed ab hitrn 1-5; d iall 6-7

L81 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2002:142498 CAPLUS

DOCUMENT NUMBER: 136:172819

TITLE: Benzoylphenylacetic acids for treatment of
angiogenesis-related disordersINVENTOR(S): Kapin, Michael A.; Bingaman, David P.; Gamache, Daniel
A.; Graff, Gustav; Yanni, John M.

PATENT ASSIGNEE(S): Alcon Universal Ltd., Switz.

SOURCE: PCT Int. Appl., 11 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013804	A2	20020221	WO 2001-US25318	20010813
WO 2002013804	A3	20020606		
W: AU, BR, CA, CN, JP, KR, MX, PL, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001083337	A5	20020225	AU 2001-83337	20010813
US 2002037929	A1	20020328	US 2001-929381	20010813
EP 1309323	A2	20030514	EP 2001-962132	20010813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003187072	A1	20031002	US 2003-344881	20030214
PRIORITY APPLN. INFO.:			US 2000-225133P	P 20000814
			WO 2001-US25318	W 20010813

OTHER SOURCE(S): MARPAT 136:172819

ED Entered STN: 22 Feb 2002

AB The use of 3-benzoylphenylacetic acids and derivs., including nepafenac, to treat **angiogenesis**-related disorders, including ophthalmic **angiogenesis**-related disorders such as diabetic retinopathy and exudative macular degeneration, is disclosed. Thus, atypical formulation contained a 3-benzoylphenylacetic acids deriv. 0.01-0.05, Plysorbate-80 0.01, benzalkonium chloride 0.01, disodium EDTA 0.1, monobasic sodium phosphate 0.03, dibasic sodium phosphate 0.1, NaCl qs (290-300 mOsm/kg) and water qs 100%.

IT 22071-22-3, 3-Benzoylphenylacetic acid 22071-22-3D,
3-Benzoylphenylacetic acid, derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzoylphenylacetic acids for treatment of **angiogenesis**
-related disorders)

L81 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1992:658203 CAPLUS

DOCUMENT NUMBER: 117:258203

TITLE: Preparation of esters and amides of substituted phenyl
acetic acids for the treatment of colonic polyps

INVENTOR(S): Pamukcu, Rifat; Gross, Paul; Brendel, Klaus
 PATENT ASSIGNEE(S): FGN, Inc., USA; University of Arizona
 SOURCE: Eur. Pat. Appl., 18 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 485158	A2	19920513	EP 1991-310205	19911105
EP 485158	A3	19930127		
R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
AU 9186986	A1	19920514	AU 1991-86986	19911104
AU 650914	B2	19940707		
CA 2054965	AA	19920507	CA 1991-2054965	19911105
JP 06065301	A2	19940308	JP 1991-289964	19911106
PRIORITY APPLN. INFO.:			US 1990-609799	19901106
			US 1991-776889	19911011

ED Entered STN: 26 Dec 1992

AB Title compds. I (R1, R2 = H, halo, alkyl, alkenyl, haloalkyl, alkynyl; R3 = halo, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, etc.; Q = deprotonated residue of a polymer or macromol. having of mol. wt. of at least 1000; n = at least 2), useful for treatment or prevention of colonic polyps (no data), are prepd. A mixt. of 4-FC6H4COME, piperidine and DMSO were reacted to give 4-piperidinoacetophenone, which was treated with morpholine, S, and 4-MeC6H4SO3H, refluxed for 17 h to give the morpholide. The morpholide was further treated with HCl to give (4-piperidinophenyl)acetic acid-HCl, which was conjugated with acetylpolylysine.

IT 22071-22-3DP, (3-Benzoylphenyl)acetic acid, reaction products with macromols.

RL: PREP (Preparation)
 (prepn. of, for treatment of colon polyp)

L81 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1986:565005 CAPLUS

DOCUMENT NUMBER: 105:165005

TITLE: Acetic acid derivatives as neoplasm inhibitors

INVENTOR(S): Ubusawa, Masanori; Kano, Tamotsu; Matsunaga, Kenichi; Fujii, Takami; Muto, Shigeaki; Furusho, Takao; Yoshikumi, Chikao

PATENT ASSIGNEE(S): Kureha Chemical Industry Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61130217	A2	19860618	JP 1984-253185	19841130
JP 06049648	B4	19940629		
PRIORITY APPLN. INFO.:			JP 1984-253185	19841130

ED Entered STN: 15 Nov 1986

AB Acetic acid derivs. such as (S)-6-methoxy-2-methyl-2-naphthaleneacetic acid (I) and 10-methyl-2-phenothiazinylacetic acid (II) are neoplasm inhibitors. Thus, I or II given orally to mice bearing sarcoma-180 at 350 and 250 mg/kg, resp., every other day for 3 wk inhibited the tumor growth by 34.5 and 46.5%, resp.

IT 22071-22-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as neoplasm inhibitor)

L81 ANSWER 4 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:266055 USPATFULL

TITLE: Method of treating **angiogenesis**-related disorders

INVENTOR(S): Kapin, Michael A., Arlington, TX, UNITED STATES
Bingaman, David P., Fort Worth, TX, UNITED STATES
Gamache, Daniel A., Arlington, TX, UNITED STATES
Graff, Gustav, Cleburne, TX, UNITED STATES
Yanni, John M., Burleson, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003187072	A1	20031002
APPLICATION INFO.:	US 2003-344881	A1	20030214 (10)
	WO 2001-US25318		20010813
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ALCON RESEARCH, LTD., R&D COUNSEL, Q-148, 6201 SOUTH FREEWAY, FORT WORTH, TX, 76134-2099		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
LINE COUNT:	256		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The use of 3-benzoylphenylacetic acids and derivatives, including nepafenac, to treat **angiogenesis**-related disorders, including ophthalmic **angiogenesis**-related disorders such as diabetic retinopathy and exudative macular degeneration, is disclosed.

IT 22071-22-3, 3-Benzoylphenylacetic acid 22071-22-3D,
3-Benzoylphenylacetic acid, derivs.
(benzoylphenylacetic acids for treatment of **angiogenesis**-related disorders)

L81 ANSWER 5 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2002:67276 USPATFULL

TITLE: Method of treating **angiogenesis**-related disorders

INVENTOR(S): Kapin, Michael A., Arlington, TX, UNITED STATES
Bingaman, David P., Lipan, TX, UNITED STATES
Gamache, Daniel A., Arlington, TX, UNITED STATES
Graff, Gustav, Cleburne, TX, UNITED STATES
Yanni, John M., Burleson, TX, UNITED STATES

PATENT ASSIGNEE(S): Alcon Universal Ltd. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037929	A1	20020328
APPLICATION INFO.:	US 2001-929381	A1	20010813 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225133P	20000814 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	R&D Counsel (Q-148), Alcon Universal Ltd., c/o Alcon Research, Ltd., 6201 South Freeway, Fort Worth, TX, 76134-2099	

NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 256

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The use of 3-benzolphenylacetic acids and derivatives, including nepafenac, to treat **angiogenesis**-related disorders, including ophthalmic **angiogenesis**-related disorders such as diabetic retinopathy and exudative macular degeneration, is disclosed.

IT 22071-22-3, 3-Benzoylphenylacetic acid 22071-22-3D,
3-Benzoylphenylacetic acid, derivs.
(benzoylphenylacetic acids for treatment of **angiogenesis**-related disorders)

L81 ANSWER 6 OF 7 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2001:8385 BIOSIS

DOCUMENT NUMBER: PREV200100008385

TITLE: Treatment of GLC1A **glaucoma** with
3-benzoyl-phenylacetic acids, esters, or amides.

AUTHOR(S): Yanni, John M. [Inventor, Reprint author]; Hellberg, Mark R. [Inventor]

CORPORATE SOURCE: Burleson, TX, USA

ASSIGNEE: Alcon Laboratories, Inc.

PATENT INFORMATION: US 6066671 May 23, 2000

SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (May 23, 2000) Vol. 1234, No. 4. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

ENTRY DATE: Entered STN: 21 Dec 2000

Last Updated on STN: 21 Dec 2000

ABSTRACT: Compositions of 3-benzoylphenylacetic acid derivatives for treating
GLC1A **glaucoma** and methods for their use are disclosed.

NAT. PATENT. CLASSIF.: 514619000

CONCEPT CODE: General biology - Miscellaneous 00532

INDEX TERMS: Major Concepts
Ophthalmology (Human Medicine, Medical Sciences);
Methods and Techniques; Pharmacology

INDEX TERMS: Diseases
GLC1A **glaucoma**: eye disease

INDEX TERMS: Chemicals & Biochemicals
3-benzoyl-phenylacetic acids: **antiglaucoma**
-drug, derivative; 3-benzoyl-phenylacetic amides:
antiglaucoma-drug, derivative;
3-benzoyl-phenylacetic esters: **antiglaucoma**
-drug, derivative

REGISTRY NUMBER: 22071-22-3 (3-benzoyl-phenylacetic acids)

L81 ANSWER 7 OF 7 TOXCENTER COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1986:147504 TOXCENTER

COPYRIGHT: Copyright 2004 ACS

DOCUMENT NUMBER: CA10519165005E

TITLE: Acetic acid derivatives as **neoplasm** inhibitors

AUTHOR(S): Ubusawa, Masanori; Kano, Tamotsu; Matsunaga, Kenichi;
Fujii, Takami; Muto, Shigeaki; Furusho, Takao; Yoshikumi,
Chikao

CORPORATE SOURCE: ASSIGNEE: Kureha Chemical Industry Co., Ltd.

PATENT INFORMATION: JP 86130217 A2 18 Jun 1986

SOURCE: (1986) Jpn. Kokai Tokyo Koho, 6 pp.
CODEN: JKXXAF.

COUNTRY: JAPAN
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 1986:565005
LANGUAGE: Japanese
ENTRY DATE: Entered STN: 20011116
Last Updated on STN: 20021105

ABSTRACT:

Acetic acid derivs. such as (S)-6-methoxy-2-methyl-2-naphthaleneacetic acid (I) and 10-methyl-2-phenothiazinylacetic acid (II) are **neoplasm** inhibitors. Thus, I or II given orally to mice bearing sarcoma-180 at 350 and 250 mg/kg, resp., every other day for 3 wk inhibited the **tumor** growth by 34.5 and 46.5%, resp.

CLASSIFICATION CODE: 1-6

SUPPLEMENTARY TERMS: Miscellaneous Descriptors
acetate deriv **neoplasm** inhibitor

REGISTRY NUMBER: 64-19-7Q (derivs.)

REGISTRY NUMBER: 7497-69-0; 13799-03-6; 13993-65-2; 18046-21-4;
22071-22-3; 22131-79-9; 22204-53-1; 35711-34-3;
36330-85-5; 41201-63-2; 104670-07-7

=> fil reg; d stat que 13
FILE 'REGISTRY' ENTERED AT 16:32:27 ON 13 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAY 2004 HIGHEST RN 681425-81-0
DICTIONARY FILE UPDATES: 12 MAY 2004 HIGHEST RN 681425-81-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L1

STR



CH—Ak
@20 21

CH—CF₃
@22 23

CH—S—Ak
@24 25 26

VAR G1=NH₂/NO₂
VAR G2=CH₂/20/22/24
VAR G3=O/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE
L3 157 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 370 ITERATIONS
SEARCH TIME: 00.00.01

157-ANSWERS

=> fil capl; d que nos l31

FILE 'CAPLUS' ENTERED AT 16:32:28 ON 13 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 May 2004 VOL 140 ISS 20
FILE LAST UPDATED: 12 May 2004 (20040512/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L1	STR
L3	157 SEA FILE=REGISTRY SSS FUL L1
L5	191 SEA FILE=CAPLUS ABB=ON L3
L6	24651 SEA FILE=CAPLUS ABB=ON ?ANGIOGEN?/BI
L8	322151 SEA FILE=CAPLUS ABB=ON NEOPLAS?/CW
L9	4426 SEA FILE=CAPLUS ABB=ON GLAUCOMA/OBI
L10	1662 SEA FILE=CAPLUS ABB=ON ANTIGLAUCOMA?/OBI
L11	3181 SEA FILE=CAPLUS ABB=ON NEOVASCULAR?/OBI
L31	12 SEA FILE=CAPLUS ABB=ON L5 AND (L6 OR (L8 OR L9 OR L10 OR L11))

=> fil uspatf; d que nos l42

FILE 'USPATFULL' ENTERED AT 16:32:29 ON 13 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 13 May 2004 (20040513/PD)
FILE LAST UPDATED: 13 May 2004 (20040513/ED)
HIGHEST GRANTED PATENT NUMBER: US6735778
HIGHEST APPLICATION PUBLICATION NUMBER: US2004093652
CA INDEXING IS CURRENT THROUGH 13 May 2004 (20040513/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 13 May 2004 (20040513/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2004
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2004

>>> USPAT2 is now available. USPATFULL contains full text of the	<<<
>>> original, i.e., the earliest published granted patents or	<<<
>>> applications. USPAT2 contains full text of the latest US	<<<
>>> publications, starting in 2001, for the inventions covered in	<<<
>>> USPATFULL. A USPATFULL record contains not only the original	<<<
>>> published document but also a list of any subsequent	<<<

```

>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```

L1          STR
L3          157 SEA FILE=REGISTRY SSS FUL L1
L33         73 SEA FILE=USPATFULL ABB=ON L3
L35         4225 SEA FILE=USPATFULL ABB=ON ?ANGIOGEN?/AB, TI, CLM OR (ANGIOGEN?
OR ANTIANGIOGEN?)/IT
L36         3120 SEA FILE=USPATFULL ABB=ON ANGIOGEN?/IT
L37         24055 SEA FILE=USPATFULL ABB=ON NEOPLAS?/IT
L38         1747 SEA FILE=USPATFULL ABB=ON GLAUCOMA?/IT OR ANTIGLAUCOMA?/IT
L39         658 SEA FILE=USPATFULL ABB=ON NEOVASCULAR?/IT
L42         14 SEA FILE=USPATFULL ABB=ON L33 AND (L35 OR L36 OR L37 OR L38
OR L39)

```

=> fil biosis toxcenter; d que nos 152

FILE 'BIOSIS' ENTERED AT 16:32:30 ON 13 MAY 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'TOXCENTER' ENTERED AT 16:32:30 ON 13 MAY 2004
COPYRIGHT (C) 2004 ACS

```

L1          STR
L3          157 SEA FILE=REGISTRY SSS FUL L1
L44         263 SEA L3
L46         41628 SEA ?ANGIOGEN?
L47         14920 SEA ?NEOVASCULAR?
L48         1103931 SEA ?NEOPLAS?
L49         842201 SEA ?CANCER?
L50         1429591 SEA ?TUMOR? OR ?TUMOUR?
L51         30737 SEA ?GLAUCOMA?
L52         17 SEA L44 AND (L46 OR L47 OR L48 OR L49 OR L50 OR L51)

```

=> fil embase; d que nos 172

FILE 'EMBASE' ENTERED AT 16:32:31 ON 13 MAY 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE COVERS 1974 TO 6 May 2004 (20040506/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate

substance identification.

```
L1          STR
L3          157 SEA FILE=REGISTRY SSS FUL L1
L68         231 SEA FILE=EMBASE ABB=ON  L3
L69         156789 SEA FILE=EMBASE ABB=ON  NEOPLASM+NT/CT(L)DT/CT
L70         23829 SEA FILE=EMBASE ABB=ON  GLAUCOMA+NT/CT
L71         11183 SEA FILE=EMBASE ABB=ON  "NEOVASCULARIZATION (PATHOLOGY)"+NT/CT

L72         9 SEA FILE=EMBASE ABB=ON  L68 AND (L69 OR L70 OR L71)
```

=> fil biotechno ipa anabstr; d que nos l61

FILE 'BIOTECHNO' ENTERED AT 16:32:32 ON 13 MAY 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IPA' ENTERED AT 16:32:32 ON 13 MAY 2004
COPYRIGHT (C) 2004 American Society of Hospital Pharmacists (ASHP)

FILE 'ANABSTR' ENTERED AT 16:32:32 ON 13 MAY 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

```
L1          STR
L3          157 SEA FILE=REGISTRY SSS FUL L1
L54         58 SEA L3
L55         9920 SEA ANGIOGEN? OR ANTIANGIOGEN?
L56         1866 SEA NEOVASCULAR? OR ANTINEOVASCULAR?
L57         61125 SEA NEOPLAS? OR ANTINEOPLAS?
L58         137592 SEA CANCER? OR ANTICANCER?
L59         169305 SEA TUMOR? OR ANTITUMOR? OR TUMOUR? OR ANTITUMOUR?
L60         1303 SEA GLAUCOMA? OR ANTIGLAUCOMA?
L61         9 SEA L54 AND (L55 OR L56 OR L57 OR L58 OR L59 OR L60)
```

=> fil medl cancer; d que nos l67

FILE 'MEDLINE' ENTERED AT 16:32:33 ON 13 MAY 2004

FILE 'CANCERLIT' ENTERED AT 16:32:33 ON 13 MAY 2004

```
L1          STR
L3          157 SEA FILE=REGISTRY SSS FUL L1
L62         59 SEA L3
L63         307831 SEA C4./CT(L) DT/CT = Neoplasms (d) Drug therapy
L64         25816 SEA GLAUCOMA+NT/CT
L65         21042 SEA NEOVASCULARIZATION, PATHOLOGIC+NT/CT
L66         3518 SEA ANGIOGENESIS INHIBITORS/CT
L67         0 SEA L62 AND (L63 OR L64 OR L65 OR L66)
```

=> fil drugu; d que nos l78

FILE 'DRUGU' ENTERED AT 16:32:34 ON 13 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE LAST UPDATED: 12 MAY 2004 <20040512/UP>
>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<
>>> THESAURUS AVAILABLE IN /CT <<<

>>> A RECENT REVIEW OF PSYCHIATRIC DISEASE KEYWORDS USED
IN DERWENT DRUG FILE HAS PROMPTED A REVISION BASED
ON STANDARD TERMS USED IN DSM-IV (DIAGNOSTIC AND
STATISTICAL MANUAL OF MENTAL DISORDERS - FOURTH
EDITION).

FOR FURTHER DETAILS:

http://thomsonderwent.com/derwenthome/support/userguides/lit_guide

L1 STR
L3 157 SEA FILE=REGISTRY SSS FUL L1
L73 55 SEA FILE=DRUGU ABB=ON L3
L74 1085 SEA FILE=DRUGU ABB=ON GLAUCOMA/CT
L75 193 SEA FILE=DRUGU ABB=ON NEOVASCULARIZATION/CT
L76 1978 SEA FILE=DRUGU ABB=ON ANGIOGENESIS/CT
L77 127140 SEA FILE=DRUGU ABB=ON NEOPLASM+NT/CT
L78 0 SEA FILE=DRUGU ABB=ON L73 AND (L74 OR L75 OR L76 OR L77)

=> dup rem l31,l42,l61,l72,l52

FILE 'CAPLUS' ENTERED AT 16:32:35 ON 13 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:32:35 ON 13 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 16:32:35 ON 13 MAY 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IPA' ENTERED AT 16:32:35 ON 13 MAY 2004
COPYRIGHT (C) 2004 American Society of Hospital Pharmacists (ASHP)

FILE 'EMBASE' ENTERED AT 16:32:35 ON 13 MAY 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.


FILE 'BIOSIS' ENTERED AT 16:32:35 ON 13 MAY 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'TOXCENTER' ENTERED AT 16:32:35 ON 13 MAY 2004
COPYRIGHT (C) 2004 ACS
PROCESSING COMPLETED FOR L31
PROCESSING COMPLETED FOR L42
PROCESSING COMPLETED FOR L61
PROCESSING COMPLETED FOR L72
PROCESSING COMPLETED FOR L52
L82 49 DUP REM L31 L42 L61 L72 L52 (12 DUPLICATES REMOVED)
ANSWERS '1-12' FROM FILE CAPLUS
ANSWERS '13-24' FROM FILE USPATFULL
ANSWERS '25-29' FROM FILE BIOTECHNO
ANSWERS '30-33' FROM FILE IPA
ANSWERS '34-38' FROM FILE EMBASE
ANSWERS '39-42' FROM FILE BIOSIS
ANSWERS '43-49' FROM FILE TOXCENTER


=> d ibib ed abs hitstr 1-24; d iall 25-49

L82 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 6
 ACCESSION NUMBER: 2002:142498 CAPLUS
 DOCUMENT NUMBER: 136:172819
 TITLE: Benzoylphenylacetic acids for treatment of
angiogenesis-related disorders
 INVENTOR(S): Kapin, Michael A.; Bingaman, David P.; Gamache, Daniel
 A.; Graff, Gustav; Yanni, John M.
 PATENT ASSIGNEE(S): Alcon Universal Ltd., Switz.
 SOURCE: PCT Int. Appl., 11 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013804	A2	20020221	WO 2001-US25318	20010813
WO 2002013804	A3	20020606		
W: AU, BR, CA, CN, JP, KR, MX, PL, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001083337	A5	20020225	AU 2001-83337	20010813
US 2002037929	A1	20020328	US 2001-929381	20010813
EP 1309323	A2	20030514	EP 2001-962132	20010813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003187072	A1	20031002	US 2003-344881	20030214
PRIORITY APPLN. INFO.: US 2000-225133P P 20000814				
WO 2001-US25318 W 20010813				
OTHER SOURCE(S): MARPAT 136:172819				
ED Entered STN: 22 Feb 2002				
AB The use of 3-benzoylphenylacetic acids and derivs., including nepafenac, to treat angiogenesis -related disorders, including ophthalmic angiogenesis -related disorders such as diabetic retinopathy and exudative macular degeneration, is disclosed. Thus, atypical formulation contained a 3-benzoylphenylacetic acids deriv. 0.01-0.05, Plrysorbate-80 0.01, benzalkonium chloride 0.01, disodium EDTA 0.1, monobasic sodium phosphate 0.03, dibasic sodium phosphate 0.1, NaCl qs (290-300 mOsm/kg) and water qs 100%.				
IT 78281-72-8 , Nepafenac 78281-73-9 , 2-Amino-3-(4- chlorobenzoyl)benzeneacetamide 78281-77-3 , 2-Amino-3-(4- fluorobenzoyl)benzeneacetamide RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (benzoylphenylacetic acids for treatment of angiogenesis -related disorders)				
RN 78281-72-8 CAPLUS				
CN Benzeneacetamide, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)				



RN 78281-73-9 CAPLUS
 CN Benzeneacetamide, 2-amino-3-(4-chlorobenzoyl)- (9CI) (CA INDEX NAME)



RN 78281-77-3 CAPLUS
 CN Benzeneacetamide, 2-amino-3-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 7
 ACCESSION NUMBER: 2002:575766 CAPLUS
 DOCUMENT NUMBER: 137:119709
 TITLE: Use of nonsteroidal antiinflammatory agents in combination with prostaglandin FP receptor agonists to treat **glaucoma** and ocular hypertension
 INVENTOR(S): Hellberg, Mark R.; Nixon, Jon C.
 PATENT ASSIGNEE(S): Alcon Manufacturing, Ltd., USA
 SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 575,833.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002103255	A1	20020801	US 2002-59692	20020128
US 6646001	B2	20031111		
US 6066671	A	20000523	US 1997-994903	19971219
US 6342524	B1	20020129	US 2000-575833	20000522
PRIORITY APPLN. INFO.:			US 1997-994903	A2 19971219
			US 2000-575833	A2 20000522

OTHER SOURCE(S): MARPAT 137:119709

ED Entered STN: 02 Aug 2002


AB Methods and compns. are disclosed for the treatment of glaucoma and ocular hypertension, comprising the administration of a prostaglandin FP receptor agonist (e.g. travoprost) and a prostaglandin synthesis inhibitor (e.g. nepafenac).

IT **78281-72-8, Nepafenac**

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (NSAID-prostaglandin FP receptor agonist combination to treat **glaucoma**)

RN 78281-72-8 CAPLUS

CN Benzeneacetamide, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



IT 78281-73-9 78281-77-3 392230-89-6


392230-90-9 444279-06-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(NSAID-prostaglandin FP receptor agonist combination to treat
glaucoma)


RN 78281-73-9 CAPLUS

CN Benzeneacetamide, 2-amino-3-(4-chlorobenzoyl)- (9CI) (CA INDEX NAME)



RN 78281-77-3 CAPLUS

CN Benzeneacetamide, 2-amino-3-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)



RN 392230-89-6 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-, 1-methylethyl ester, (5Z)-, mixt. with 2-amino-3-benzoylbenzeneacetamide (9CI) (CA INDEX NAME)

CM 1

CRN 157283-68-6

CMF C26 H35 F3 O6


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



CM 2

CRN 78281-72-8

CMF C15 H14 N2 O2



RN 392230-90-9 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)-, mixt. with 2-amino-3-benzoylbenzeneacetamide (9CI) (CA INDEX NAME)

CM 1

CRN 130209-82-4

CMF C26 H40 O5


Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 78281-72-8

CMF C15 H14 N2 O2



RN 444279-06-5 CAPLUS


CN Benzeneacetamide, 2-amino-3-benzoyl-, mixt. with (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide (9CI) (CA INDEX NAME)

CM 1

CRN 155206-00-1

CMF C25 H37 N O4


Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 78281-72-8

CMF C15 H14 N2 O2



L82 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 8

ACCESSION NUMBER: 2002:84603 CAPLUS

DOCUMENT NUMBER: 136:129085

TITLE: Use of nonsteroidal anti-inflammatory agents in combination with compounds that have FP prostaglandin agonist activity to treat **glaucoma** and ocular hypertension

INVENTOR(S): Hellberg, Mark R.; Nixon, Jon C.

PATENT ASSIGNEE(S): Alcon Manufacturing, Ltd., USA

SOURCE: U.S., 10 pp., Cont.-in-part of U.S. 6,066,671.

CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6342524	B1	20020129	US 2000-575833	20000522
US 6066671	A	20000523	US 1997-994903	19971219
PT 1039895	T	20021031	PT 1998-960732	19981204
ES 2178291	T3	20021216	ES 1998-960732	19981204
US 2002103255	A1	20020801	US 2002-59692	20020128
US 6646001	B2	20031111		

PRIORITY APPLN. INFO.:
 US 1997-994903 A2 19971219
 US 2000-575833 A2 20000522

OTHER SOURCE(S): MARPAT 136:129085

ED Entered STN: 31 Jan 2002

AB Methods and compns. are provided for the treatment of glaucoma and ocular hypertension, comprising the administration of a prostaglandin analog (e.g. travoprost) and a prostaglandin synthesis inhibitor (e.g. nepafenac).

IT 78281-72-8, Nepafenac 78281-73-9 78281-77-3


392230-89-6 392230-90-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nonsteroidal anti-inflammatory agents in combination with compds. having FP prostaglandin agonist activity to treat glaucoma and ocular hypertension)


RN 78281-72-8 CAPLUS

CN Benzeneacetamide, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)




RN 78281-73-9 CAPLUS

CN Benzeneacetamide, 2-amino-3-(4-chlorobenzoyl)- (9CI) (CA INDEX NAME)



RN 78281-77-3 CAPLUS

CN Benzeneacetamide, 2-amino-3-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)



RN 392230-89-6 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-, 1-methylethyl ester, (5Z)-, mixt. with 2-amino-3-benzoylbenzeneacetamide (9CI) (CA INDEX NAME)

CM 1

CRN 157283-68-6

CMF C26 H35 F3 O6


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



CM 2

CRN 78281-72-8

CMF C15 H14 N2 O2



RN 392230-90-9 CAPLUS


CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)-, mixt. with 2-amino-3-benzoylbenzeneacetamide (9CI) (CA INDEX NAME)

CM 1

CRN 130209-82-4

CMF C26 H40 O5


Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 78281-72-8

CMF C15 H14 N2 O2




REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L82 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 9
 ACCESSION NUMBER: 2000:475494 CAPLUS
 DOCUMENT NUMBER: 133:99537
 TITLE: Amide derivatives for antiangiogenic and/or antitumorigenic use
 INVENTOR(S): Kalgutkar, Amit S.; Marnett, Lawrence J.
 PATENT ASSIGNEE(S): Vanderbilt University, USA
 SOURCE: PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040088	A1	20000713	WO 1999-US30220	19991216
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6207700	B1	20010327	US 1999-226693	19990107
CA 2358289	AA	20000713	CA 1999-2358289	19991216
BR 9916800	A	20011023	BR 1999-16800	19991216
EP 1146788	A1	20011024	EP 1999-967417	19991216
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO
 JP 2002534362 T2 20021015 JP 2000-591862 19991216
 AU 760555 B2 20030515 AU 2000-23698 19991216
 US 2001034361 A1 20011025 US 2001-818201 20010327
 US 6399647 B2 20020604
 PRIORITY APPLN. INFO.: US 1999-226693 A 19990107
 WO 1999-US30220 W 19991216
 ED Entered STN: 14 Jul 2000
 AB Secondary amide derivs. of various COOH-contg. drugs, such as COOH-contg. NSAIDs, for instance, indomethacin were prepd. and tested for anti-inflammatory, COX-2 inhibitory, **antiangiogenic**, and antitumor activity. Many of the tested compds. showed potent activity. Structure activity relations are discussed.
 IT 51579-82-9, Amfenac 91714-94-2, Bromfenac
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (prepn. and structure activity relations of amide derivs. of NSAIDs as **antiangiogenic** and antitumor agents and as inhibitors of cyclooxygenase 2)
 RN 51579-82-9 CAPLUS
 CN Benzeneacetic acid, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



RN 91714-94-2 CAPLUS
 CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2004:270085 CAPLUS
 DOCUMENT NUMBER: 140:297513
 TITLE: Method using immunophilin-binding compounds for inhibiting choroidal **neovascularization**, animal model, and screening method
 INVENTOR(S): Laties, Alan; Wen, Rong; Lou, Zhijun
 PATENT ASSIGNEE(S): Trustees of the University of Pennsylvania, USA
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

 WO 2004027027 A2 20040401 WO 2003-US29188 20030918
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
 GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2002-412088P P 20020918

ED Entered STN: 02 Apr 2004


AB The invention discloses compns. and methods for inhibiting unwanted
angiogenesis, particularly those of ocular tissues. The
 treatment, inhibition, and/or prevention of choroidal neovasculture (CNV)
 is provided, along with an animal model for CNV and imaging techniques
 that permit the screening of potential agents as anti-**angiogenesis**
 and anti-CNV agents. The methodol. of the invention uses
 immunophilin-binding compds., e.g. rapamycin.

IT 78281-72-8, Nepafenac

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (immunophilin-binding compds. for inhibiting choroidal
neovascularization, animal model, screening method, and use
 with other agents)

RN 78281-72-8 CAPLUS

CN Benzeneacetamide, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



L82 ANSWER 6 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:41217 CAPLUS

DOCUMENT NUMBER: 140:111135

TITLE: Preparation of nitrosated nonsteroidal
 antiinflammatory compounds

INVENTOR(S): Earl, Richard A.; Ezawa, Maiko; Fang, Xinqin; Garvey,
 David S.; Gaston, Ricky D.; Khanapure, Subhash P.;
 Letts, Gordon L.; Lin, Chia-En; Ranatunge, Ramani R.;
 Richardson, Stewart K.; Schroeder, Joseph D.;
 Stevenson, Cheri A.; Wey, Shiow-Jyi

PATENT ASSIGNEE(S): Nitromed, Inc., USA

SOURCE: PCT Int. Appl., 145 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004648	A2	20040115	WO 2003-US21026	20030703

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004024057 A1 20040205 US 2003-612014 20030703
 PRIORITY APPLN. INFO.: US 2002-393111P P 20020703
 US 2002-397979P P 20020724
 US 2002-418353P P 20021016
 US 2003-449798P P 20030226
 US 2003-456182P P 20030321

OTHER SOURCE(S): MARPAT 140:111135
 ED Entered STN: 18 Jan 2004
 GI




AB Title compds. RnRmHC-CO-X [Rm = H, alkyl; Rn = 4-((thiophen-2-yl)carbonyl)phenyl, 3-(benzoyl)phenyl, etc.; X = Y-alkyl-aryl, etc.; Y = O, S; I] are prep'd. For instance, naproxen is coupled to 2,2'-thiodiethanol (CH₂Cl₂, DMAP, EDCI) and treated with Ac₂O/HNO₃ at 0.degree. to give II. I are nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) used alone or are combined with one compd. that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase. The invention provides methods for treating inflammation, pain, fever, gastrointestinal disorders, etc.

IT 51579-82-9D, Amfenac, nitrosated derivs. 91714-94-2D, Bromfenac, nitrosated derivs.
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination pharmaceutical; prepn. of naproxen-derived nitrosated antiinflammatory compds.)


RN 51579-82-9 CAPLUS

CN Benzeneacetic acid, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



RN 91714-94-2 CAPLUS

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 7 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:633448 CAPLUS

DOCUMENT NUMBER: 139:185666

TITLE: Coated pharmaceutical tablets with speckled appearance

INVENTOR(S): Martino, Alice C.; Noack, Robert M.; Pierman, Steven A.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066030	A2	20030814	WO 2003-US3837	20030206
WO 2003066030	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003180357	A1	20030925	US 2003-359939	20030206
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 2002-355705P P 20020207

OTHER SOURCE(S): MARPAT 139:185666

ED Entered STN: 15 Aug 2003


AB A pharmaceutical tablet is provide comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-sol. dye distributed in a matrix and (b) the coating comprises gellan gum. The tablet is suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject. The tablet has a speckled appearance that renders the tablet readily identifiable.

IT 51579-82-9, Amfenac 91714-94-2, Bromfenac

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(active ingredients for coated pharmaceutical tablets with speckled appearance)


RN 51579-82-9 CAPLUS

CN Benzeneacetic acid, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



RN 91714-94-2 CAPLUS

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:633447 CAPLUS

DOCUMENT NUMBER: 139:185665

TITLE: Pharmaceutical dosage form for mucosal delivery

INVENTOR(S): Martino, Alice C.; Pierman, Steven A.; Noack, Robert M.; Britten, Nancy

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066029	A2	20030814	WO 2003-US3836	20030206
WO 2003066029	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2003235617 A1 20031225

US 2003-360167 20030206

PRIORITY APPLN. INFO.:

US 2002-355703P P 20020207

ED Entered STN: 15 Aug 2003

AB A pharmaceutical tablet is provided comprising an intraorally disintegratable core and an excipient coating adherent thereto, wherein the coating comprises gellan gum. The tablet is suitable for intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject, at least in part by absorption of the drug via oral mucosa of the subject.


IT 51579-82-9, Amfenac 91714-94-2, Bromfenac

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(active ingredients for coated sublingual tablets)


RN 51579-82-9 CAPLUS

CN Benzeneacetic acid, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



RN 91714-94-2 CAPLUS

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:777704 CAPLUS

DOCUMENT NUMBER: 137:284364

TITLE: Treatment of ocular inflammatory and
angiogenesis-related disorders of the
 posterior segment of the eye by using an amide from
 flurbiprofen or ketorolac

INVENTOR(S): Graff, Gustav; Hellberg, Mark R.; Yanni, John M.

PATENT ASSIGNEE(S): Alcon, Inc., Switz.

SOURCE: PCT Int. Appl., 14 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078681	A2	20021010	WO 2002-US6958	20020307
WO 2002078681	A3	20030501		
W: AU, BR, CA, CN, JP, KR, MX, PH, PL, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 2002183376	A1	20021205	US 2002-92969	20020307
US 6646003	B2	20031111		

PRIORITY APPLN. INFO.: US 2001-280886P P 20010402

OTHER SOURCE(S): MARPAT 137:284364

ED Entered STN: 11 Oct 2002

AB The topical use of amide derivs. of flurbiprofen and ketorolac to treat
 ophthalmic **angiogenesis**-related and inflammatory disorders of
 the posterior segment of the eye is disclosed. Thus, a compn. contained
 the active ingredient 0.01-0.05, Polysorbate-800.01, benzalkonium chloride
 0.01, disodium-EDTA 0.1, monobasic sodium phosphate 0.03, dibasic sodium
 phosphate 0.1, NaCl qs and water qs to 100%.


IT 78281-72-8, Nepafenac 91714-94-2, Bromfenac

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
 (ocular inflammatory and **angiogenesis**-related disorders of
 posterior segment of eye by using amides from flurbiprofen or
 ketorolac)


RN 78281-72-8 CAPLUS

CN Benzeneacetamide, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



RN 91714-94-2 CAPLUS

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:338762 CAPLUS

DOCUMENT NUMBER: 134:362292

TITLE: Methods of determining individual hypersensitivity to
 a pharmaceutical agent from gene expression profile

INVENTOR(S): Farr, Spencer

PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA

SOURCE: PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105
 US 2000-196571P P 20000411

ED Entered STN: 11 May 2001

AB The invention discloses methods, gene databases, gene arrays, protein
 arrays, and devices that may be used to det. the hypersensitivity of
 individuals to a given agent, such as drug or other chem., in order to

prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes assocd. with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes assocd. with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes assocd. with hypersensitivity. The expression of the genes predetd. to be assocd. with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and app. useful for identifying hypersensitivity in a subject are also disclosed.


IT 91714-94-2, Bromfenac

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

RN 91714-94-2 CAPLUS

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 11 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:425738 CAPLUS

DOCUMENT NUMBER: 131:63452

TITLE: Use of 3-benzoylphenylacetic acids, esters, or amides for treatment of GLC1A **glaucoma**

INVENTOR(S): Yanni, John M.; Hellberg, Mark R.

PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA

SOURCE: PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932104	A1	19990701	WO 1998-US25744	19981204
W: AU, BR, CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6066671	A	20000523	US 1997-994903	19971219
CA 2313386	AA	19990701	CA 1998-2313386	19981204
AU 9916259	A1	19990712	AU 1999-16259	19981204
AU 746075	B2	20020411		
BR 9813767	A	20001003	BR 1998-13767	19981204
EP 1039895	A1	20001004	EP 1998-960732	19981204
EP 1039895	B1	20020605		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, FI
 JP 2001526218 T2 20011218 JP 2000-525095 19981204
 AT 218336 E 20020615 AT 1998-960732 19981204
 PT 1039895 T 20021031 PT 1998-960732 19981204
 ES 2178291 T3 20021216 ES 1998-960732 19981204
 HK 1027748 A1 20021011 HK 2000-106632 20001019
 PRIORITY APPLN. INFO.: US 1997-994903 A 19971219
 WQ 1998-US25744 W 19981204

OTHER SOURCE(S): MARPAT 131:63452

ED Entered STN: 09 Jul 1999

AB Compns. of 3-benzoylphenylacetic acid derivs. for treating GLC1A glaucoma and methods for their use are disclosed. The most preferred compn. for use in an eye drop is nepafenac.


IT 78281-72-8, Nepafenac

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(benzoylphenylacetic acids and their derivs. for treatment of GLC1A glaucoma)

RN 78281-72-8 CAPLUS

CN Benzeneacetamide, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L82 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:431723 CAPLUS

DOCUMENT NUMBER: 125:67821

TITLE: Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds

INVENTOR(S): Desai, Suketu Dipakbhai; Nelms, Diane S.

PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA

SOURCE: PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9614829	A1	19960523	WO 1995-US14910	19951116
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5603929	A	19970218	US 1994-340763	19941116
CA 2180554	AA	19960523	CA 1995-2180554	19951116
CA 2180554	C	20010821		
AU 9641622	A1	19960606	AU 1996-41622	19951116
AU 686917	B2	19980212		
EP 739197	A1	19961030	EP 1995-939996	19951116
EP 739197	B1	20010808		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09503791	T2	19970415	JP 1995-509750	19951116

JP 2954356 B2 19990927
 AT 203897 E 20010815 AT 1995-939996 19951116
 ES 2160722 T3 20011116 ES 1995-939996 19951116
 PT 739197 T 20011228 PT 1995-939996 19951116
 US 5653972 A 19970805 US 1996-700960 19960821
 HK 1012556 A1 20011130 HK 1998-113829 19981217
 GR 3036622 T3 20011231 GR 2001-401480 20010917
 PRIORITY APPLN. INFO.: US 1994-340763 A 19941116
 WO 1995-US14910 W 19951116

ED Entered STN: 23 Jul 1996


AB Disclosed are storage-stable preserved ophthalmic compns. contg. acidic drugs in combination with polymeric quaternary ammonium compds. and boric acid. For example, an ophthalmic prepn. contained Na diclofenac 0.1, hydroxypropyl Me cellulose 0.1, tromethamine 2.0, boric acid 1.2, vitamin E polyethylene glycol succinate 3.0, mannitol 3.5, Polyquad 0.005, HCl/NaOH q.s. to pH 7.4, and purified water to 100 %.

IT 91714-94-2, Bromfenac

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preserved ophthalmic drug compns. contg. polymeric quaternary ammonium compds.)

RN 91714-94-2 CAPLUS

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 13 OF 49 USPATFULL on STN

ACCESSION NUMBER: 2004:31915 USPATFULL

TITLE: Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications

INVENTOR(S): Earl, Richard A., Westford, MA, UNITED STATES
 Ezawa, Maiko, Acton, MA, UNITED STATES
 Fang, Xinqin, Lexington, MA, UNITED STATES
 Garvey, David S., Dover, MA, UNITED STATES
 Gaston, Ricky D., Malden, MA, UNITED STATES
 Khanapure, Subhash P., Clinton, MA, UNITED STATES
 Letts, L. Gordon, Dover, MA, UNITED STATES
 Lin, Chia-En, Burlington, MA, UNITED STATES
 Ranatunga, Ramani R., Lexington, MA, UNITED STATES
 Richardson, Stewart K., Tolland, CT, UNITED STATES
 Schroeder, Joseph D., Minneapolis, MN, UNITED STATES
 Stevenson, Cheri A., Haverhill, MA, UNITED STATES
 Wey, Shiow-Jyi, Woburn, MA, UNITED STATES

PATENT ASSIGNEE(S): NitroMed, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004024057	A1	20040205
APPLICATION INFO.:	US 2003-612014	A1	20030703 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-393111P	20020703 (60)
	US 2002-397979P	20020724 (60)
	US 2002-418353P	20021016 (60)

US 2003-449798P 20030226 (60)
US 2003-456182P 20030321 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: EDWARD D GRIEFF, HALE & DORR LLP, 1455 PENNSYLVANIA
AVE, NW, WASHINGTON, DC, 20004
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
LINE COUNT: 5705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 51579-82-9D, Amfenac, nitrosated derivs. 91714-94-2D,
Bromfenac, nitrosated derivs.
(combination pharmaceutical; prepn. of naproxen-derived nitrosated
antiinflammatory compds.)


RN 51579-82-9 USPATFULL

CN Benzeneacetic acid, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



RN 91714-94-2 USPATFULL

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 14 OF 49 USPATFULL on STN

ACCESSION NUMBER: 2003:334741 USPATFULL
TITLE: Pharmaceutical dosage form for mucosal delivery
INVENTOR(S): Martino, Alice C., Kalamazoo, MI, UNITED STATES
Pierman, Steven A., Portage, MI, UNITED STATES
Noack, Robert M., Grand Rapids, MI, UNITED STATES
Britten, Nancy J., Portage, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235617	A1	20031225
APPLICATION INFO.:	US 2003-360167	A1	20030206 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-355703P	20020207 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST OFFICE BOX 1027, ST. LOUIS, MO, 63006	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1173	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A pharmaceutical tablet is provided comprising an intraorally disintegratable core and an excipient coating adherent thereto, wherein the coating comprises gellan gum. The tablet is suitable for intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject, at least in part by absorption of the drug via oral mucosa of the subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 51579-82-9, Amfenac 91714-94-2, Bromfenac
(active ingredients for coated sublingual tablets)


RN 51579-82-9 USPATFULL

CN Benzeneacetic acid, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



RN 91714-94-2 USPATFULL

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 15 OF 49 USPATFULL on STN

ACCESSION NUMBER: 2003:294923 USPATFULL

TITLE: Method of treating vascular endothelial growth factor

mediated vascular disorders
INVENTOR(S): Bingaman, David P., Fort Worth, TX, UNITED STATES
Kapin, Michael A., Arlington, TX, UNITED STATES
Gamache, Daniel A., Arlington, TX, UNITED STATES
Graff, Gustav, Cleburne, TX, UNITED STATES
Yanni, John M., Burleson, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207941	A1	20031106
APPLICATION INFO.:	US 2003-417466	A1	20030416 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-377429P	20020503 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALCON RESEARCH, LTD., R&D COUNSEL, Q-148, 6201 SOUTH FREEWAY, FORT WORTH, TX, 76134-2099	

NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 255
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The use of amfenac and derivatives, including nepafenac, to treat vascular endothelial growth factor mediated vascular disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 51579-82-9, Amfenac 78281-72-8, Nepafenac
(treatment of vascular endothelial growth factor-mediated ocular vascular disorders)


RN 51579-82-9 USPATFULL

CN Benzeneacetic acid, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



RN 78281-72-8 USPATFULL

CN Benzeneacetamide, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



L82 ANSWER 16 OF 49 USPATFULL on STN

ACCESSION NUMBER: 2003:266055 USPATFULL

TITLE: Method of treating angiogenesis-related disorders

INVENTOR(S): Kapin, Michael A., Arlington, TX, UNITED STATES
Bingaman, David P., Fort Worth, TX, UNITED STATES

Gamache, Daniel A., Arlington, TX, UNITED STATES
 Graff, Gustav, Cleburne, TX, UNITED STATES
 Yanni, John M., Burleson, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003187072	A1	20031002
APPLICATION INFO.:	US 2003-344881	A1	20030214 (10)
	WO 2001-US25318		20010813
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ALCON RESEARCH, LTD., R&D COUNSEL, Q-148, 6201 SOUTH FREEWAY, FORT WORTH, TX, 76134-2099		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
LINE COUNT:	256		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The use of 3-benzolphenylacetic acids and derivatives, including nepafenac, to treat **angiogenesis**-related disorders, including ophthalmic **angiogenesis**-related disorders such as diabetic retinopathy and exudative macular degeneration, is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 78281-72-8, Nepafenac 78281-73-9, 2-Amino-3-(4-chlorobenzoyl)benzeneacetamide 78281-77-3, 2-Amino-3-(4-fluorobenzoyl)benzeneacetamide
 (benzoylphenylacetic acids for treatment of **angiogenesis**-related disorders)


RN 78281-72-8 USPATFULL

CN Benzeneacetamide, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)




RN 78281-73-9 USPATFULL

CN Benzeneacetamide, 2-amino-3-(4-chlorobenzoyl)- (9CI) (CA INDEX NAME)



RN 78281-77-3 USPATFULL

CN Benzeneacetamide, 2-amino-3-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 17 OF 49 USPATFULL on STN

ACCESSION NUMBER: 2003:257307 USPATFULL

TITLE: Pharmaceutical tablet

INVENTOR(S): Martino, Alice C., Kalamazoo, MI, UNITED STATES
Noack, Robert M., Grand Rapids, MI, UNITED STATES
Pierman, Steven A., Portage, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003180357	A1	20030925
APPLICATION INFO.:	US 2003-359939	A1	20030206 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-355705P	20020207 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST OFFICE BOX 1027, ST. LOUIS, MO, 63006	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1000	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A pharmaceutical tablet is provided comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix, and (b) the coating comprises gellan gum. The tablet is suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject. The tablet has a speckled appearance that renders the tablet readily identifiable.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 51579-82-9, Amfenac 91714-94-2, Bromfenac
(active ingredients for coated pharmaceutical tablets with speckled appearance)


RN 51579-82-9 USPATFULL

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



RN 91714-94-2 USPATFULL

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 18 OF 49 USPATFULL on STN

ACCESSION NUMBER: 2002:323207 USPATFULL

TITLE: Method of treating ocular inflammatory and **angiogenesis**-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolacINVENTOR(S): Graff, Gustav, Cleburne, TX, UNITED STATES
Hellberg, Mark R., Highland Village, TX, UNITED STATES

Yanni, John M., Burleson, TX, UNITED STATES

PATENT ASSIGNEE(S): Alcon, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002183376	A1	20021205
	US 6646003	B2	20031111 <i>pro filed 4/2/01</i>
APPLICATION INFO.:	US 2002-92969	A1	20020307 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-280886P	20010402 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Alcon, Inc., c/o Alcon Research, Ltd., Patrick M. Ryan(Q-148), 6201 So. Freeway, Fort Worth, TX, 76134-2099	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	303	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The topical use of certain flurbiprofen amide derivatives and ketorolac amide derivatives to treat ophthalmic **angiogenesis**-related and inflammatory disorders of the posterior segment of the eye is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 78281-72-8, Nepafenac 91714-94-2, Bromfenac
(ocular inflammatory and **angiogenesis**-related disorders of posterior segment of eye by using amides from flurbiprofen or ketorolac)


RN 78281-72-8 USPATFULL

CN Benzeneacetamide, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



RN 91714-94-2 USPATFULL

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 19 OF 49 USPATFULL on STN

ACCESSION NUMBER: 2002:67276 USPATFULL

TITLE: Method of treating **angiogenesis**-related disorders

INVENTOR(S): Kapin, Michael A., Arlington, TX, UNITED STATES
 Bingaman, David P., Lipan, TX, UNITED STATES
 Gamache, Daniel A., Arlington, TX, UNITED STATES
 Graff, Gustav, Cleburne, TX, UNITED STATES
 Yanni, John M., Burleson, TX, UNITED STATES

PATENT ASSIGNEE(S): Alcon Universal Ltd. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037929	A1	20020328
APPLICATION INFO.:	US 2001-929381	A1	20010813 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225133P	20000814 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	R&D Counsel (Q-148), Alcon Universal Ltd., c/o Alcon Research, Ltd., 6201 South Freeway, Fort Worth, TX, 76134-2099	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	256	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The use of 3-benzolphenylacetic acids and derivatives, including nepafenac, to treat **angiogenesis**-related disorders, including ophthalmic **angiogenesis**-related disorders such as diabetic retinopathy and exudative macular degeneration, is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT **78281-72-8**, Nepafenac **78281-73-9**, 2-Amino-3-(4-chlorobenzoyl)benzeneacetamide **78281-77-3**, 2-Amino-3-(4-fluorobenzoyl)benzeneacetamide
 (benzoylphenylacetic acids for treatment of **angiogenesis**-related disorders)

RN 78281-72-8 USPATFULL


CN Benzeneacetamide, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



RN 78281-73-9 USPATFULL
 CN Benzeneacetamide, 2-amino-3-(4-chlorobenzoyl)- (9CI) (CA INDEX NAME)



RN 78281-77-3 USPATFULL
 CN Benzeneacetamide, 2-amino-3-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 20 OF 49 USPATFULL on STN
 ACCESSION NUMBER: 2001:188727 USPATFULL
 TITLE: Amide derivatives for antiangiogenic and/or
 antitumorigenic use
 INVENTOR(S): Kalgutkar, Amit S., Nashville, TN, United States
 Marnett, Lawrence J., Nashville, TN, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001034361	A1	20011025
	US 6399647	B2	20020604
APPLICATION INFO.:	US 2001-818201	A1	20010327 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-226693, filed on 7 Jan 1999, GRANTED, Pat. No. US 6207700		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1312		


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating animals having cancer by administration of secondary amide derivatives of various COOH-containing drugs, such as COOH-containing NSAIDs, for instance, indomethacin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 51579-82-9, Amfenac 91714-94-2, Bromfenac
 (prepn. and structure activity relations of amide derivs. of NSAIDs as
antiangiogenic and antitumor agents and as inhibitors of
 cyclooxygenase 2)

RN 51579-82-9 USPATFULL
 CN Benzeneacetic acid, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



RN 91714-94-2 USPATFULL

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 21 OF 49 USPATFULL on STN

ACCESSION NUMBER: 2001:44258 USPATFULL

TITLE: Amide derivatives for antiangiogenic and/or antitumorigenic use

INVENTOR(S): Kalgutkar, Amit S., Nashville, TN, United States
Marnett, Lawrence J., Nashville, TN, United States
PATENT ASSIGNEE(S): Vanderbilt University, Nashville, TN, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6207700	B1	20010327
APPLICATION INFO.:	US 1999-226693		19990107 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jones, Dwayne C.		
LEGAL REPRESENTATIVE:	Jenkins & Wilson, P.A.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1497		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A method of treating animals having cancer by administration of secondary amide derivatives of various COOH-containing drugs, such as COOH-containing NSAIDs, for instance, indomethacin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 51579-82-9, Amfenac 91714-94-2, Bromfenac
(prepn. and structure activity relations of amide derivs. of NSAIDs as antiangiogenic and antitumor agents and as inhibitors of cyclooxygenase 2)

RN 51579-82-9 USPATFULL

CN Benzeneacetic acid, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



RN 91714-94-2 USPATFULL
 CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 22 OF 49 USPATFULL on STN
 ACCESSION NUMBER: 2000:64896 USPATFULL
 TITLE: Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
 INVENTOR(S): Yanni, John M., Burleson, TX, United States
 Hellberg, Mark R., Arlington, TX, United States
 PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6066671		20000523
APPLICATION INFO.:	US 1997-994903		19971219 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fay, Zohreh		
LEGAL REPRESENTATIVE:	Yeager, Sally		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	348		


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions of 3-benzoylphenylacetic acid derivatives for treating GLC1A glaucoma and methods for their use are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 78281-72-8, Nepafenac
 (benzoylphenylacetic acids and their derivs. for treatment of GLC1A glaucoma)

RN 78281-72-8 USPATFULL
 CN Benzeneacetamide, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)



L82 ANSWER 23 OF 49 USPATFULL on STN

ACCESSION NUMBER: 97:68150 USPATFULL
TITLE: Preserved ophthalmic drug compositions containing
polymeric quaternary ammonium compounds
INVENTOR(S): Desai, Suketu Dipakbhai, Fort Worth, TX, United States
Nelms, Diane S., Fort Worth, TX, United States
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United States
(U.S. corporation)


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5653972		19970805
APPLICATION INFO.:	US 1996-700960		19960821 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-340763, filed on 16 Nov 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Howard, Sharon		
LEGAL REPRESENTATIVE:	Ryan, Patrick M.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
LINE COUNT:	309		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are storage-stable preserved ophthalmic compositions
containing acidic drugs in combination with polymeric quaternary
ammonium compounds and boric acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 91714-94-2, Bromfenac
(preserved ophthalmic drug compns. contg. polymeric quaternary ammonium
comps.)
RN 91714-94-2 USPATFULL
CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 24 OF 49 USPATFULL on STN

ACCESSION NUMBER: 97:14409 USPATFULL
TITLE: Preserved ophthalmic drug compositions containing
polymeric quaternary ammonium compounds
INVENTOR(S): Desai, Suketu D., Fort Worth, TX, United States
Nelms, Diane S., Fort Worth, TX, United States
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5603929		19970218
APPLICATION INFO.:	US 1994-340763		19941116 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		


PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Howard, Sharon
LEGAL REPRESENTATIVE: Ryan, Patrick M.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 361

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are storage-stable preserved ophthalmic compositions containing acidic drugs in combination with polymeric quaternary ammonium compounds and boric acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 91714-94-2, Bromfenac
(preserved ophthalmic drug compns. contg. polymeric quaternary ammonium compds.)
RN 91714-94-2 USPATFULL
CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)



L82 ANSWER 25 OF 49 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 2003:36681619 BIOTECHNO
TITLE: Status of therapies in development for the treatment of age-related macular degeneration
AUTHOR: Hunt D.W.C.; Margaron P.
CORPORATE SOURCE: D.W.C. Hunt, QLT Inc., Preclinical Development, 887 Great Northern Way, Vancouver, BC V5T 4T5, Canada. E-mail: dhunt@qltinc.com
SOURCE: IDrugs, (01 MAY 2003), 6/5 (464-469), 55 reference(s)
CODEN: IDRUFN ISSN: 1369-7056
DOCUMENT TYPE: Journal; General Review
COUNTRY: United Kingdom
LANGUAGE: English
SUMMARY LANGUAGE: English
ABSTRACT: Age-related macular degeneration (AMD) is among the leading causes of visual impairment in the elderly. The FDA has approved only two treatments, laser photocoagulation and Visudyne.RTM. photodynamic therapy (PDT), approved for the wet form of AMD, a progressive condition characterized by the presence of choroidal **neovascularization** (CNV). Current pharmaceutical activities aimed at the treatment of wet-type AMD are largely focused on the development of anti-**angiogenic** drugs that would inhibit further CNV formation or even reduce existing CNV. However, other lines of attack for the treatment of wet AMD include anti-inflammatory agents as well as new PDT agents. This review will summarize ongoing activities for these different approaches. .COPYRG.T. Current Drugs.

CONTROLLED TERM: *retina macula age related degeneration; *
angiogenesis inhibitor; human; clinical trial;
 nonhuman; elderly care; visual impairment; food and
 drug administration; laser coagulation; photodynamic
 therapy; disease course; subretinal
neovascularization; pharmaceutical care; drug
 manufacture; wettability; drug effect; drug safety;
 side effect; photosensitivity; drug delivery system;
 gene therapy; blood vessel injury; Combretum; drug
 structure; in vitro study; in vivo study; sustained
 release preparation; review; benzoporphyrin
 derivative; antiinflammatory agent; placebo;
 photosensitizing agent; etiopurpurin; tin;
 rostoporfin; porphyrin derivative; atx s 10; lutetium
 texaphyrin; vasculotropin antibody; pegaptanib sodium;
 aptamer; recombinant antibody; recombinant human
 vasculotropin monoclonal antibody v2; pigment
 epithelium derived factor; plant extract;
 combretastatin A4 prodrug; triamcinolone acetone;
 corticosteroid; fluocinolone acetone; amfenac;
 nepafenac; cyclooxygenase 1 inhibitor; cyclooxygenase
 2 inhibitor; steroid; anecortave; squalamine;
 unindexed drug; unclassified drug; macugen
 (benzoporphyrin derivative) 113719-89-4; (tin)
 14314-35-3, 7440-31-5; (rostoporfin) 284041-10-7;
 (lutetium texaphyrin) 156436-90-7, 165254-25-1,
 194083-74-4, 218291-00-0; (pigment epithelium derived
 factor) 197980-93-1; (triamcinolone acetone)
 76-25-5; (fluocinolone acetone) 67-73-2; (amfenac)
 7753-60-8; (squalamine) 148717-90-2, 160022-48-0
 Drug Trade Name: visudyne; visudyne; atx s 10; atx s
 10; macugen; macugen; macugen
 Device Trade Name: Envision TD; Envision TD
 Drug Manufacturer: Novartis; QLT; Miravant; Allergan;
 Hamamatsu; Pharmacoclics; eyetech; Gilead; Pfizer;
 Genentech; Genvec; Warner Lambert; Oxigene; Alcon;
 Bausch and Lomb; Control Delivery Systems; Genaera
 Device Manufacturer: Bausch and Lomb; Control Delivery
 Systems

CAS REGISTRY NUMBER: (benzoporphyrin derivative) 113719-89-4; (tin)
 14314-35-3, 7440-31-5; (rostoporfin) 284041-10-7;
 (lutetium texaphyrin) 156436-90-7, 165254-25-1,
 194083-74-4, 218291-00-0; (pigment epithelium derived
 factor) 197980-93-1; (triamcinolone acetone)
 76-25-5; (fluocinolone acetone) 67-73-2; (amfenac)
 7753-60-8; (squalamine) 148717-90-2, 160022-48-0

structures for hits
 from Biotechno, IPA,
 Embase, Bidsis & Toxcenter
 printed at →

CHEMICAL NAME: The end
 of this
 section

TRADE NAME: Device Trade Name: Envision TD; Envision TD

CORPORATE NAME: Drug Manufacturer: Novartis; QLT; Miravant; Allergan;
 Hamamatsu; Pharmacoclics; eyetech; Gilead; Pfizer;
 Genentech; Genvec; Warner Lambert; Oxigene; Alcon;
 Bausch and Lomb; Control Delivery Systems; Genaera
 Device Manufacturer: Bausch and Lomb; Control Delivery
 Systems

L82 ANSWER 26 OF 49 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
 DUPLICATE

ACCESSION NUMBER: 2003:36134303 BIOTECHNO

TITLE: Topical nepafenac inhibits ocular
neovascularization

AUTHOR: Takahashi K.; Saishin Y.; Saishin Y.; Mori K.; Ando
 A.; Yamamoto S.; Oshima Y.; Nambu H.; Melia M.B.;
 Bingaman D.P.; Campochiaro P.A.

CORPORATE SOURCE: P.A. Campochiaro, Maumenee 719, Johns Hopkins Univ.
 Sch. of Medicine, 600 N. Wolfe Street, Baltimore, MD
 21287-9277, United States.
 E-mail: pcampo@jhmi.edu

SOURCE: Investigative Ophthalmology and Visual Science, (01
 JAN 2003), 44/1 (409-415), 45 reference(s)
 CODEN: IOVSDA ISSN: 0146-0404

DOCUMENT TYPE: Journal; Article

COUNTRY: United States

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: PURPOSE. Topical nepafenac readily penetrates the
 cornea and is metabolized to amfenac, a potent

cyclooxygenase (COX)-1 and COX-2 inhibitor. In this study, we tested the effect of topical nepafenac in three murine models of ocular **neovascularization** (NV)). **METHODS.** A masked trial was performed to compare the topical effects of vehicle with one of several concentrations of nepafenac (0.01%, 0.03%, 0.1%, or 0.5%), 0.1% diclofenac, or 0.5% ketorolac tromethamine in mice with oxygen-induced ischemic retinopathy, mice with choroidal NV (CNV) due to laser-induced rupture of Bruch's membrane, or transgenic mice with increased expression of vascular endothelial growth factor (VEGF) in photoreceptors (rho/VEGF transgenic mice). **RESULTS.** Mice treated with 0.1% or 0.5% nepafenac had significantly less CNV and significant less ischemia-induced retinal NV than did vehicle-treated mice. Nepafenac also blunted the increase in VEGF mRNA in the retina induced by ischemia. In rho/VEGF transgenic mice, nepafenac failed to inhibit **neovascularization**. In additional studies, compared with vehicle-treated mice, mice treated with 0.1% or 0.03% nepafenac had significantly less CNV, whereas eyes treated with 0.1% diclofenac showed no significant difference. Mice treated with 0.5% ketorolac tromethamine for 14 days had high mortality, but when evaluated after 7 days of treatment showed no difference from mice treated with vehicle for 7 days. **CONCLUSIONS.** Topical nepafenac inhibits CNV and ischemia-induced retinal **neovascularization** by decreasing production of VEGF. The absence of effect in rho/VEGF transgenic mice is consistent with this mechanism. Topical nepafenac may provide an effective new treatment for ocular **neovascularization**. The excellent corneal penetration of nepafenac certainly plays an important role in this effect. It is possible that other **antiangiogenic** agents are also amenable to topical application after formulations are identified that maximize their corneal penetration. Because of the many advantages of the topical route of delivery, this is a possible topic for exploration.

CONTROLLED TERM: *retina ischemia; *subretinal **neovascularization**; *prostaglandin synthase inhibitor; *nepafenac; *amfenac; *diclofenac; *ketorolac trometamol; Bruch membrane; transgenic mouse; drug penetration; drug metabolism; photoreceptor; mortality; cornea perforation; laser; nonhuman; female; mouse; animal experiment; animal model; controlled study; article; priority journal; vasculotropin; messenger RNA; nonsteroid antiinflammatory agent; unclassified drug

CAS REGISTRY NUMBER: (amfenac) 51579-82-9, 61941-56-8; (diclofenac) 15307-79-6, 15307-86-5; (ketorolac trometamol) 74103-07-4; (vasculotropin) 127464-60-2

CORPORATE NAME: Drug Manufacturer: Alcon, United States; Ciba Vision, United States; Allergan, United States

L82 ANSWER 27 OF 49 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE
ACCESSION NUMBER: 2003:37361690 BIOTECHNO
TITLE: A brief history of novel drug discovery technologies
AUTHOR: Gershell L.J.; Atkins J.H.

CORPORATE SOURCE: L.J. Gershell, AGW BioStrategy, 55 West 26 Street, New York, NY 10010, United States.
E-mail: consultant@agwgroup.com

SOURCE: Nature Reviews Drug Discovery, (2003), 2/4 (321-327), 38 reference(s)
CODEN: NRDDAG ISSN: 1474-1776

DOCUMENT TYPE: Journal; Article
COUNTRY: United Kingdom
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: Laypersons, researchers and clinicians alike speak of the biotechnology revolution with excitement. Media coverage of new breakthroughs in medicine often have the public and the investment community on the edge of their seats, eager for the next blockbuster drug to cure everything from high cholesterol levels to **cancer**. In this perspective, we examine some of the more popularized and influential new technologies in drug discovery and assess their relative impact on the actual attainment of new therapeutics.

CONTROLLED TERM: *drug research; *new drug; biotechnology; drug industry; medical genetics; Human immunodeficiency virus infection; drug approval; asthma; nonhodgkin lymphoma; pharmacogenomics; hypercholesterolemia; rhabdomyolysis; pain; liver toxicity; irritable colon; ischemic colitis; digestive system function disorder; heart arrhythmia; bronchospasm; non insulin dependent diabetes mellitus; allergy; depression; infection; congestive heart failure; human; nonhuman; mouse; article; priority journal; recombinant erythropoietin; insulin; rituximab; omalizumab; nelfinavir; amprenavir; proteinase inhibitor; atorvastatin; cerivastatin; bromfenac; alosetron; cisapride; rapacuronium bromide; troglitazone; terfenadine; nefazodone; trovafloxacin; zileuton; carvedilol; enalapril maleate; beta adrenergic receptor blocking agent; dipeptidyl carboxypeptidase inhibitor; antihypertensive agent; valsartan; spironolactone; bosentan; omapatrilat; endothelin receptor antagonist; unindexed drug

CAS REGISTRY NUMBER: (recombinant erythropoietin) 113427-24-0, 122312-54-3, 130455-76-4; (insulin) 9004-10-8; (rituximab) 174722-31-7; (omalizumab) 242138-07-4; (nelfinavir) 159989-64-7, 159989-65-8; (amprenavir) 161814-49-9; (proteinase inhibitor) 37205-61-1; (atorvastatin) 134523-00-5, 134523-03-8; (cerivastatin) 143201-11-0; (bromfenac) 91714-94-2; (alosestron) 122852-42-0; (cisapride) 81098-60-4; (rapacuronium bromide) 156137-99-4; (troglitazone) 97322-87-7; (terfenadine) 50679-08-8; (nefazodone) 82752-99-6, 83366-66-9; (trovafloxacin) 146836-84-2; (zileuton) 111406-87-2, 132880-11-6; (carvedilol) 72956-09-3; (enalapril maleate) 76095-16-4; (valsartan) 137862-53-4; (spironolactone) 52-01-7; (bosentan) 147536-97-8, 157212-55-0; (omapatrilat) 167305-00-2

CHEMICAL NAME: Drug Trade Name: rituxan; rituxan; xolair; viracept; agenerase; agenerase; lipitor; xolair; xolair; baycol; duract; lotronex; propulsid; raplon; rezulin; seldane; serzone; trovan; zyflo; coreg; vasotec; diovan; aldactone; traclear; traclear; vanlev

CORPORATE NAME: Drug Manufacturer: Genentech; Idec; Agouron; Vertex;

Glaxo SmithKline; Pfizer; Novartis; Tanox; Bayer;
Wyeth Ayerst; Janssen; Organon; Warner Lambert Parke
Davis; Hoechst; Bristol Myers Squibb; Abbott; Merck;
Searle; Actelion

L82 ANSWER 28 OF 49 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
DUPLICATE

ACCESSION NUMBER: 1999:29505841 BIOTECHNO
TITLE: Wyeth-Ayerst
SOURCE: Formulary, (1999), 34/10 SUPPL. (103-107), 8
reference(s)
CODEN: FORMFO ISSN: 1082-801X
DOCUMENT TYPE: Journal; General Review
COUNTRY: United States
LANGUAGE: English
CONTROLLED TERM: *drug industry; conjugated estrogen; bisoprolol
fumarate plus hydrochlorothiazide; venlafaxine;
platelet derived growth factor; recombinant
interleukin 11; piperacillin plus tazobactam;
rapamycin; zaleplon; cyclosporin; pyrazolopyrimidine
derivative; estradiol; cefixime; toxin antibody; cma
676; cdp 771; medroxyprogesterone acetate; etanercept;
antirheumatic agent; meningococcus vaccine;
mitoxantrone; pantoprazole; pneumococcus vaccine;
recombinant blood clotting factor 8; bone
morphogenetic protein 2; recombinant blood clotting
factor 9; metoclopramide; levonorgestrel; etodolac;
bromfenac; unindexed drug; prempo; **tumor**
necrosis factor receptor fc fusion protein; protonix;
prevenar; refacto; drug approval; drug research; drug
indication; drug labeling; drug formulary; pain; blood
disease; neurologic disease; cardiovascular disease;
depression; infection; insomnia; **cancer**;
bone disease; arthropathy; esophagus disease; drug
induced disease; human; review
CAS REGISTRY NUMBER: (venlafaxine) 93413-69-5; (recombinant interleukin 11)
145941-26-0; (rapamycin) 53123-88-9; (zaleplon)
151319-34-5; (cyclosporin) 79217-60-0; (estradiol)
50-28-2; (cefixime) 79350-37-1; (medroxyprogesterone
acetate) 71-58-9; (mitoxantrone) 65271-80-9,
70476-82-3; (pantoprazole) 102625-70-7; (recombinant
blood clotting factor 9) 177403-26-8, 178900-90-8;
(metoclopramide) 12707-59-4, 2576-84-3, 364-62-5,
7232-21-5; (levonorgestrel) 797-63-7; (etodolac)
41340-25-4; (bromfenac) **91714-94-2**
CHEMICAL NAME: Drug Trade Name: premarin; ziac; effexor; neumega;
zosyn; rapamune; sonata; suprax; cma 676; cdp 771;
prempo; enbrel; novantrone; protonix; prevenar;
refacto; benefix; reglan; norplant; lodine; duract
CORPORATE NAME: Drug Manufacturer: Wyeth Ayerst, United States

L82 ANSWER 29 OF 49 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN

ACCESSION NUMBER: 2003:37205494 BIOTECHNO
TITLE: Canadian and US drug approval times and safety
considerations
AUTHOR: Rawson N.S.B.; Kaitin K.I.
CORPORATE SOURCE: Dr. N.S.B. Rawson, Ctr. for Hlth. Care Plcy. and
Eval., 12125 Technology Dr., Eden Prairie, MN
55344-7302, United States.
E-mail: nigel_rawson@uhc.com
SOURCE: Annals of Pharmacotherapy, (01 OCT 2003), 37/10
(1403-1408), 30 reference(s)

CODEN: APHRER ISSN: 1060-0280
DOCUMENT TYPE: Journal; Article
COUNTRY: United States
LANGUAGE: English
SUMMARY LANGUAGE: English; Spanish; French
ABSTRACT: BACKGROUND: Approval times of new drugs are frequently longer in Canada than in the US, but it has been argued that reducing approval times might lead to unsafe drugs receiving marketing approval. OBJECTIVE: To compare new drug approval times in Canada and the US over a 10-year period and to relate them to safety discontinuations. METHODS: Application and approval dates of all new drugs except diagnostic products, new salts, esters, isomers, and dosage forms of already-marketed drugs, as well as combinations containing previously approved substances approved in the US and Canada between January 1992 and December 2001 were obtained from the respective drug regulatory agencies and other sources. Information about drugs discontinued for safety reasons was obtained from the agencies' publications and Web sites and from journal articles. RESULTS: New drug approval times were significantly longer in Canada than in the US. The difference occurs in all drug categories and by review type (priority/standard). However, the proportion of new drugs approved and later discontinued for safety reasons from the Canadian market (2.0%) was just over half that in the US (3.6%). CONCLUSIONS: When serious drug safety problems were identified in a timely manner after US approval, the products were not subsequently approved in Canada. Canada avoided potential dangers because its longer approval times provided an opportunity to observe actual market experience in other countries. However, the trade-off is that new drugs, including those for conditions for which current therapy has limited efficacy, take significantly longer to be approved in Canada and, hence, to be available to Canadians.

CONTROLLED TERM: *drug safety; licensing; Canada; United States; drug marketing; drug manufacture; publication; drug industry; hemolytic anemia; kidney failure; drug fatality; heart arrhythmia; liver toxicity; rhabdomyolysis; intestine obstruction; bronchospasm; constipation; aplastic anemia; human; article; priority journal; temafloxacin; flosequinan; cisapride; troglitazone; mibefradil; cerivastatin; bromfenac; grepafloxacin; Rotavirus vaccine; rapacuronium bromide; alosetron; remoxipride; imiglucerase; indinavir; interferon beta serine; irinotecan; paclitaxel; pamidronic acid; Pneumococcus vaccine; rifabutin; riluzole; risperidone; ritonavir; saquinavir; sumatriptan; terbinafine; benzoporphyrin derivative; **antineoplastic agent**; antiinfective agent; unindexed drug

CAS REGISTRY NUMBER: (temafloxacin) 105784-61-0, 108319-06-8; (flosequinan) 76568-02-0; (cisapride) 81098-60-4; (troglitazone) 97322-87-7; (mibefradil) 116666-63-8; (cerivastatin) 143201-11-0; (bromfenac) **91714-94-2**; (grepafloxacin) 119914-60-2; (rapacuronium bromide) 156137-99-4; (alosestron) 122852-42-0; (remoxipride) 78810-02-3, 80125-14-0, 82935-42-0; (imiglucerase) 154248-97-2; (indinavir) 150378-17-9, 157810-81-6,

180683-37-8; (interferon beta serine) 90598-63-3;
(irinotecan) 100286-90-6; (paclitaxel) 33069-62-4;
(pamidronic acid) 40391-99-9, 57248-88-1; (rifabutin)
72559-06-9; (riluzole) 1744-22-5; (risperidone)
106266-06-2; (ritonavir) 155213-67-5; (saquinavir)
127779-20-8, 149845-06-7; (sumatriptan) 103628-46-2;
(terbinafine) 91161-71-6; (benzoporphyrin derivative)
113719-89-4

L82 ANSWER 30 OF 49 IPA COPYRIGHT 2004 ASHP on STN DUPLICATE 11

ACCESSION NUMBER: 1998:4139 IPA
DOCUMENT NUMBER: 35-14281
TITLE: Class of 1997. Part 1. Make way for 39 new drug approvals
AUTHOR: Vinson, M. C.; Davis, W. M.; Waters, I. W.
CORPORATE SOURCE: Dept. of Pharmacol., Res. Inst. of Pharm. Sci., Sch. of
Pharm., Univ. of Mississippi, University, MS, USA
SOURCE: Drug Topics (USA), (Feb 2 1998) Vol. 142, pp. 66-82.
CODEN: DRTOAJ; ISSN: 0012-6616.
DOCUMENT TYPE: Journal
LANGUAGE: English
ABSTRACT:

The indications, pharmacology, contraindications, precautions, drug interactions, adverse reactions, dosage, and patient information are presented for 18 drugs approved by the U.S. Food and Drug Administration (FDA) in 1997, including ardeparin sodium (Normiflo), bromfenac sodium (Duract), cerivastatin sodium (Baycol), delavirdine mesylate (Rescriptor), fenoldopam mesylate (Corlopam), imiquimod (Aldara), letrozole (Femara), mibefradil dihydrochloride (Posicor), nelfinavir mesylate (Viracept), pramipexole dihydrochloride (Mirapex), quetiapine fumarate (Seroquel), ropinirole hydrochloride (Requip), sibutramine hydrochloride monohydrate (Meridia), tamsulosin hydrochloride (Flomax), tazarotene (Tazorac), tiludronate disodium (Skelid), toremifene citrate (Fareston), and troglitazone (Rezulin).

This article qualifies for 3 hours U.S. CE credit by the ACPE.

Ellen Katz Neumann

SECTION: 11 Pharmacology; 6 Drug Evaluations; 7 Drug Interactions; 4
Toxicity
CLASSIFICATION: 20:12.04 Anticoagulants; 28:08.04 Anti-inflammatory agents;
24:06 Antilipemic agents; 24:08 Hypotensive agents; 10:00
Antineoplastic agents; 24:04 Cardiac drugs; 12:08.04
Antiparkinson agents; 12:08.04 Antiparkinson agents; 28:20
Anorexics; 12:16 Sympatholytic agents; 84:28 Keratolytic
agents; 10:00 Antineoplastic agents; 68:20 Antidiabetic
agents
INDEX TERM: Ardeparin sodium; new drugs; 1997
INDEX TERM: Bromfenac sodium; new drugs; 1997
INDEX TERM: Cerivastatin sodium; new drugs; 1997
INDEX TERM: Delavirdine mesylate; new drugs; 1997
INDEX TERM: Fenoldopam mesylate; new drugs; 1997
INDEX TERM: Imiquimod; new drugs; 1997
INDEX TERM: Letrozole; new drugs; 1997
INDEX TERM: Mibefradil dihydrochloride; new drugs; 1997
INDEX TERM: Nelfinavir mesylate; new drugs; 1997
INDEX TERM: Pramipexole dihydrochloride; new drugs; 1997
INDEX TERM: Quetiapine fumarate; new drugs; 1997
INDEX TERM: Ropinirole hydrochloride; new drugs; 1997
INDEX TERM: Sibutramine hydrochloride monohydrate; new drugs; 1997
INDEX TERM: Tamsulosin hydrochloride; new drugs; 1997
INDEX TERM: Tazarotene; new drugs; 1997
INDEX TERM: Tiludronate disodium; new drugs; 1997
INDEX TERM: Toremifene citrate; new drugs; 1997
INDEX TERM: Troglitazone; new drugs; 1997

INDEX TERM: Anticoagulants; ardeparin sodium; new drugs
 INDEX TERM: Anti-inflammatory agents; bromfenac sodium; new drugs
 INDEX TERM: Antilipemic agents; cerivastatin sodium; new drugs
 INDEX TERM: Antiretroviral agents; delavirdine mesylate; new drugs
 INDEX TERM: Hypotensive agents; fenoldopam mesylate; new drugs
 INDEX TERM: Immunotherapy; imiquimod; new drugs
 INDEX TERM: **Antineoplastic** agents; letrozole; new drugs
 INDEX TERM: Cardiac drugs; mibefradil dihydrochloride; new drugs
 INDEX TERM: Antiretroviral agents; nelfinavir mesylate; new drugs
 INDEX TERM: Antiparkinson agents; pramipexole dihydrochloride; new drugs
 INDEX TERM: Antipsychotic agents; quetiapine fumarate; new drugs
 INDEX TERM: Antiparkinson agents; ropinirole hydrochloride; new drugs
 INDEX TERM: Anorexics; sibutramine hydrochloride monohydrate; new drugs
 INDEX TERM: Sympatholytic agents; tamsulosin hydrochloride; new drugs
 INDEX TERM: Keratolytic agents; tazarotene; new drugs
 INDEX TERM: Bisphosphonates; tiludronate disodium; new drugs
 INDEX TERM: **Antineoplastic** agents; toremifene citrate; new drugs
 INDEX TERM: Antidiabetic agents; troglitazone; new drugs
 INDEX TERM: Drugs; new; 1997
 INDEX TERM: Contraindications; new drugs; 1997
 INDEX TERM: Drug interactions; new drugs; 1997
 INDEX TERM: Toxicity; new drugs; 1997
 INDEX TERM: Dosage; new drugs; 1997
 INDEX TERM: Patient information; new drugs; 1997
 INDEX TERM: CE credit; new drugs
 CAS REGISTRY NO.: 9041-08-1 (Ardeparin sodium)
 CAS REGISTRY NO.: **120638-55-3 (Bromfenac sodium)**
 CAS REGISTRY NO.: 143201-11-0 (Cerivastatin sodium)
 CAS REGISTRY NO.: 147221-93-0 (Delavirdine mesylate)
 CAS REGISTRY NO.: 67227-57-0 (Fenoldopam mesylate)
 CAS REGISTRY NO.: 99011-02-6 (Imiquimod)
 CAS REGISTRY NO.: 112809-51-5 (Letrozole)
 CAS REGISTRY NO.: 116666-63-8 (Mibefradil dihydrochloride)
 CAS REGISTRY NO.: 159989-65-8 (Nelfinavir mesylate)
 CAS REGISTRY NO.: 104632-25-9 (Pramipexole dihydrochloride)
 CAS REGISTRY NO.: 111974-72-2 (Quetiapine fumarate)
 CAS REGISTRY NO.: 91374-20-8 (Ropinirole hydrochloride)
 CAS REGISTRY NO.: 125494-59-9 (Sibutramine hydrochloride monohydrate)
 CAS REGISTRY NO.: 106463-17-6 (Tamsulosin hydrochloride)
 CAS REGISTRY NO.: 118292-40-3 (Tazarotene)
 CAS REGISTRY NO.: 149845-07-8 (Tiludronate disodium)
 CAS REGISTRY NO.: 89778-27-8 (Toremifene citrate)
 CAS REGISTRY NO.: 97322-87-7 (Troglitazone)
 CHEMICAL NAME: Ardeparin sodium (Normiflo); Bromfenac sodium (Duract);
 Cerivastatin sodium (Baycol); Delavirdine mesylate
 (Rescriptor); Fenoldopam mesylate (Corlopam); Imiquimod
 (Aldara); Letrozole (Femara); Mibefradil dihydrochloride
 (Posicor); Nelfinavir mesylate (Viracept); Pramipexole
 dihydrochloride (Mirapex); Quetiapine fumarate (Seroquel);
 Ropinirole hydrochloride (Requip); Sibutramine
 hydrochloride monohydrate (Meridia); Tamsulosin
 hydrochloride (Flomax); Tazarotene (Tazorac); Tiludronate
 disodium (Skelid); Toremifene citrate (Fareston);
 Troglitazone (Rezulin)

L82 ANSWER 31 OF 49 IPA COPYRIGHT 2004 ASHP on STN

ACCESSION NUMBER: 1998:1949 IPA
 DOCUMENT NUMBER: 35-10298
 TITLE: New drugs of 1997

AUTHOR: Hussar, D. A.
CORPORATE SOURCE: Philadelphia Coll. of Pharm. and Sci., 600 S. Forty-third St., Philadelphia, PA 19104-4495, USA
SOURCE: Journal of the American Pharmaceutical Association (USA), (Mar-Apr 1998) Vol. 38, pp. 155-198.
CODEN: JPHAF8; ISSN: 1086-5802.
DOCUMENT TYPE: Journal
LANGUAGE: English
ABSTRACT:

An overview of 45 new therapeutic agents that were marketed in 1997 is presented, including fosfomycin tromethamine (Monuril), sparfloxacin (Zagam), grepafloxacin hydrochloride (Raxar), nelfinavir mesylate (Viracept), delavirdine mesylate (Rescriptor), penciclovir (Denavir), interferon alfacon-1 (Infergen), butenafine hydrochloride (Mentax), ivermectin (Stromectol), imiquimod (Aldara), valsartan (Diovan), irbesartan (Avapro), mibefradil dihydrochloride (Posicor), carvedilol (Coreg), atorvastatin calcium (Lipitor), reteplase (Retavase), ardeparin sodium (Normiflo), danaparoid sodium (Orgaran), quetiapine fumarate (Seroquel), donepezil hydrochloride (Aricept), topiramate (Topamax), tiagabine hydrochloride (Gabitril), pramipexole dihydrochloride (Mirapex), ropinirole hydrochloride (Requip), glatiramer acetate (Copaxone), tizanidine hydrochloride (Zanaflex), bromfenac sodium (Duract), samarium Sm-153 lexidronam (Quadramet), daclizumab (Zenapax), zileuton (Zyflo), azelastine hydrochloride (Astelin), olopatadine hydrochloride (Patanol), dolasetron mesylate (Anzemet), troglitazone (Rezulin), tamsulosin hydrochloride (Flomax), tiludronate disodium (Skelid), cabergoline (Dostinex), letrozole (Femara), toremifene citrate (Fareston), rituximab (Rituxan), oprelvekin (Neumega), anagrelide hydrochloride (Agrylin), amlexanox (Aphthasol), tazarotene (Tazorac), and fomepizole (Antizol).

The article qualifies for 6 hours U.S. CE credit by the ACPE.

M. Therese Gyi

SECTION: 11 Pharmacology; 6 Drug Evaluations
CLASSIFICATION: 84:00 Skin and mucous membrane preparations; 24:08 Hypotensive agents; 68:20 Antidiabetic agents; 10:00 Antineoplastic agents; 28:12 Anticonvulsants; 12:20 Skeletal muscle relaxants; 28:12 Anticonvulsants; 84:00 Skin and mucous membrane preparations; 12:16 Sympatholytic agents; 8:22 Quinolones; 78:00 Radiopharmaceuticals; 12:08.04 Antiparkinson agents; 20:40 Thrombolytic agents; 12:08.04 Antiparkinson agents; 8:18 Antivirals; 4:00 Antihistamines; 24:04 Cardiac drugs; 10:00 Antineoplastic agents; 8:08 Anthelmintics; 8:18 Antivirals; 84:00 Skin and mucous membrane preparations; 8:22 Quinolones; 8:00 Anti-infective agents; 28:00 Central nervous system drugs; 56:22 Anti-emetics; 24:04 Cardiac drugs; 8:12.04 Antifungals; 28:08.04 Anti-inflammatory agents; 4:00 Antihistamines; 24:06 Antilipemic agents; 20:12.04 Anticoagulants; 20:12.04 Anticoagulants; 10:00 Antineoplastic agents; 20:12.04 Platelet aggregation inhibitors; 92:00 Immunosuppressive agents; 24:08 Hypotensive agents
INDEX TERM: Amlexanox; overview
INDEX TERM: Anagrelide hydrochloride; overview
INDEX TERM: Daclizumab; overview
INDEX TERM: Irbesartan; overview
INDEX TERM: Oprelvekin; overview
INDEX TERM: Rituximab; overview
INDEX TERM: Ardeparin sodium; overview
INDEX TERM: Atorvastatin calcium; overview
INDEX TERM: Azelastine hydrochloride; overview
INDEX TERM: Bromfenac sodium; overview
INDEX TERM: Butenafine hydrochloride; overview
INDEX TERM: Cabergoline; overview

INDEX TERM: Carvedilol; overview
 INDEX TERM: Danaparoid sodium; overview
 INDEX TERM: Delavirdine mesylate; overview
 INDEX TERM: Dolasetron mesylate; overview
 INDEX TERM: Donepezil hydrochloride; overview
 INDEX TERM: Fomepizole; overview
 INDEX TERM: Fosfomycin tromethamine; overview
 INDEX TERM: Glatiramer acetate; overview
 INDEX TERM: Grepafloxacin hydrochloride; overview
 INDEX TERM: Imiquimod; overview
 INDEX TERM: Interferon alfacon-1; overview
 INDEX TERM: Ivermectin; overview
 INDEX TERM: Letrozole; overview
 INDEX TERM: Mibefradil dihydrochloride; overview
 INDEX TERM: Nelfinavir mesylate; overview
 INDEX TERM: Olopatadine hydrochloride; overview
 INDEX TERM: Penciclovir; overview
 INDEX TERM: Pramipexole dihydrochloride; overview
 INDEX TERM: Quetiapine fumarate; overview
 INDEX TERM: Reteplase; overview
 INDEX TERM: Ropinirole hydrochloride; overview
 INDEX TERM: Samarium Sm 153 lexidronam; overview
 INDEX TERM: Sparfloxacin; overview
 INDEX TERM: Tamsulosin hydrochloride; overview
 INDEX TERM: Tazarotene; overview
 INDEX TERM: Tiagabine hydrochloride; overview
 INDEX TERM: Tiludronate disodium; overview
 INDEX TERM: Tizanidine hydrochloride; overview
 INDEX TERM: Topiramate; overview
 INDEX TERM: Toremifene citrate; overview
 INDEX TERM: Troglitazone; overview
 INDEX TERM: Valsartan; overview
 INDEX TERM: Zileuton; overview
 INDEX TERM: Skin and mucous membrane preparations; amlexanox; overview
 INDEX TERM: Leukotriene antagonists; zileuton; overview
 INDEX TERM: Hypotensive agents; valsartan; overview
 INDEX TERM: Antidiabetic agents; troglitazone; overview
 INDEX TERM: **Antineoplastic** agents; toremifene citrate; overview
 INDEX TERM: Anticonvulsants; topiramate; overview
 INDEX TERM: Skeletal muscle relaxants; tizanidine hydrochloride; overview
 INDEX TERM: Calcium regulators; tiludronate disodium; overview
 INDEX TERM: Anticonvulsants; tiagabine hydrochloride; overview
 INDEX TERM: Skin and mucous membrane preparations; tazarotene; overview
 INDEX TERM: Sympatholytic agents; tamsulosin hydrochloride; overview
 INDEX TERM: Quinolones; sparfloxacin; overview
 INDEX TERM: Radiopharmaceuticals; samarium Sm 153 lexidronam; overview
 INDEX TERM: Antiparkinson agents; ropinirole hydrochloride; overview
 INDEX TERM: Thrombolytic agents; reteplase; overview
 INDEX TERM: Drugs; new; 1997
 INDEX TERM: Antipsychotic agents; quetiapine fumarate; overview
 INDEX TERM: Antiparkinson agents; pramipexole dihydrochloride; overview
 INDEX TERM: Antivirals; penciclovir; overview
 INDEX TERM: Antihistamines; olopatadine hydrochloride; overview
 INDEX TERM: Antiretroviral agents; nelfinavir mesylate; overview
 INDEX TERM: Cardiac drugs; mibefradil dihydrochloride; overview
 INDEX TERM: **Antineoplastic** agents; letrozole; overview
 INDEX TERM: Anthelmintics; ivermectin; overview
 INDEX TERM: Antivirals; interferon alfacon-1; overview
 INDEX TERM: Skin and mucous membrane preparations; imiquimod; overview
 INDEX TERM: Quinolones; grepafloxacin hydrochloride; overview

INDEX TERM: Immunotherapy; glatiramer acetate; overview
INDEX TERM: Anti-infective agents; fosfomycin tromethamine; overview
INDEX TERM: Antidotes; fomepizole; overview
INDEX TERM: Central nervous system drugs; donepezil hydrochloride; overview
INDEX TERM: Anti-emetics; dolasetron mesylate; overview
INDEX TERM: Antiretroviral agents; delavirdine mesylate; overview
INDEX TERM: Cardiac drugs; carvedilol; overview
INDEX TERM: Prolactin inhibitors; cabergoline; overview
INDEX TERM: Antifungals; butenafine hydrochloride; overview
INDEX TERM: Anti-inflammatory agents; bromfenac sodium; overview
INDEX TERM: Antihistamines; azelastine hydrochloride; overview
INDEX TERM: Antilipemic agents; atorvastatin calcium; overview
INDEX TERM: Anticoagulants; ardeparin sodium; overview
INDEX TERM: Anticoagulants; danaparoid sodium; overview
INDEX TERM: **Antineoplastic** agents; rituximab; overview
INDEX TERM: Platelet aggregation inhibitors; anagrelide hydrochloride; overview
INDEX TERM: Immunosuppressive agents; daclizumab; overview
INDEX TERM: Hypotensive agents; irbesartan; overview
INDEX TERM: Growth factors; oprelvekin; overview
INDEX TERM: CE credit; new drugs
CAS REGISTRY NO.: 68302-57-8 (Amlexanox)
CAS REGISTRY NO.: 58579-51-4 (Anagrelide hydrochloride)
CAS REGISTRY NO.: 152923-56-3 (Daclizumab)
CAS REGISTRY NO.: 138402-11-6 (Irbesartan)
CAS REGISTRY NO.: 145941-26-0 (Oprelvekin)
CAS REGISTRY NO.: 174722-31-7 (Rituximab)
CAS REGISTRY NO.: 9041-08-1 (Ardeparin sodium)
CAS REGISTRY NO.: 134523-03-8 (Atorvastatin calcium)
CAS REGISTRY NO.: 79307-93-0 (Azelastine hydrochloride)
CAS REGISTRY NO.: **120638-55-3 (Bromfenac sodium)**
CAS REGISTRY NO.: 101827-46-7 (Butenafine hydrochloride)
CAS REGISTRY NO.: 81409-90-7 (Cabergoline)
CAS REGISTRY NO.: 72956-09-3 (Carvedilol)
CAS REGISTRY NO.: 83513-48-8 (Danaparoid sodium)
CAS REGISTRY NO.: 147221-93-0 (Delavirdine mesylate)
CAS REGISTRY NO.: 115956-13-3 (Dolasetron mesylate)
CAS REGISTRY NO.: 120011-70-3 (Donepezil hydrochloride)
CAS REGISTRY NO.: 7554-65-6 (Fomepizole)
CAS REGISTRY NO.: 78964-85-9 (Fosfomycin tromethamine)
CAS REGISTRY NO.: 147245-92-9 (Glatiramer acetate)
CAS REGISTRY NO.: 161967-81-3 (Grepafloxacin hydrochloride)
CAS REGISTRY NO.: 99011-02-6 (Imiquimod)
CAS REGISTRY NO.: 118390-30-0 (Interferon alfacon-1)
CAS REGISTRY NO.: 70288-86-7 (Ivermectin)
CAS REGISTRY NO.: 112809-51-5 (Letrozole)
CAS REGISTRY NO.: 116666-63-8 (Mibefradil dihydrochloride)
CAS REGISTRY NO.: 159989-65-8 (Nelfinavir mesylate)
CAS REGISTRY NO.: 140462-76-6 (Olopatadine hydrochloride)
CAS REGISTRY NO.: 39809-25-1 (Penciclovir)
CAS REGISTRY NO.: 104632-25-9 (Pramipexole dihydrochloride)
CAS REGISTRY NO.: 111974-72-2 (Quetiapine fumarate)
CAS REGISTRY NO.: 133652-38-7 (Reteplase)
CAS REGISTRY NO.: 91374-20-8 (Ropinirole hydrochloride)
CAS REGISTRY NO.: 154427-83-5 (Samarium Sm 153 lexicidronam)
CAS REGISTRY NO.: 110871-86-8 (Sparfloxacin)
CAS REGISTRY NO.: 106463-17-6 (Tamsulosin hydrochloride)
CAS REGISTRY NO.: 118292-40-3 (Tazarotene)
CAS REGISTRY NO.: 145821-59-6 (Tiagabine hydrochloride)
CAS REGISTRY NO.: 149845-07-8 (Tiludronate disodium)
CAS REGISTRY NO.: 64461-82-1 (Tizanidine hydrochloride)

CAS REGISTRY NO.: 97240-79-4 (Topiramate)
CAS REGISTRY NO.: 89778-27-8 (Toremifene citrate)
CAS REGISTRY NO.: 97322-87-7 (Troglitazone)
CAS REGISTRY NO.: 137862-53-4 (Valsartan)
CAS REGISTRY NO.: 111406-87-2 (Zileuton)
CHEMICAL NAME: Amlexanox (Aphthasol); Anagrelide hydrochloride (Agrylin);
Daclizumab (Zenapax); Irbesartan (Avapro); Oprelvekin
(Neumega); Rituximab (Rituxan); Ardeparin sodium
(Normiflo); Atorvastatin calcium (Lipitor); Azelastine
hydrochloride (Astelin); Bromfenac sodium (Duract);
Butenafine hydrochloride (Mentax); Cabergoline (Dostinex);
Carvedilol (Coreg); Danaparoid sodium (Orgaran);
Delavirdine mesylate (Rescriptor); Dolasetron mesylate
(Anzemet); Donepezil hydrochloride (Aricept); Fomepizole
(Antizol); Fosfomycin tromethamine (Monuril); Glatiramer
acetate (Copaxone); Grepafloxacin hydrochloride (Raxar);
Imiquimod (Aldara); Interferon alfacon-1 (Infergen);
Ivermectin (Stromectol); Letrozole (Femara); Mibefradil
dihydrochloride (Posicor); Nelfinavir mesylate (Viracept);
Olopatadine hydrochloride (Patanol); Penciclovir (Denavir);
Pramipexole dihydrochloride (Mirapex); Quetiapine fumarate
(Seroquel); Reteplase (Retavase); Ropinirole hydrochloride
(Requip); Samarium Sm 153 leixidronam (Quadramet);
Sparfloxacin (Zagam); Tamsulosin hydrochloride (Flomax);
Tazarotene (Tazorac); Tiagabine hydrochloride (Gabitril);
Tiludronate disodium (Skelid); Tizanidine hydrochloride
(Zanaflex); Topiramate (Topamax); Toremifene citrate
(Fareston); Troglitazone (Rezulin); Valsartan (Diovan);
Zileuton (Zyflo)

L82 ANSWER 32 OF 49 IPA COPYRIGHT 2004 ASHP on STN

ACCESSION NUMBER: 1999:5871 IPA
DOCUMENT NUMBER: 36-07103
TITLE: New drugs of 1997
AUTHOR: Mancano, M. A.
CORPORATE SOURCE: Drug Info. Ctr., Temple Univ. Hosp., Philadelphia, PA, USA
SOURCE: Pharmacy Times (USA), (Mar 1998) Vol. 64, pp. 81-109.
CODEN: PYTMAO; ISSN: 0003-0627.
DOCUMENT TYPE: Journal
LANGUAGE: English
ABSTRACT:

An overview of new drugs of 1997 is presented, including anagrelide hydrochloride (Agrylin), ardeparin sodium (Normiflo), becaplermin (Regranex), bromfenac sodium (Duract), cefdinir (OmniCef), cerivastatin sodium (Baycol), clopidogrel bisulfate (Plarix), daclizumab (Zenapax), delavirdine mesylate (Rescriptor), dolasetron mesylate (Anzemet), emedastine difumarate (Emadine), eprosartan mesylate (Teveten), fenoldopam mesylate (Corlopam), fomepizole (Antizol), grepafloxacin hydrochloride (Raxar), imiquimod (Aldara), interferon alfacon-1 (Infergen), irbesartan (Avapro), letrozole (Femara), mibefradil dihydrochloride (Posicor), nelfinavir mesylate (Viracept), oprelvekin (Neumega), pramipexole dihydrochloride (Mirapex), quetiapine fumarate (Seroquel), raloxifene hydrochloride (Evista), repaglinide (Prandin), rituximab (Rituxan), ropinirole hydrochloride (Requip), sibutramine hydrochloride monohydrate (Meridia), talc sterile powder (Sclerosol Intrapleural Aerosol), tamsulosin hydrochloride (Flomax), tazarotene (Tazorac), tiagabine hydrochloride (Gabitril), tiludronate disodium (Skelid), toremifene citrate (Fareston), troglitazone (Rezulin, Prelay), trovafloxacin mesylate (Trovan), alatrofloxacin mesylate (Trovan), and zolmitriptan (Zomig).

This article qualifies for 4 hours of U.S. CE credit by the ACPE.

M. Therese Gyi

SECTION: 11 Pharmacology; 6 Drug Evaluations

CLASSIFICATION: 8:22 Quinolones; 68:20 Antidiabetic agents; 10:00 Antineoplastic agents; 28:12 Anticonvulsants; 84:28 Keratolytic agents; 12:16 Sympatholytic agents; 24:16 Sclerosing agents; 28:20 Anorexics; 12:08.04 Antiparkinson agents; 10:00 Antineoplastic agents; 68:20 Antidiabetic agents; 12:08.04 Antiparkinson agents; 24:04 Cardiac drugs; 10:00 Antineoplastic agents; 8:18 Antivirals; 84:00 Skin and mucous membrane preparations; 8:22 Quinolones; 24:08 Hypotensive agents; 24:08 Hypotensive agents; 56:22 Anti-emetics; 92:00 Immunosuppressive agents; 20:12.04 Platelet aggregation inhibitors; 8:12.06 Cephalosporins; 24:06 Antilipemic agents; 28:08.04 Anti-inflammatory agents; 8:22 Quinolones; 4:00 Antihistamines; 20:12.04 Anticoagulants; 20:12.04 Platelet aggregation inhibitors

INDEX TERM: Alatrofloxacin mesylate; overview
INDEX TERM: Emedastine difumarate; overview
INDEX TERM: Becaplermin; overview
INDEX TERM: Anagrelide hydrochloride; overview
INDEX TERM: Ardeparin sodium; overview
INDEX TERM: Becaplermin; overview
INDEX TERM: Bromfenac sodium; overview
INDEX TERM: Cefdinir; overview
INDEX TERM: Cerivastatin sodium; overview
INDEX TERM: Clopidogrel bisulfate; overview
INDEX TERM: Daclizumab; overview
INDEX TERM: Delavirdine mesylate; overview
INDEX TERM: Dolasetron mesylate; overview
INDEX TERM: Eprosartan mesylate; overview
INDEX TERM: Fenoldopam mesylate; overview
INDEX TERM: Fomepizole; overview
INDEX TERM: Grepafloxacin hydrochloride; overview
INDEX TERM: Imiquimod; overview
INDEX TERM: Interferon alfacon-1; overview
INDEX TERM: Irbesartan; overview
INDEX TERM: Letrozole; overview
INDEX TERM: Mibefradil dihydrochloride; overview
INDEX TERM: Nelfinavir mesylate; overview
INDEX TERM: Oprelvekin; overview
INDEX TERM: Pramipexole dihydrochloride; overview
INDEX TERM: Quetiapine fumarate; overview
INDEX TERM: Raloxifene hydrochloride; overview
INDEX TERM: Repaglinide; overview
INDEX TERM: Rituximab; overview
INDEX TERM: Ropinirole hydrochloride; overview
INDEX TERM: Sibutramine hydrochloride monohydrate; overview
INDEX TERM: Talc; overview
INDEX TERM: Tamsulosin hydrochloride; overview
INDEX TERM: Tazarotene; overview
INDEX TERM: Tiagabine hydrochloride; overview
INDEX TERM: Tiludronate disodium; overview
INDEX TERM: Toremifene citrate; overview
INDEX TERM: Troglitazone; overview
INDEX TERM: Trovafloxacin mesylate; overview
INDEX TERM: Zolmitriptan; overview
INDEX TERM: CE credit; new drugs, 1997
INDEX TERM: Serotonin agonists; zolmitriptan; overview
INDEX TERM: Quinolones; trovafloxacin mesylate; overview
INDEX TERM: Antidiabetic agents; troglitazone; overview
INDEX TERM: **Antineoplastic** agents; toremifene citrate; overview
INDEX TERM: Bisphosphonates; tiludronate disodium; overview
INDEX TERM: Anticonvulsants; tiagabine hydrochloride; overview

INDEX TERM: Keratolytic agents; tazarotene; overview
INDEX TERM: Sympatholytic agents; tamsulosin hydrochloride; overview
INDEX TERM: Sclerosing agents; talc; overview
INDEX TERM: Anorexics; sibutramine hydrochloride monohydrate; overview
INDEX TERM: Antiparkinson agents; ropinirole hydrochloride; overview
INDEX TERM: **Antineoplastic** agents; rituximab; overview
INDEX TERM: Antidiabetic agents; repaglinide; overview
INDEX TERM: Anti-estrogens; raloxifene hydrochloride; overview
INDEX TERM: Antipsychotic agents; quetiapine fumarate; overview
INDEX TERM: Antiparkinson agents; pramipexole dihydrochloride; overview
INDEX TERM: Growth factors; oprelvekin; overview
INDEX TERM: Antiretroviral agents; nelfinavir mesylate; overview
INDEX TERM: Cardiac drugs; mibefradil dihydrochloride; overview
INDEX TERM: **Antineoplastic** agents; letrozole; overview
INDEX TERM: Angiotensin antagonists; irbesartan; overview
INDEX TERM: Antivirals; interferon alfacon-1; overview
INDEX TERM: Skin and mucous membrane preparations; imiquimod; overview
INDEX TERM: Quinolones; grepafloxacin hydrochloride; overview
INDEX TERM: Antidotes; fomepizole; overview
INDEX TERM: Hypotensive agents; fenoldopam mesylate; overview
INDEX TERM: Hypotensive agents; eprosartan mesylate; overview
INDEX TERM: Anti-emetics; dolasetron mesylate; overview
INDEX TERM: Antiretroviral agents; delavirdine mesylate; overview
INDEX TERM: Immunosuppressive agents; daclizumab; overview
INDEX TERM: Platelet aggregation inhibitors; clopidogrel bisulfate; overview

INDEX TERM: Cephalosporins; cefdinir; overview
INDEX TERM: Antilipemic agents; cerivastatin sodium; overview
INDEX TERM: Anti-inflammatory agents; bromfenac sodium; overview
INDEX TERM: Quinolones; alatrofloxacin mesylate; overview
INDEX TERM: Antihistamines; emedastine difumarate; overview
INDEX TERM: Anticoagulants; ardeparin sodium; overview
INDEX TERM: Growth factors; becaplermin; overview
INDEX TERM: Platelet aggregation inhibitors; anagrelide hydrochloride; overview

INDEX TERM: Drugs; new; 1997
CAS REGISTRY NO.: 157605-25-9 (Alatrofloxacin mesylate)
CAS REGISTRY NO.: 165101-51-9 (Becaplermin)
CAS REGISTRY NO.: 58579-51-4 (Anagrelide hydrochloride)
CAS REGISTRY NO.: 9041-08-1 (Ardeparin sodium)
CAS REGISTRY NO.: **120638-55-3 (Bromfenac sodium)**
CAS REGISTRY NO.: 91832-40-5 (Cefdinir)
CAS REGISTRY NO.: 143201-11-0 (Cerivastatin sodium)
CAS REGISTRY NO.: 120202-66-6 (Clopidogrel bisulfate)
CAS REGISTRY NO.: 152923-56-3 (Daclizumab)
CAS REGISTRY NO.: 147221-93-0 (Delavirdine mesylate)
CAS REGISTRY NO.: 115956-13-3 (Dolasetron mesylate)
CAS REGISTRY NO.: 144143-96-4 (Eprosartan mesylate)
CAS REGISTRY NO.: 67227-57-0 (Fenoldopam mesylate)
CAS REGISTRY NO.: 7554-65-6 (Fomepizole)
CAS REGISTRY NO.: 161967-81-3 (Grepafloxacin hydrochloride)
CAS REGISTRY NO.: 99011-02-6 (Imiquimod)
CAS REGISTRY NO.: 118390-30-0 (Interferon alfacon-1)
CAS REGISTRY NO.: 138402-11-6 (Irbesartan)
CAS REGISTRY NO.: 112809-51-5 (Letrozole)
CAS REGISTRY NO.: 116666-63-8 (Mibefradil dihydrochloride)
CAS REGISTRY NO.: 159989-65-8 (Nelfinavir mesylate)
CAS REGISTRY NO.: 145941-26-0 (Oprelvekin)
CAS REGISTRY NO.: 104632-25-9 (Pramipexole dihydrochloride)
CAS REGISTRY NO.: 111974-72-2 (Quetiapine fumarate)
CAS REGISTRY NO.: 82640-04-8 (Raloxifene hydrochloride)
CAS REGISTRY NO.: 135062-02-1 (Repaglinide)

CAS REGISTRY NO.: 174722-31-7 (Rituximab)
CAS REGISTRY NO.: 91374-20-8 (Ropinirole hydrochloride)
CAS REGISTRY NO.: 125494-59-9 (Sibutramine hydrochloride monohydrate)
CAS REGISTRY NO.: 14807-96-6 (Talc)
CAS REGISTRY NO.: 106463-17-6 (Tamsulosin hydrochloride)
CAS REGISTRY NO.: 118292-40-3 (Tazarotene)
CAS REGISTRY NO.: 145821-59-6 (Tiagabine hydrochloride)
CAS REGISTRY NO.: 149845-07-8 (Tiludronate disodium)
CAS REGISTRY NO.: 89778-27-8 (Toremifene citrate)
CAS REGISTRY NO.: 97322-87-7 (Troglitazone)
CAS REGISTRY NO.: 147059-75-4 (Trovafloracin mesylate)
CAS REGISTRY NO.: 139264-17-8 (Zolmitriptan)
CHEMICAL NAME: Emedastine difumarate; Becaplermin
CHEMICAL NAME: Emedastine difumarate (Emadine); Alatrofloracin mesylate (Trovan); Becaplermin (Regranex); Anagrelide hydrochloride (Agrylin); Ardeparin sodium (Normiflo); Becaplermin (Regranex); Bromfenac sodium (Duract); Cefdinir (OmniCef); Cerivastatin sodium (Baycol); Clopidogrel bisulfate (Plavix); Daclizumab (Zenapax); Delavirdine mesylate (Rescriptor); Dolasetron mesylate (Anzemet); Emedastine difumarate (Emadine); Eprosartan mesylate (Teveten); Fenoldopam mesylate (Corlopam); Fomepizole (Antizol); Grepafloxacin hydrochloride (Raxar); Imiquimod (Aldara); Interferon alfacon-1 (Infergen); Irbesartan (Avapro); Letrozole (Femara); Mibefradil dihydrochloride (Posicor); Nelfinavir mesylate (Viracept); Oprelvekin (Neumega); Quetiapine fumarate (Seroquel); Pramipexole dihydrochloride (Mirapex); Raloxifene hydrochloride (Evista); Repaglinide (Prandin); Rituximab (Rituxan); Ropinirole hydrochloride (Requip); Sibutramine hydrochloride monohydrate (Meridia); Talc (Sclerosal Intrapleural Aerosol); Tamsulosin hydrochloride (Flomax); Tazarotene (Tazorac); Tiagabine hydrochloride (Gabitril); Tiludronate disodium (Skelid); Toremifene citrate (Fareston); Troglitazone (Rezulin); Trovafloracin mesylate (Trovan); Alatrofloracin mesylate (Trovan); Zolmitriptan (Zomig)

L82 ANSWER 33 OF 49 IPA COPYRIGHT 2004 ASHP on STN

ACCESSION NUMBER: 1999:4574 IPA
DOCUMENT NUMBER: 36-05806
TITLE: Major new drugs. Part 1
AUTHOR: Bergman, H. D.
SOURCE: Community Pharmacist (USA), (Jan-Feb 1998) Vol. 90, pp. 29-33.
ISSN: 0192-5792.

DOCUMENT TYPE: Journal

LANGUAGE: English

ABSTRACT:

A brief overview of some new drugs recently introduced in the United States is presented: adapalene (Differin), atorvastatin calcium (Lipitor), azelastine hydrochloride (Astelin), betaine (Cystadane), brimonidine tartrate (Alphagan), bromfenac sodium (Duract), butenafine hydrochloride (Mentax), cabergoline (Dostinex), carvedilol (Coreg), cidofovir (Vistide), donepezil hydrochloride (Aricept), fosfomycin tromethamine (Monurol), fosphenytoin sodium (Cerebyx), gemcitabine hydrochloride (Gemzar), glatiramer acetate (Copaxone), irinotecan hydrochloride (Camptosar), ivermectin (Stromectol), latanoprost (Xalatan), levofloxacin (Levaquin), and mibefradil dihydrochloride (Posicor).

This article qualifies for 1.5 hours U.S. CE credit by the ACPE.

Ramune T. Dailide

SECTION: 11 Pharmacology; 6 Drug Evaluations

CLASSIFICATION: 84:28 Keratolytic agents; 24:06 Antilipemic agents; 4:00

Antihistamines; 28:08.04 Anti-inflammatory agents; 8:12.04
 Antifungals; 24:04 Cardiac drugs; 8:18 Antivirals; 12:04
 Parasympathomimetic agents; 8:36 Urinary anti-infectives;
 28:12 Anticonvulsants; 10:00 Antineoplastic agents; 10:00
 Antineoplastic agents; 8:08 Anthelmintics; 8:22 Quinolones;
 24:04 Cardiac drugs
 INDEX TERM: Adapalene; overview
 INDEX TERM: Atorvastatin calcium; overview
 INDEX TERM: Azelastine hydrochloride; overview
 INDEX TERM: Betaine; overview
 INDEX TERM: Brimonidine tartrate; overview
 INDEX TERM: Bromfenac sodium; overview
 INDEX TERM: Butenafine hydrochloride; overview
 INDEX TERM: Cabergoline; overview
 INDEX TERM: Carvedilol; overview
 INDEX TERM: Cidofovir; overview
 INDEX TERM: Donepezil hydrochloride; overview
 INDEX TERM: Fosfomycin tromethamine; overview
 INDEX TERM: Fosphenytoin sodium; overview
 INDEX TERM: Gemcitabine hydrochloride; overview
 INDEX TERM: Glatiramer acetate; overview
 INDEX TERM: Irinotecan hydrochloride; overview
 INDEX TERM: Ivermectin; overview
 INDEX TERM: Latanoprost; overview
 INDEX TERM: Levofloxacin; overview
 INDEX TERM: Mibefradil dihydrochloride; overview
 INDEX TERM: CE credit; new drugs
 INDEX TERM: United States; new drugs
 INDEX TERM: Drugs; new; U.S.
 INDEX TERM: Keratolytic agents; adapalene; overview
 INDEX TERM: Antilipemic agents; atorvastatin calcium; overview
 INDEX TERM: Antihistamines; azelastine hydrochloride; overview
 INDEX TERM: Cytoprotectants; betaine; overview
 INDEX TERM: Prolactin inhibitors; brimonidine tartrate; overview
 INDEX TERM: Anti-inflammatory agents; bromfenac sodium; overview
 INDEX TERM: Antifungals; butenafine hydrochloride; overview
 INDEX TERM: Prolactin inhibitors; cabergoline; overview
 INDEX TERM: Cardiac drugs; carvedilol; overview
 INDEX TERM: Antivirals; cidofovir; overview
 INDEX TERM: Parasympathomimetic agents; donepezil hydrochloride;
 overview
 INDEX TERM: Urinary anti-infectives; fosfomycin tromethamine; overview
 INDEX TERM: Anticonvulsants; fosphenytoin sodium; overview
 INDEX TERM: **Antineoplastic** agents; gemcitabine hydrochloride;
 overview
 INDEX TERM: **Antineoplastic** agents; irinotecan hydrochloride;
 overview
 INDEX TERM: Anthelmintics; ivermectin; overview
 INDEX TERM: Prostaglandins; latanoprost; overview
 INDEX TERM: Quinolones; levofloxacin; overview
 INDEX TERM: Cardiac drugs; mibefradil dihydrochloride; overview
 CAS REGISTRY NO.: 106685-40-9 (Adapalene)
 CAS REGISTRY NO.: 134523-03-8 (Atorvastatin calcium)
 CAS REGISTRY NO.: 79307-93-0 (Azelastine hydrochloride)
 CAS REGISTRY NO.: 107-43-7 (Betaine)
 CAS REGISTRY NO.: 70359-46-5 (Brimonidine tartrate)
 CAS REGISTRY NO.: **120638-55-3 (Bromfenac sodium)**
 CAS REGISTRY NO.: 101827-46-7 (Butenafine hydrochloride)
 CAS REGISTRY NO.: 81409-90-7 (Cabergoline)
 CAS REGISTRY NO.: 72956-09-3 (Carvedilol)
 CAS REGISTRY NO.: 149394-66-1 (Cidofovir)
 CAS REGISTRY NO.: 120011-70-3 (Donepezil hydrochloride)

CAS REGISTRY NO.: 78964-85-9 (Fosfomycin tromethamine)
 CAS REGISTRY NO.: 92134-98-0 (Fosphenytoin sodium)
 CAS REGISTRY NO.: 122111-03-9 (Gemcitabine hydrochloride)
 CAS REGISTRY NO.: 147245-92-9 (Glatiramer acetate)
 CAS REGISTRY NO.: 136572-09-3 (Irinotecan hydrochloride)
 CAS REGISTRY NO.: 70288-86-7 (Ivermectin)
 CAS REGISTRY NO.: 130209-82-4 (Latanoprost)
 CAS REGISTRY NO.: 138199-71-0 (Levofloxacin)
 CAS REGISTRY NO.: 116666-63-8 (Mibefradil dihydrochloride)
 CHEMICAL NAME: Adapalene (Differin); Atorvastatin calcium (Lipitor);
 Azelastine hydrochloride (Astelin); Betaine (Cystadane);
 Brimonidine tartrate (Alphagan); Bromfenac sodium (Duract);
 Butenafine hydrochloride (Mentax); Cabergoline (Dostinex);
 Carvedilol (Coreg); Cidofovir (Vistide); Donepezil
 hydrochloride (Aricept); Fosfomycin tromethamine (Monurol);
 Fosphenytoin sodium (Cerebyx); Gemcitabine hydrochloride
 (Gemzar); Glatiramer acetate (Copaxone); Irinotecan
 hydrochloride (Camptosar); Ivermectin (Stromectol);
 Latanoprost (Xalatan); Levofloxacin (Levaquin); Mibefradil
 dihydrochloride (Posicor)

L82 ANSWER 34 OF 49 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN DUPLICATE 4

ACCESSION NUMBER: 2003111728 EMBASE
 TITLE: Effect of non-steroidal anti-inflammatory ophthalmic
 solution on intraocular pressure reduction by latanoprost.
 AUTHOR: Kashiwagi K.; Tsukahara S.
 CORPORATE SOURCE: Dr. K. Kashiwagi, Department of Ophthalmology, Yamanashi
 Medical University, 1110 Shimakoto, Tamaho, Yamanashi
 409-3898, Japan. kenjik@res.yamanashi-med.ac.jp
 SOURCE: British Journal of Ophthalmology, (1 Mar 2003) 87/3
 (297-301).
 Refs: 41
 ISSN: 0007-1161 CODEN: BJOPAL
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 012 Ophthalmology
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ABSTRACT:

Aim: To investigate the effects of a non-steroidal anti-inflammatory drug (NSAID) ophthalmic solution on latanoprost induced intraocular pressure (IOP) reduction using normal volunteers. Methods: This study was conducted as a prospective and observer masked clinical trial. 13 normal volunteers were enrolled. After measurement of basal IOP and ophthalmic examination, latanoprost ophthalmic solution was initially administered to both eyes once daily. Four weeks later, an NSAID ophthalmic solution, sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate (refer to bromfenac sodium hydrate), was co-administered to one randomly selected eye (NSAID group) twice daily for 2 weeks. The other eye was employed as a control (non-NSAID group). After withdrawal of the NSAID ophthalmic solution, latanoprost ophthalmic solution was continuously administered for another 2 weeks and was then withdrawn. After a 4 week washout, only bromfenac sodium hydrate ophthalmic solution was administered to the eyes of the NSAID group for 2 weeks. During the study period, ophthalmic examination, including IOP measurement was performed in an observer masked fashion. Results: Before initiation of bromfenac sodium hydrate, baseline IOPs of the non-NSAID group and the NSAID group were 15.73 (SD 1.97) mm Hg and 15.86 (2.06) mm Hg, respectively (p=0.88). Although latanoprost ophthalmic solution significantly reduced IOP in both groups, co-administration of bromfenac sodium hydrate

significantly inhibited latanoprost induced IOP reduction compared with the non-NSAID group. The IOPs of the non-NSAID and NSAID groups were 10.18 (1.17) mm Hg and 11.63 (1.35) mm Hg with a 2 week co-administration, respectively ($p < 0.01$). Withdrawal of bromfenac sodium hydrate ophthalmic solution diminished the difference between the two groups. Re-administration of bromfenac sodium ophthalmic solution only did not affect IOP. Conclusion: These results indicate that NSAID ophthalmic solution may interfere with IOP reduction by latanoprost ophthalmic solution in normal volunteers and that we should take this into account when treating patients with glaucoma using latanoprost ophthalmic solution.

CONTROLLED TERM: Medical Descriptors:
 *glaucoma: DI, diagnosis
 *glaucoma: DT, drug therapy
 intraocular pressure
 measurement
 dose response
 treatment planning
 tonometry
 conjunctival hyperemia: SI, side effect
 slit lamp
 ophthalmoscopy
 cornea erosion: SI, side effect
 human
 male
 human experiment
 normal human
 clinical trial
 controlled study
 adult
 article
 priority journal
 Drug Descriptors:
 *nonsteroid antiinflammatory agent: CT, clinical trial
 *nonsteroid antiinflammatory agent: CB, drug combination
 *nonsteroid antiinflammatory agent: DT, drug therapy
 *nonsteroid antiinflammatory agent: IO, intraocular drug administration
 *latanoprost: AE, adverse drug reaction
 *latanoprost: CT, clinical trial
 *latanoprost: CB, drug combination
 *latanoprost: DT, drug therapy
 *latanoprost: PD, pharmacology
 *latanoprost: IO, intraocular drug administration
 bromfenac: CT, clinical trial
 bromfenac: CB, drug combination
 bromfenac: DT, drug therapy
 bromfenac: IO, intraocular drug administration
 CAS REGISTRY NO.: (latanoprost) 130209-82-4; (bromfenac) 91714-94-2
 COMPANY NAME: Senju (Japan)

L82 ANSWER 35 OF 49 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN DUPLICATE 5

ACCESSION NUMBER: 2003089025 EMBASE
 TITLE: A case of cystoid macular edema following prolonged latanoprost instillation.
 AUTHOR: Nakamura M.; Ono H.; Fujiwara R.; Mohri Y.
 CORPORATE SOURCE: M. Nakamura, Department of Ophthalmology, Asagiri Hospital, 1120-2 Asagiridai, Akashi-shi 673-0852, Japan
 SOURCE: Japanese Journal of Clinical Ophthalmology, (2003) 57/2 (195-199).
 Refs: 13

ISSN: 0370-5579 CODEN: RIGAA3
 COUNTRY: Japan
 DOCUMENT TYPE: Journal; Conference Article
 FILE SEGMENT: 009 Surgery
 012 Ophthalmology
 037 Drug Literature Index
 038 Adverse Reactions Titles

LANGUAGE: Japanese
 SUMMARY LANGUAGE: English; Japanese
 ABSTRACT:

A 70-year-old woman presented with impaired visual acuity in her left eye. She had been diagnosed with primary open-angle glaucoma 14 years before. She had received intraocular surgery once in her right eye and four times in her left eye. She had been using topical latanoprost in both eyes since one year before. Her corrected visual acuity was 1.2 right and 0.2 left. Funduscopy showed cystoid macular edema (CME) in the left eye. Optical coherence tomography (OCT) showed CME in both eyes. After discontinuation of latanoprost, she was given topical bromfenac to the left eye and peroral acetazolamide. Eight weeks later, CME in both eyes disappeared and her left visual acuity improved to 0.6. This case illustrates that topical latanoprost may induce CME in eyes with prior history of intraocular surgery.

CONTROLLED TERM: Medical Descriptors:
 *retina macula cystoid edema: DI, diagnosis
 *retina macula cystoid edema: SI, side effect
 *open angle glaucoma: DT, drug therapy
 *open angle glaucoma: SU, surgery
 visual acuity
 clinical feature
 disease course
 eye surgery
 treatment outcome
 ophthalmoscopy
 optical coherence tomography
 drug withdrawal
 human
 female
 case report
 aged
 conference paper
 Drug Descriptors:
 *latanoprost: AE, adverse drug reaction
 *latanoprost: TP, topical drug administration
 bromfenac: DT, drug therapy
 bromfenac: TP, topical drug administration
 acetazolamide: DT, drug therapy
 acetazolamide: PO, oral drug administration
 CAS REGISTRY NO.: (latanoprost) 130209-82-4; (bromfenac) 91714-94-2
 ; (acetazolamide) 1424-27-7, 59-66-5

L82 ANSWER 36 OF 49 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN

ACCESSION NUMBER: 2003061996 EMBASE
 TITLE: The role of biomarkers in drug research.
 AUTHOR: Palazzolo M.
 CORPORATE SOURCE: Dr. M. Palazzolo, RJM Consulting, Madison, WI, United States. rjmconsulting@charter.net
 SOURCE: Good Clinical Practice Journal, (1 Feb 2003) 10/2 (23-26).
 Refs: 8
 ISSN: 1350-0961 CODEN: GCPJFJ
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; (Short Survey)

FILE SEGMENT: 037 Drug Literature Index
030 Pharmacology
036 Health Policy, Economics and Management
038 Adverse Reactions Titles
006 Internal Medicine
029 Clinical Biochemistry
022 Human Genetics

LANGUAGE: English

CONTROLLED TERM: Medical Descriptors:
*drug research
human
clinical trial
nonhuman
drug marketing
technology
proteomics
genomics
drug industry
drug cost
drug efficacy
toxicity: DI, diagnosis
gene expression
genetic regulation
oncogene neu
breast cancer: DI, diagnosis
breast cancer: DT, drug therapy
breast cancer: DM, disease management
protein expression
rheumatoid arthritis: DI, diagnosis
bladder cancer: DI, diagnosis
Alzheimer disease: DI, diagnosis
lung cancer
cardiovascular disease: DT, drug therapy
cardiovascular disease: DM, disease management
inflammatory disease: DT, drug therapy
inflammatory disease: DM, disease management
cancer
cytotoxicity
liver toxicity: DI, diagnosis
cardiotoxicity: DI, diagnosis
drug metabolism
diagnostic value
increased appetite: DT, drug therapy
increased appetite: DM, disease management
non insulin dependent diabetes mellitus: DT, drug therapy
non insulin dependent diabetes mellitus: DM, disease management
gastrointestinal disease: DT, drug therapy
gastrointestinal disease: DM, disease management
infection: DT, drug therapy
infection: DM, disease management
pain: DT, drug therapy
pain: DM, disease management
valvular heart disease: SI, side effect
liver failure: SI, side effect
ischemic colitis: SI, side effect
torsade des pointes: SI, side effect
short survey
Drug Descriptors:
*biological marker: EC, endogenous compound
tumor necrosis factor alpha: EC, endogenous compound

trastuzumab: DT, drug therapy
 monoclonal antibody: EC, endogenous compound
 tau protein: EC, endogenous compound
 amyloid beta 42 protein: EC, endogenous compound
 protein bcl 2: EC, endogenous compound
 annexin: EC, endogenous compound
 immunoglobulin enhancer binding protein: EC, endogenous compound
 C reactive protein: EC, endogenous compound
 caspase 8: EC, endogenous compound
 mitogen activated protein kinase: EC, endogenous compound
 heat shock protein 60: EC, endogenous compound
 heat shock protein 61: EC, endogenous compound
 stress activated protein kinase 4: EC, endogenous compound
 heat shock protein 62: EC, endogenous compound
 synaptophysin delta: EC, endogenous compound
 BLCA4 protein: EC, endogenous compound
 drug: DT, drug therapy
 drug: PD, pharmacology
 drug: PE, pharmacoeconomics
 drug: AE, adverse drug reaction
 drug: CT, clinical trial
 xenobiotic agent: PK, pharmacokinetics
 fenfluramine: DT, drug therapy
 fenfluramine: AE, adverse drug reaction
 troglitazone: DT, drug therapy
 troglitazone: AE, adverse drug reaction
 alosetron: DT, drug therapy
 alosetron: AE, adverse drug reaction
 terfenadine: DT, drug therapy
 terfenadine: AE, adverse drug reaction
 mibefradil: DT, drug therapy
 mibefradil: AE, adverse drug reaction
 astemizole: DT, drug therapy
 astemizole: AE, adverse drug reaction
 cisapride: DT, drug therapy
 cisapride: AE, adverse drug reaction
 grepafloxacin: DT, drug therapy
 grepafloxacin: AE, adverse drug reaction
 bromfenac: DT, drug therapy
 bromfenac: AE, adverse drug reaction
 unindexed drug
 unclassified drug

CAS REGISTRY NO.: (trastuzumab) 180288-69-1; (protein bcl 2) 219306-68-0; (C reactive protein) 9007-41-4; (mitogen activated protein kinase) 142243-02-5; (fenfluramine) 404-82-0, 458-24-2; (troglitazone) 97322-87-7; (alosetron) 122852-42-0; (terfenadine) 50679-08-8; (mibefradil) 116666-63-8; (astemizole) 68844-77-9; (cisapride) 81098-60-4; (grepafloxacin) 119914-60-2; (bromfenac) 91714-94-2
 CHEMICAL NAME: Herceptin; Pondimin; Rezulin; Lotronex; Seldane; Posicor; Hismanal; Propulsid; Raxar; Duract

L82 ANSWER 37 OF 49 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2002359452 EMBASE
 TITLE: Policy developments in regulatory approval.
 AUTHOR: Temple R.
 CORPORATE SOURCE: R. Temple, Center Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, United States. temple@cder.fda.gov
 SOURCE: Statistics in Medicine, (15 Oct 2002) 21/19 (2939-2948).

Refs: 10
ISSN: 0277-6715 CODEN: SMEDDA
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT:

Although radical changes in drug regulation are rare (e.g., the Federal Food, Drug and Cosmetic Act of 1938 and the 1962 amendment to the Act creating an effectiveness requirement), regulations and guidance do evolve significantly in the face of new problems and accumulating experience. Recent changes have been driven by the Food and Drug Administration Modernization Act (FDAMA), user fee legislation, the International Conference on Harmonization, recent safety related drug withdrawals, and concerns about trial ethics and investigator conflict of interest. FDAMA and guidance developed in response to it has helped circumstances in which FDA would rely on a single study to support effectiveness and the circumstances in which surrogate endpoints could support approval. An ICH Document 'Choice of control group and related design issues in clinical trials' focussed attention on the ethics of placebo controls (acceptable, even if there is existing therapy, when the placebo-treated patient will suffer no irreversible injury) and the design of 'equivalence' or 'non-inferiority' trials. There has been greatly increased attention to obtaining good dose-response information and to assessing need for modifying treatment in demographic (age, gender, race) and concomitant disease (renal or hepatic function abnormalities) subgroups, and in assessing drug-drug interactions. Other important trends are increasing reliance on non-U.S. data, increasing numbers of FDA-industry meetings during drug development, and new focus on risk assessment and risk management. Published in 2002 by John Wiley & Sons, Ltd.

CONTROLLED TERM: Medical Descriptors:
*drug research
policy
law
food and drug administration
drug withdrawal
safety
medical ethics
practice guideline
dose response
demography
age
race
gender
kidney disease
liver disease
comorbidity
drug interaction
drug development
risk assessment
risk management
heart infarction: DT, drug therapy
orthostatic hypotension: DT, drug therapy
colon polyposis: DT, drug therapy
multiple sclerosis: DT, drug therapy
torsade des pointes: SI, side effect
liver toxicity: SI, side effect
risk benefit analysis
human

clinical trial
controlled study
article
Drug Descriptors:
placebo
dipeptidyl carboxypeptidase inhibitor: CT, clinical trial
dipeptidyl carboxypeptidase inhibitor: DT, drug therapy
beta adrenergic receptor blocking agent: AE, adverse drug reaction
beta adrenergic receptor blocking agent: CT, clinical trial
beta adrenergic receptor blocking agent: DT, drug therapy
hydroxymethylglutaryl coenzyme A reductase inhibitor: CT, clinical trial
hydroxymethylglutaryl coenzyme A reductase inhibitor: DT, drug therapy
midodrine: DT, drug therapy
celecoxib: DT, drug therapy
beta interferon: DT, drug therapy
antibiotic agent: CT, clinical trial
fibrinolytic agent: CT, clinical trial
fenfluramine: AE, adverse drug reaction
astemizole: AE, adverse drug reaction
cisapride: AE, adverse drug reaction
terfenadine: AE, adverse drug reaction
dilevalol: AE, adverse drug reaction
cholinesterase inhibitor: AE, adverse drug reaction
clozapine: AE, adverse drug reaction
dofetilide: AE, adverse drug reaction
bromfenac: AE, adverse drug reaction
drug metabolite
mibefradil: AE, adverse drug reaction
CAS REGISTRY NO.: (midodrine) 3092-17-9, 42794-76-3; (celecoxib) 169590-42-5;
(fenfluramine) 404-82-0, 458-24-2; (astemizole) 68844-77-9;
(cisapride) 81098-60-4; (terfenadine) 50679-08-8;
(dilevalol) 75659-07-3; (clozapine) 5786-21-0; (dofetilide) 115256-11-6; (bromfenac) 91714-94-2; (mibefradil) 116666-63-8

L82 ANSWER 38 OF 49 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2001154800 EMBASE
TITLE: Hepatology.
AUTHOR: Moseley R.H.
CORPORATE SOURCE: Dr. R.H. Moseley, Medical Service (111), VA Medical Center,
2215 Fuller Road, Ann Arbor, MI 48105, United States.
rmoseley@umich.edu
SOURCE: Current Opinion in Gastroenterology, (2001) 17/3 (193-196).
Refs: 11
ISSN: 0267-1379 CODEN: COGAEK
COUNTRY: United States
DOCUMENT TYPE: Journal; Editorial
FILE SEGMENT: 037 Drug Literature Index
038 Adverse Reactions Titles
048 Gastroenterology
LANGUAGE: English

CONTROLLED TERM: Medical Descriptors:
*liver disease: DI, diagnosis
*liver disease: DT, drug therapy
*liver disease: ET, etiology
*liver disease: PC, prevention
*liver disease: SI, side effect

*liver disease: SU, surgery
*liver disease: TH, therapy
alcohol liver disease: DT, drug therapy
metabolic disorder: DI, diagnosis
metabolic disorder: DT, drug therapy
metabolic disorder: ET, etiology
liver toxicity: SI, side effect
cholestasis: ET, etiology
liver abscess: ET, etiology
hepatitis C: DT, drug therapy
hepatitis C: PC, prevention
hepatitis C: SU, surgery
autoimmune hepatitis: DI, diagnosis
autoimmune hepatitis: DT, drug therapy
liver cell carcinoma: DT, drug therapy
liver cell carcinoma: PC, prevention
portal hypertension
bleeding: CO, complication
bleeding: DT, drug therapy
bleeding: PC, prevention
bacterial peritonitis: CO, complication
bacterial peritonitis: DT, drug therapy
liver failure: ET, etiology
liver failure: TH, therapy
stem cell transplantation
virus hepatitis: DT, drug therapy
virus hepatitis: SU, surgery
liver transplantation
human
editorial
Drug Descriptors:
corticosteroid: CB, drug combination
corticosteroid: DT, drug therapy
troglitazone: AE, adverse drug reaction
2,4 thiazolidinedione derivative: AE, adverse drug reaction
trovafloxacin: AE, adverse drug reaction
quinoline derived antiinfective agent: AE, adverse drug reaction
reaction
cisapride: AE, adverse drug reaction
4 phenylbutyric acid: DT, drug therapy
4 phenylbutyric acid: PO, oral drug administration
azathioprine: CB, drug combination
azathioprine: DT, drug therapy
mycophenolic acid 2 morpholinoethyl ester: DT, drug therapy
hepatitis vaccine: DT, drug therapy
interferon: DT, drug therapy
beta adrenergic receptor blocking agent: DT, drug therapy
antibiotic agent: DT, drug therapy
cefotaxime: DT, drug therapy
paracetamol: TO, drug toxicity
nefazodone: AE, adverse drug reaction
bromfenac: AE, adverse drug reaction
immunosuppressive agent: DT, drug therapy
CAS REGISTRY NO.: (troglitazone) 97322-87-7; (trovafloxacin) 146836-84-2;
(cisapride) 81098-60-4; (azathioprine) 446-86-6;
(mycophenolic acid 2 morpholinoethyl ester) 116680-01-4,
128794-94-5; (cefotaxime) 63527-52-6, 64485-93-4;
(paracetamol) 103-90-2; (nefazodone) 82752-99-6,
83366-66-9; (bromfenac) **91714-94-2**

L82 ANSWER 39 OF 49 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2003:165352 BIOSIS

DOCUMENT NUMBER: PREV200300165352
 TITLE: Topical Ocular Delivery of Nepafenac Inhibits Preretinal
Neovascularization.
 AUTHOR(S): Bingaman, D. P. [Reprint Author]; Holt, K. [Reprint
 Author]; Kapin, M. A. [Reprint Author]
 CORPORATE SOURCE: Pharmaceutical Products Research, Alcon Research Ltd., Fort
 Worth, TX, USA
 SOURCE: ARVO Annual Meeting Abstract Search and Program Planner,
 (2002) Vol. 2002, pp. Abstract No. 3920. cd-rom.
 Meeting Info.: Annual Meeting of the Association For
 Research in Vision and Ophthalmology. Fort Lauderdale,
 Florida, USA. May 05-10, 2002.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 2 Apr 2003
 Last Updated on STN: 2 Apr 2003

ABSTRACT: Purpose: COX II activation has been implicated in ischemia-related
 VEGF upregulation and pathologic **angiogenesis**. Nepafenac, a
 topically delivered NSAID, has excellent corneal penetration. We investigated
 the utility of nepafenac against posterior segment **neovascularization**
 following topical ocular delivery in a rat OIR model. Methods: Preretinal
 neovascularization (NV) was produced in a rat model of oxygen-induced
 retinopathy (OIR) by modulating inspired oxygen levels between 50% & 10% from
 P0-P14 in neonatal rat pups, where 50% was maintained for 48 hours from P11-12.
 From P14-20, 4 litters of rat pups were removed into room air and each litter
 was randomized into 3 topical QID OU dosing groups, including vehicle (n=18
 pups), 0.1% nepafenac (n=23 pups), and 0.5% nepafenac (n=22 pups). At P20, all
 rats were euthanized and retinas were harvested, ADPase-stained, and prepared
 as flat mounts. Computerized image analysis was used to determine the median
 clockhours of preretinal NV per pup in each treatment group. Treatment group
 medians were compared via nonparametric analyses, where $P < 0.05$ was considered
 significant. Results: Topical ocular delivery of 0.1% nepafenac QID OU
 significantly inhibited preretinal NV by 55% in this rat OIR model as compared
 to vehicle ($P = 0.02$). Topical ocular delivery of 0.5% nepafenac appeared to
 decrease preretinal NV >30%, however, the difference was not significant. The
 preretinal NV scores per treatment group were as follows: vehicle = 3.75, 0.1%
 nepafenac = 1.7, and 0.5% nepafenac = 2.5. Conclusion: Nepafenac, a novel
 nonsteroidal antiinflammatory prodrug that has rapid corneal penetration, is
 able to inhibit ischemia-related preretinal NV following topical ocular dosing.
 The level of **antiangiogenic** activity provided by topical nepafenac is
 equivalent to a variety of agents tested in rodent OIR models through
 intravitreal and systemic routes of administration.

CONCEPT CODE: General biology - Symposia, transactions and proceedings
 00520
 Pathology - Therapy 12512
 Cardiovascular system - Physiology and biochemistry 14504
 Sense organs - Physiology and biochemistry 20004
 Pharmacology - General 22002

INDEX TERMS: Major Concepts
 Cardiovascular System (Transport and Circulation);
 Pharmacology; Sense Organs (Sensory Reception)
 INDEX TERMS: Parts, Structures, & Systems of Organisms
 retina: sensory system
 INDEX TERMS: Diseases
 oxygen-induced retinopathy
 INDEX TERMS: Diseases
 preretinal **neovascularization**
 INDEX TERMS: Chemicals & Biochemicals
 nepafenac: topical ocular delivery; oxygen
 INDEX TERMS: Methods & Equipment
 computerized image analysis: imaging and microscopy

techniques, laboratory techniques
ORGANISM: Classifier
Muridae 86375
Super Taxa
Rodentia; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
rat (common): neonate
Taxa Notes
Animals, Chordates, Mammals, Nonhuman Vertebrates,
Nonhuman Mammals, Rodents, Vertebrates
REGISTRY NUMBER: 78281-72-8 (nepafenac)
7782-44-7 (oxygen)

L82 ANSWER 40 OF 49 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2003:154861 BIOSIS

DOCUMENT NUMBER: PREV200300154861

TITLE: Studies of the Effect and Mechanism of Action of Topical
Nepafenac in a Rat Model of ROP.

AUTHOR(S): Penn, J. S. [Reprint Author]; Qi, X. [Reprint Author];
Percinel, P. A. [Reprint Author]; Rajaratnam, V. S.
[Reprint Author]; Bingaman, D. P.

CORPORATE SOURCE: Ophthalmology and Visual Sciences, Vanderbilt Univ School
of Med, Nashville, TN, USA

SOURCE: ARVO Annual Meeting Abstract Search and Program Planner,
(2002) Vol. 2002, pp. Abstract No. 2741. cd-rom.
Meeting Info.: Annual Meeting of the Association For
Research in Vision and Ophthalmology. Fort Lauderdale,
Florida, USA. May 05-10, 2002.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 26 Mar 2003

Last Updated on STN: 26 Mar 2003

ABSTRACT: Purpose: To investigate the angiostatic potential of Nepafenac, or 2-amino-3-benzoylbenzeneacetamide, and its mechanism of action using well-established in vitro and in vivo systems. As a prodrug, the topical NSAID Nepafenac has rapid corneal penetration, and it is metabolized to a potent cyclo-oxygenase (COX I & II) inhibitor, AL-6295A. Methods: Bovine retinal microvascular endothelial cells (BRMEC) were used at 6th passage in VEGF-stimulated proliferation and tube formation assays. In addition, preretinal **neovascularization** (NV) was produced in rat pups maintained from birth in a variable oxygen atmosphere for 14 days and then removed to room air for up to 6 days before euthanasia (Penn et al, 2001; IOVS, 42:283-290). Starting 1 day prior to removal to room air, some rats received topical QID OU delivery of 0.1% Nepafenac or vehicle (0.5% carbopol, 2.4% mannitol, 0.1% tyloxapol in water). Retinas were harvested at 1, 2, 4, and 6 days post-exposure for retinal VEGF measurement by ELISA. In other rats, topical QID OU delivery of 0.1% Nepafenac, vehicle, or two marketed NSAIDs, 0.5% ketorolac tromethamine or 0.1% diclofenac, was administered from P14-19. Retinas were harvested at P20 for assessment of preretinal NV. Results: Nepafenac showed no significant effect on VEGF-stimulated BRMEC proliferation or tube formation at concentrations between 0.1-10µM. Its metabolite, AL-6295A, significantly inhibited both proliferation and tube formation in a potent, dose-dependent manner. In the rat ROP model, 0.1% Nepafenac caused a 56% inhibition of preretinal NV (p = 0.0292) as compared to vehicle, and the two marketed NSAIDs had no effect. Topical ocular delivery of 0.1% Nepafenac marginally inhibited retinal VEGF protein levels only at P18 (p = 0.0498). Conclusion: COX activity is suspected to provide regulation of ***angiogenesis*** in colon **cancer** and Alzheimer's disease. This is the first evidence of COX inhibition preventing ocular **angiogenesis** in an animal model. Our VEGF ELISA results suggest that the mechanism by which Nepafenac/AL-6295A inhibits NV is primarily downstream of VEGF, but additional

experiments are in progress to further elucidate the link between COX activity and ischemia-induced preretinal NV. Nepafenac is formulated for topical ocular delivery, which restricts its angiostatic action to the eye and may eliminate the systemic toxicity that has limited the clinical utility of other ***antiangiogenic*** agents.

CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Pathology - Therapy 12512
Sense organs - Physiology and biochemistry 20004
Sense organs - Pathology 20006
Pharmacology - General 22002
Pharmacology - Connective tissue, bone and collagen-acting drugs 22012
Pharmacology - Immunological processes and allergy 22018
Development and Embryology - Pathology 25503

INDEX TERMS: Major Concepts
Pharmacology; Sense Organs (Sensory Reception)

INDEX TERMS: Parts, Structures, & Systems of Organisms
cornea: sensory system; retina: sensory system

INDEX TERMS: Diseases
preretinal **neovascularization**: eye disease

INDEX TERMS: Diseases
retinitis pigmentosa: congenital disease, eye disease
Retinitis Pigmentosa (MeSH)

INDEX TERMS: Chemicals & Biochemicals
nepafenac [2-amino-3-benzoylbenzeneacetamide]:
antiinflammatory-drug, immunologic-drug, mechanism of
action, topical administration

ORGANISM: Classifier
Bovidae 85715
Super Taxa
Artiodactyla; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
BRMEC cell line (cell line): bovine retinal
microvascular endothelial cells
Taxa Notes
Animals, Artiodactyls, Chordates, Mammals, Nonhuman
Vertebrates, Nonhuman Mammals, Vertebrates

ORGANISM: Classifier
Muridae 86375
Super Taxa
Rodentia; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
rat (common): animal model
Taxa Notes
Animals, Chordates, Mammals, Nonhuman Vertebrates,
Nonhuman Mammals, Rodents, Vertebrates

REGISTRY NUMBER: 78281-72-8 (nepafenac)
78281-72-8 (2-amino-3-benzoylbenzeneacetamide)

L82 ANSWER 41 OF 49 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2003:143039 BIOSIS

DOCUMENT NUMBER: PREV200300143039

TITLE: Topical Nepafenac Inhibits Ocular
Neovascularization.

AUTHOR(S): Takahashi, K. [Reprint Author]; Saishin, Y. [Reprint
Author]; Mori, K. [Reprint Author]; Ando, A. [Reprint
Author]; Yamamoto, S. [Reprint Author]; Oshima, Y. [Reprint
Author]; Nambu, H. [Reprint Author]; Bingamen, D.;
Campochiaro, P. A. [Reprint Author]

CORPORATE SOURCE: Wilmer Eye Institute, Johns Hopkins University School of
Medicine, Baltimore, MD, USA

SOURCE: ARVO Annual Meeting Abstract Search and Program Planner, (2002) Vol. 2002, pp. Abstract No. 1268. cd-rom.
Meeting Info.: Annual Meeting of the Association For Research in Vision and Ophthalmology. Fort Lauderdale, Florida, USA. May 05-10, 2002.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 19 Mar 2003
Last Updated on STN: 19 Mar 2003

ABSTRACT: Purpose: Topical Nepafenac readily penetrates the cornea and is metabolized to a potent cyclo-oxygenase-1 (COX-1) and COX-2 inhibitor, AL-6295A. In this study we tested the effect of topical nepafenac in two murine models of ocular **neovascularization** (NV). Methods: A masked trial was performed to compare the topical effects of vehicle with one of several concentrations of nepafenac (0.01, 0.03, 0.1, or 0.5%), 0.1% diclofenac, or 0.5% ketorolac tromethamine in mice with oxygen-induced ischemic retinopathy or mice with choroidal NV (CNV) due to laser-induced rupture of Bruch's membrane. Mice with ischemic retinopathy were given one drop four times a day between P12 and P17 and then preretinal NV was measured by image analysis. Starting one day after rupture of Bruch's membrane, mice were treated for two weeks with one drop 4 times a day and then the amount of CNV at each rupture site was measured. Results: Mice treated with 0.1% (n=16) or 0.5% (n=16) nepafenac had significantly less CNV (0.0072+-0.0012 mm2, p=0.0037 and 0.0074+-0.0015 mm2, p=0.0029, respectively) than vehicle-treated mice (0.0254+-0.0060 mm2). In the ischemic retinopathy model, compared to vehicle-treated mice (n=7) in which the average area of preretinal NV was 0.0444+-0.0079 mm2, mice treated with 0.1% (n=9) or 0.5% (n=13) nepafenac had significantly less preretinal NV (0.0165+-0.0029 mm2, p=0.0011 and 0.0186+-0.0043 mm2, p=0.0075). In additional studies, compared to vehicle-treated mice (CNV = 0.0279+-0.0076 mm2), mice treated with 0.1% or 0.03% nepafenac had significantly less CNV (0.0181+-0.0033 and 0.0133+-0.0017 mm2, respectively) whereas eyes treated with 0.1% diclofenac had no significant difference (0.0232+-0.0038 mm2, p=0.72). Mice treated with 0.5% ketorolac tromethamine for 14 days had high mortality, but when evaluated after 7 days of treatment showed no difference from mice treated with vehicle for 7 days.

Conclusion: Topical nepafenac inhibits ocular NV.

CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Biochemistry studies - General 10060
Pathology - Therapy 12512
Cardiovascular system - Physiology and biochemistry 14504
Sense organs - Physiology and biochemistry 20004
Sense organs - Pathology 20006
Pharmacology - General 22002
Pharmacology - Sense organs, associated structures and functions 22031

INDEX TERMS: Major Concepts
Cardiovascular System (Transport and Circulation);
Pharmacology; Sense Organs (Sensory Reception)

INDEX TERMS: Parts, Structures, & Systems of Organisms
cornea: sensory system; eye: sensory system

INDEX TERMS: Diseases
ocular **neovascularization**: eye disease

INDEX TERMS: Diseases
oxygen-induced ischemic retinopathy: eye disease

INDEX TERMS: Chemicals & Biochemicals
diclofenac: enzyme inhibitor-drug; ketorolac
tromethamine: enzyme inhibitor-drug; nepafenac:
ophthalmic-drug

REGISTRY NUMBER: 15307-86-5 (diclofenac)
74103-07-4 (ketorolac tromethamine)

78281-72-8 (nepafenac)

L82 ANSWER 42 OF 49 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 1998:249541 BIOSIS
DOCUMENT NUMBER: PREV199800249541
TITLE: Bromfenac, BAC and placebo in tension-type headache.
AUTHOR(S): Diamond, S. [Reprint author]; Freitag, F.; Vavra, I.
CORPORATE SOURCE: Diamond Headache Clinic, Chicago, IL, USA
SOURCE: Clinical Pharmacology and Therapeutics, (Feb., 1998) Vol. 63, No. 2, pp. 142. print.
Meeting Info.: Ninety-ninth Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. New Orleans, Louisiana, USA. March 30-April 1, 1998. American Society for Clinical Pharmacology and Therapeutics.
CODEN: CLPTAT. ISSN: 0009-9236.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 4 Jun 1998
Last Updated on STN: 4 Jun 1998
CONCEPT CODE: Pharmacology - Neuropharmacology 22024
Nervous system - Pathology 20506
General biology - Symposia, transactions and proceedings 00520
Biochemistry studies - General 10060
INDEX TERMS: Major Concepts
Neurology (Human Medicine, Medical Sciences);
Pharmacology
INDEX TERMS: Diseases
tension-type headache: nervous system disease
Tension Headache (MeSH)
INDEX TERMS: Chemicals & Biochemicals
bromfenac: **antineoplastic-drug**; BAC
[butalbital/aspirin/caffeine]: analgesic-drug
INDEX TERMS: Miscellaneous Descriptors
Meeting Abstract; Meeting Poster
ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
REGISTRY NUMBER: 91714-94-2 (bromfenac)
50-78-2 (ASPIRIN)
58-08-2 (CAFFEINE)

L82 ANSWER 43 OF 49 TOXCENTER COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:52219 TOXCENTER
COPYRIGHT: Copyright 2004 ACS
DOCUMENT NUMBER: CA13610156464S
TITLE: Therapeutic polyesters and polyamides
AUTHOR(S): Uhrich, Kathryn E.
CORPORATE SOURCE: ASSIGNEE: Rutgers, the State University of New Jersey
PATENT INFORMATION: WO 2002009768 A2 7 Feb 2002
SOURCE: (2002) PCT Int. Appl., 51 pp.
CODEN: PIXXD2.
COUNTRY: UNITED STATES
DOCUMENT TYPE: Patent

FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2002:107167
LANGUAGE: English
ENTRY DATE: Entered STN: 20020226
Last Updated on STN: 20020313

ABSTRACT:

Polymers (i.e. polyesters, polyamides, and polythioesters or a mixt. thereof) which degrade hydrolytically into biol. active compds. are provided. Methods of producing these polymers, intermediates useful for prepg. these polymers, and methods of using these polymers to deliver biol. active compds. to a host are also provided. The biol. active compd. is a non-steroidal anti-inflammatory drug, antibacterial, antifungal, anticancer, antithrombotic, immunosuppressant, or analgesic. For example, morphine was copolymerized with a diacid chloride to provide a polyester.

CLASSIFICATION CODE: 63-6

SUPPLEMENTARY TERMS: Miscellaneous Descriptors

polyamide polyester polythioester prepn hydrolysis
prodrug; drug polymer conjugate prepn hydrolysis prodrug

REGISTRY NUMBER: 51-61-6 (Dopamine)
57-27-2 (Morphine)
59-05-2 (Methotrexate)
89-57-6 (5-Aminosalicylic acid)
20830-81-3 (Daunorubicin)
23214-92-8 (Doxorubicin)
24280-93-1 (Mycophenolic acid)
65589-70-0 (Acriflavine)
51-61-6Q (Dopamine, polymers with diacid chlorides)
57-27-2Q (Morphine, polymers with diacid chlorides)
59-05-2Q (Methotrexate, polymers with diacid chlorides)
89-57-6Q (5-Aminosalicylic acid, polymers with diacid chlorides)
20830-81-3Q (Daunorubicin, polymers with diacid chlorides)
22803-06-1Q (2,7-Anthracenediamine, polymers with diacid chlorides)
23214-92-8Q (Doxorubicin, polymers with diacid chlorides)
24280-93-1Q (Mycophenolic acid, polymers with diacid chlorides)
50-07-7 (Mitomycin C)
50-44-2 (6-Mercaptopurine)
50-91-9 (Floxuridine)
53-79-2 (Puromycin)
56-75-7 (Chloramphenicol)
57-22-7 (Vincristine)
57-62-5 (Chlortetracycline)
57-92-1 (Streptomycin)
59-01-8 (Kanamycin)
60-54-8 (Tetracycline)
61-24-5 (Cephalosporin C)
61-68-7 (Mefenamic acid)
66-76-2 (Dicoumarol)
69-33-0 (Tubercidin)
69-53-4 (Ampicillin)
69-72-7 (Salicylic acid)
76-41-5 (Oxymorphone)
79-57-2 (Oxytetracycline)
80-03-5 (Acediasulfone)
80-08-0 (Dapsone)
80-80-8 (Acetosulfone)
87-21-8 (Piridocaine)
87-28-5 (Glycol salicylate)
89-38-3 (Pteropterin)
90-01-7 (Salicyl alcohol)

103-12-8 (Sulfamidochrysoidine)
104-29-0 (Chlorphenesin)
113-73-5 (Gramicidin S)
114-07-8 (Erythromycin)
115-02-6 (Azaserine)
119-59-5 (4,4'-Sulfinyldianiline)
121-57-3 (Sulfanilic acid)
127-33-3 (Demeclocycline)
128-46-1 (Dihydrostreptomycin)
133-65-3 (Solasulfone)
144-76-3 (Sulfoxone)
147-94-4 (Cytarabine)
148-82-3 (Melphalan)
154-21-2 (Lincomycin)
154-42-7 (Thioguanine)
157-03-9 (6-Diazo-5-oxo-L-norleucine)
320-67-2 (Azacitidine)
473-30-3 (Thiazolsulfone)
485-41-6 (Sulfachrysoidine)
488-41-5 (Mitobronitol)
490-79-9 (Gentisic acid)
490-98-2 (Hydroxytetracaine)
493-75-4 (Bialamicol)
525-94-0 (Penicillin N)
530-78-9 (Flufenamic acid)
536-25-4 (Orthocaine)
548-00-5 (Ethyl biscoumacetate)
552-94-3 (Salsalate)
554-18-7 (Glucosulfone)
564-25-0 (Doxycycline)
576-68-1 (Mannomustine)
589-44-6 (3-Amino-4-hydroxybutyric acid)
599-79-1 (Sulfasalazine)
644-62-2 (Meclofenamic acid)
657-24-9 (Metformin)
671-16-9 (Procarbazine)
738-70-5 (Trimethoprim)
751-97-3 (Rolitettracycline)
808-26-4 (Sancycline)
865-21-4 (Vinblastine)
914-00-1 (Methacycline)
992-21-2 (Lymecycline)
1066-17-7 (Colistin)
1110-80-1 (Pipacycline)
1181-54-0 (Clomocycline)
1392-21-8 (Leucomycin)
1393-48-2 (Thiostrepton)
1397-89-3 (Amphotericin B)
1400-61-9 (Nystatin)
1403-17-4 (Candicidin)
1403-66-3 (Gentamicin)
1404-00-8 (Mitomycin)
1404-04-2 (Neomycin)
1404-15-5 (Nogalamycin)
1404-19-9 (Oligomycin)
1404-55-3 (Ristocetin)
1404-90-6 (Vancomycin)
1405-87-4 (Bacitracin)
1405-97-6 (Gramicidin)
1406-11-7 (Polymyxin)
1596-63-0 (Quinacillin)
1695-77-8 (Spectinomycin)

2013-58-3 (Meclocycline)
2090-89-3 (Butethamine)
2188-67-2 (Naepaine)
2315-08-4 (Salazosulfadimidine)
2316-64-5 (Bromosaligenin)
2750-76-7 (Rifamide)
3094-09-5 (Doxifluridine)
3485-14-1 (Cyclacillin)
3511-16-8 (Hetacillin)
3577-01-3 (Cephaloglycin)
3583-64-0 (Bumadizon)
3922-90-5 (Oleandomycin)
3930-19-6 (Streptonigrin)
4291-63-8 (Cladribine)
4366-18-1 (Coumetarol)
4393-19-5 (p-Sulfanilylbenzylamine)
4394-00-7 (Niflumic acid)
4564-87-8 (Carbomycin)
4697-36-3 (Carbenicillin)
4803-27-4 (Anthramycin)
5581-52-2 (Thiamiprine)
5934-14-5 (Succisulfone)
5964-62-5 (Diathymosulfone)
6202-21-7 (4-Sulfanilamidosalicylic acid)
6834-98-6 (Fungichromin)
6998-60-3 (Rifamycin SV)
7681-93-8 (Natamycin)
8025-81-8 (Spiramycin)
10118-90-8 (Minocycline)
10318-26-0 (Mitolactol)
11003-38-6 (Capreomycin)
11006-70-5 (Olivomycin)
11015-37-5 (Bambermycin)
11056-06-7 (Bleomycin)
11075-36-8 (Tuberactinomycin)
11078-21-0 (Filipin)
11120-15-3 (Dermostatin)
11121-32-7 (Mepartricin)
12650-69-0 (Mupirocin)
12772-35-9 (Butirosin)
13058-67-8 (Lucensomycin)
13292-46-1 (Rifampin)
13665-88-8 (Mopidamol)
13710-19-5 (Tolfenamic acid)
13838-08-9 (Azidamfenicol)
15307-86-5 (Diclofenac)
15318-45-3 (Thiamphenicol)
15599-51-6 (Apicycline)
15686-71-2 (Cephalexin)
15722-48-2 (Olsalazine)
16545-11-2 (Guamecycline)
16846-24-5 (Josamycin)
18323-44-9 (Clindamycin)
18378-89-7 (Plicamycin)
18471-20-0 (Ditazol)
18559-94-9 (Albuterol)
18883-66-4 (Streptozocin)
20594-83-6 (Nalbuphine)
21679-14-1 (Fludarabine)
22006-84-4 (Denopterin)
22494-42-4 (Diflunisal)
22619-35-8 (Tioclomarol)

23049-93-6 (Enfenamic acid)
23249-97-0 (Procodazole)
25546-65-0 (Ribostamycin)
26774-90-3 (Epicillin)
26787-78-0 (Amoxicillin)
29069-24-7 (Prednimustine)
29767-20-2 (Teniposide)
30516-87-1 (Zidovudine)
30544-47-9 (Etofenamate)
31698-14-3 (Ancitabine)
32385-11-8 (Sisomicin)
32986-56-4 (Tobramycin)
33069-62-4 (Paclitaxel)
33103-22-9 (Enviomycin)
33419-42-0 (Etoposide)
33996-33-7 (Oxaceprol)
34444-01-4 (Cefamandole)
34493-98-6 (Dibekacin)
34616-39-2 (Fenalcomine)
34787-01-4 (Ticarcillin)
35457-80-8 (Midecamycin)
36981-91-6 (Fepradinol)
37321-09-8 (Apramycin)
37517-28-5 (Amikacin)
38821-53-3 (Cephradine)
39718-89-3 (Alminoprofen)
41340-25-4 (Etodolac)
41575-94-4 (Carboplatin)
42408-82-2 (Butorphanol)
50370-12-2 (Cefadroxil)
50935-04-1 (Carubicin)
51025-85-5 (Arbekacin)
51333-22-3 (Budesonide)
51384-51-1 (Metoprolol)
51579-82-9 (Amfenac)
51627-14-6 (Cefatrizine)
51762-05-1 (Cefroxadine)
51940-44-4 (Pipemidic acid)
52093-21-7 (Micronomicin)
52128-35-5 (Trimetrexate)
52443-21-7 (Glucametacin)
52485-79-7 (Buprenorphine)
53123-88-9 (Sirolimus)
53597-27-6 (Fendosal)
53643-48-4 (Vindesine)
53714-56-0 (Leuprolide)
53716-49-7 (Carprofen)
53808-87-0 (Tetroxoprim)
53910-25-1 (Pentostatin)
53994-73-3 (Cefaclor)
54083-22-6 (Zorubicin)
54749-90-5 (Chlorozotocin)
55726-47-1 (Enocitabine)
56391-56-1 (Netilmicin)
56420-45-2 (Epirubicin)
56518-41-3 (Brodinoprim)
56824-20-5 (Amiprilose)
58152-03-7 (Isepamicin)
58337-35-2 (Elliptinium)
58957-92-9 (Idarubicin)
58970-76-6 (Ubenimex)
58994-96-0 (Ranimustine)

REGISTRY NUMBER:

59277-89-3 (Acyclovir)
60925-61-3 (Ceforanide)
61036-62-2 (Teicoplanin)
61270-58-4 (Cefonicid)
61379-65-5 (Rifapentine)
61622-34-2 (Cefotiam)
62013-04-1 (Dirithromycin)
62327-61-1 (Perimycin A)
62571-86-2 (Captopril)
62893-19-0 (Cefoperazone)
63358-49-6 (Aspoxicillin)
63469-19-2 (Apalcillin)
63527-52-6 (Cefotaxime)
64221-86-9 (Imipenem)
64952-97-2 (Moxalactam)
65002-17-7 (Bucillamine)
65052-63-3 (Cefetamet)
65085-01-0 (Cefmenoxime)
65271-80-9 (Mitoxantrone)
66148-78-5 (Temocillin)
66357-35-5 (Ranitidine)
66376-36-1 (Alendronate)
66676-88-8 (Aclacinomycin)
68247-85-8 (Peplomycin)
69712-56-7 (Cefotetan)
69739-16-8 (Cefodizime)
70052-12-9 (Eflornithine)
70458-96-7 (Norfloxacin)
70797-11-4 (Cefpiramide)
71426-83-0 (Fortimicin)
71486-22-1 (Vinorelbine)
71628-96-1 (Menogaril)
72496-41-4 (Pirarubicin)
72558-82-8 (Ceftazidime)
72732-56-0 (Piritrexim)
73384-59-5 (Ceftriaxone)
74011-58-8 (Enoxacin)
74014-51-0 (Rokitamycin)
74863-84-6 (Argatroban)
74913-06-7 (Chromomycin)
75607-67-9 (Fludarabine phosphate)
75847-73-3 (Enalapril)
76547-98-3 (Lisinopril)
76610-84-9 (Cefbuperazone)
76824-35-6 (Famotidine)
76963-41-2 (Nizatidine)
78110-38-0 (Aztreonam)
78113-36-7 (Romurtide)
78919-13-8 (Iloprost)
79217-60-0 (Cyclosporin)
79350-37-1 (Cefixime)
80214-83-1 (Roxithromycin)
80576-83-6 (Edatrexate)
80621-81-4 (Rifaximin)
81093-37-0 (Pravastatin)
81103-11-9 (Clarithromycin)
82009-34-5 (Cilastatin)
82219-78-1 (Cefuzonam)
82547-58-8 (Cefteram)
83905-01-5 (Azithromycin)
84305-41-9 (Cefminox)
84420-34-8 (Paromomycin)

84845-57-8 (Ritipenem)
84880-03-5 (Cefpimizole)
84957-29-9 (Cefpirome)
85441-61-8 (Quinapril)
85721-33-1 (Ciprofloxacin)
86541-75-5 (Benazepril)
87638-04-8 (Carumonam)
87726-17-8 (Panipenem)
88040-23-7 (Cefepime)
88669-04-9 (Trospectomycin)
89365-50-4 (Salmeterol)
89796-99-6 (Aceclofenac)
91714-94-2 (Bromfenac)
91832-40-5 (Cefdinir)
92665-29-7 (Cefprozil)
93957-54-1 (Fluvastatin)
95058-81-4 (Gemcitabine)
96036-03-2 (Meropenem)
97519-39-6 (Ceftibuten)
98079-51-7 (Lomefloxacin)
98629-43-7 (Gusperimus)
99665-00-6 (Flomoxef)
100490-36-6 (Tosufloxacin)
102507-71-1 (Tigemonam)
104145-95-1 (Cefditoren)
104987-11-3 (Tacrolimus)
105239-91-6 (Cefclidin)
105956-97-6 (Clinafloxacin)
106486-76-4 (Carzinophillin A)
108319-06-8 (Temaefloxacin)
108945-35-3 (Taprostene)
110871-86-8 (Sparfloxacin)
113359-04-9 (Cefozopran)
113441-12-6 (Primycin)
114977-28-5 (Docetaxel)
119914-60-2 (Grepafloxacin)
120410-24-4 (Biapenem)
123948-87-8 (Topotecan)
124858-35-1 (Nadifloxacin)
127045-41-4 (Pazufloxacin)
134523-00-5 (Atorvastatin)
134678-17-4 (Lamivudine)
144412-49-7 (Lamifiban)
144494-65-5 (Tirofiban)
147059-72-1 (Trovaefloxacin)
150378-17-9 (Indinavir)
154361-50-9 (Capecitabine)
REGISTRY NUMBER: 80-02-4; 1508-45-8; 1821-16-5; 14376-16-0; 29908-03-0;
35834-26-5; 112887-68-0

L82 ANSWER 44 OF 49 TOXCENTER COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:161772 TOXCENTER
COPYRIGHT: Copyright 2004 ACS
DOCUMENT NUMBER: CA13705068177R
TITLE: Compositions comprising cyclodextrins and NO-releasing
drugs
AUTHOR(S): Naggi, Annamaria; Torri, Gian Giacomo; Trespidi, Laura
CORPORATE SOURCE: ASSIGNEE: Nicox S.A.
PATENT INFORMATION: EP 1219306 A1 3 Jul 2002
SOURCE: (2002) Eur. Pat. Appl., 48 pp.
CODEN: EPXXDW.
COUNTRY: FRANCE

DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2002:503335
LANGUAGE: English
ENTRY DATE: Entered STN: 20020723
Last Updated on STN: 20020730

ABSTRACT:

The present invention relates to compn. comprising cyclodextrins and a NO-releasing drug of formula A-X-L-NO_n (A = radical deriving from a drug; X = divalent radical connecting A with the NO-releasing group L-NO_n; L = O, S, NH; n = 1, 2). Cyclodextrins (CDs) are selected from .alpha.-CD, .beta.-CD, .gamma.-CD, dimethyl-.alpha.-CD, dimethyl-b-CD, dimethyl-.gamma.-CD, etc., and the drug is selected from NSAIDs, analgesics, antibacterials, antivirals, steroids, **antineoplastics**, .beta.-adrenergic agonists and blockers, antihyperlipoproteinemics, and bone resorption inhibitors. For example, three compns. contg. 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (I) were prepd.: F1 contained 1.470 g of .alpha.-CD and 0.500 g of I mixed in water and then dried; F2 contained 1.470 g of .alpha.-CD and 0.500 g of I mixed in ethanol/water and then dried; and F3 contained 2.000 g of dimethyl-.beta.-CD and 0.500 g of I mixed in water and then dried; F0 represents the comparative formula contg. I alone. Inhibition of contraction of aortic rings obtained was 54% for F1, 59% for F2, 61% for F3, and 19% for F0.

CLASSIFICATION CODE: 63-6

SUPPLEMENTARY TERMS: Miscellaneous Descriptors
nitric oxide releasing drug cyclodextrin delivery system

REGISTRY NUMBER: 10102-43-9 (Nitric oxide)
50-78-2 (Aspirin)
53-86-1 (Indomethacin)
57-55-6Q (1,2-Propanediol, ethers with .beta.-cyclodextrin)
61-68-7 (Mefenamic acid)
69-72-7 (Salicylic acid)
87-28-5 (Glycol salicylate)
89-57-6 (Mesalamine)
103-90-2 (Paracetamol)
129-20-4 (Oxyphenbutazone)
487-48-9 (Salacetamide)
504-63-2Q (1,3-Propanediol, ethers with .beta.-cyclodextrin)
515-69-5 (.alpha.-Bisabolol)
530-75-6 (Acetylsalicylsalicylic acid)
530-78-9 (Flufenamic acid)
552-94-3 (Salsalate)
644-62-2 (Meclofenamic acid)
959-10-4 (Xenbucin)
2055-44-9 (Perisoxal)
2316-64-5 (Bromosaligenin)
4394-00-7 (Niflumic acid)
5104-49-4 (Flurbiprofen)
5728-52-9 (Felbinac)
7585-39-9 (.beta.-Cyclodextrin)
7585-39-9Q (.beta.-Cyclodextrin, ethers with propanediol)
10016-20-3 (.alpha.-Cyclodextrin)
12619-70-4Q (Cyclodextrin, polymers)
13710-19-5 (Tolfenamic acid)
13799-03-6 (Protizinic acid)
13993-65-2 (Metiazinic acid)
15307-86-5 (Diclofenac)
15687-27-1 (Ibuprofen)
15722-48-2 (Olsalazine)
17465-86-0 (.gamma.-Cyclodextrin)
17969-20-9 (Fenclozic acid)

18046-21-4 (Fentiazac)
18471-20-0 (Ditazol)
20168-99-4 (Cinmetacin)
20187-55-7 (Bendazac)
21256-18-8 (Oxaprozin)
22071-15-4 (Ketoprofen)
22131-79-9 (Alclofenac)
22204-53-1 (Naproxen)
22494-42-4 (Diflunisal)
23049-93-6 (Enfenamic acid)
24237-54-5 (Tinoridine)
25395-22-6 (Salicylamide O-acetic acid)
26171-23-3 (Tolmetin)
27470-51-5 (Suxibuzone)
29679-58-1 (Fenoprofen)
30544-47-9 (Etofenamate)
30653-83-9 (Parsalmide)
31793-07-4 (Pirprofen)
31842-01-0 (Indoprofen)
32527-55-2 (Tiaramide)
32808-51-8 (Bucloxic acid)
33005-95-7 (Tiaprofenic acid)
33369-31-2 (Zomepirac)
33996-33-7 (Oxaceprol)
34148-01-1 (Clidanac)
34552-84-6 (Isoxicam)
36322-90-4 (Piroxicam)
36330-85-5 (Fenbufen)
36981-91-6 (Fepradinol)
38194-50-2 (Sulindac)
38677-85-9 (Flunixin)
39718-89-3 (Alminoprofen)
40828-46-4 (Suprofen)
41340-25-4 (Etodolac)
42779-82-8 (Clopirac)
50270-33-2 (Isofezolac)
51166-71-3 (Dimethyl-.beta.-cyclodextrin)
51579-82-9 (Amfenac)
52443-21-7 (Glucametacin)
52549-17-4 (Pranoprofen)
53164-05-9 (Acemetacin)
53597-27-6 (Fendosal)
53648-05-8 (Ibuproxam)
53716-49-7 (Carprofen)
55216-11-0 (Trimethyl-.beta.-cyclodextrin)
55453-87-7 (Isoxepac)
55837-18-8 (Butibufen)
56187-89-4 (Ximoprofen)
59804-37-4 (Tenoxicam)
65189-78-8 (Tropesin)
66934-18-7 (Flunoxaprofen)
68767-14-6 (Loxoprofen)
69956-77-0 (CS-670)
70374-39-9 (Lornoxicam)
71002-09-0 (Pirazolac)
71125-38-7 (Meloxicam)
74103-06-3 (Ketorolac)
74711-43-6 (Zaltoprofen)
76145-76-1 (Tomoxiprole)
78499-27-1 (Bermoprofen)
78828-92-9 (Dimethyl-.gamma.-cyclodextrin)
78967-07-4 (Mofezolac)

89796-99-6 (Aceclofenac)
91714-94-2 (Bromfenac)
114716-16-4 (Pemedolac)
120210-48-2 (Tenidap)
REGISTRY NUMBER: 158836-71-6; 175033-36-0; 51166-72-4; 68715-56-0;
99450-52-9; 110934-22-0

L82 ANSWER 45 OF 49 TOXCENTER COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:85088 TOXCENTER
COPYRIGHT: Copyright 2004 ACS
DOCUMENT NUMBER: CA13413178396G
TITLE: Synthesis, activity and formulations of pharmaceutical
compounds for treatment of oxidative stress and/or
endothelial dysfunction
AUTHOR(S): Del Soldato, Piero
CORPORATE SOURCE: ASSIGNEE: Nicox S.A.
PATENT INFORMATION: WO 2001012584 A2 22 Feb 2001
SOURCE: (2001) PCT Int. Appl., 94 pp.
CODEN: PIXXD2.
COUNTRY: FRANCE
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2001:137173
LANGUAGE: English
ENTRY DATE: Entered STN: 20011116
Last Updated on STN: 20030819

ABSTRACT:

Compds. or their salts of general formula (I): A-B-N(O)s wherein: s is an integer equal to 1 or 2; A = R-T1-, wherein R is the drug radical and T1 = (CO)t or (X)t', wherein X = O, S, NR1c, R1c is H or a linear or branched alkyl or a free valence, t and t' are integers and equal to zero or 1, with the proviso that t = 1 when t' = 0; t = 0 when t' = 1; B = -TB -X2-O- wherein TB = (CO) when t = 0, TB = X when t' = 0, X being as above defined; X2, bivalent radical, is such that the precursor drug of A and the precursor of B meet resp. the pharmacol. tests described in the description. Synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.

CLASSIFICATION CODE: 26-1

SUPPLEMENTARY TERMS: Miscellaneous Descriptors
pharmaceutical compd prepn oxidative stress treatment;
endothelial dysfunction treatment pharmaceutical compd
prepn; precursor antiinflammatory analgesic bronchodilator
expectorant; antiasthmatic antihistaminic ACE inhibitor
beta blocker precursor; antithrombotic vasodilator
antidiabetic antitumor antiulcer precursor;
antihyperlipidemic antibiotic antiviral antidementia
precursor; bone resorption inhibitor precursor

REGISTRY NUMBER: 34661-75-1 (Urapidil)
62571-86-2 (Captopril)
74258-86-9 (Alacepril)
76420-72-9 (Enalaprilat)
76547-98-3 (Lisinopril)
82834-16-0 (Perindopril)
83435-66-9 (Delapril)
83647-97-6 (Spirapril)
85441-61-8 (Quinapril)
85856-54-8 (Moveltipril)
86541-75-5 (Benazepril)
87333-19-5 (Ramipril)
87679-37-6 (Trandolapril)
88768-40-5 (Cilazapril)

89371-37-9 (Imidapril)
98048-97-6 (Fosinopril)
111223-26-8 (Ceronapril)
111902-57-9 (Temocapril)
114798-26-4 (Losartan)
50-33-9 (Phenylbutazone)
57-27-2 (Morphine)
76-41-5 (Oxymorphone)
76-42-6 (Oxycodone)
76-57-3 (Codeine)
76-58-4 (Ethylmorphine)
77-07-6 (Levorphanol)
94-10-0 (Ethoxazene)
97-53-0 (Eugenol)
103-97-9 (Phenocoll)
118-55-8 (Phenyl salicylate)
118-57-0 (Acetaminosalol)
125-29-1 (Hydrocodone)
127-35-5 (Phenazocine)
132-60-5 (Cinchophen)
138-52-3 (Salicin)
143-52-2 (Metopon)
144-14-9 (Anileridine)
326-43-2 (Phenylramidol hydrochloride)
359-83-1 (Pentazocine)
404-86-4 (Capsaicine)
427-00-9 (Desomorphine)
466-97-7 (Normorphine)
466-99-9 (Hydromorphone)
468-56-4 (Hydroxypethidine)
486-79-3 (Dipyracetyl)
509-60-4 (Dihydromorphine)
530-75-6 (Acetylsalicylsalicylic acid)
539-08-2 (p-Lactophenetide)
545-90-4 (Dimepheptanol)
562-26-5 (Phenoperidine)
639-48-5 (Nicomorphine)
1083-57-4 (Bucetin)
1531-12-0 (Norlevorphanol)
1553-60-2 (Ibufenac)
3567-76-8 (Aminochlorthenoxazin)
3734-52-9 (Metazocine)
3820-67-5 (Glafeine)
6064-83-1 (Fosfosal)
13739-02-1 (Diacerein)
14297-87-1 (Benzyl morphine)
17737-65-4 (Clonixin)
18699-02-0 (Actarit)
20594-83-6 (Nalbuphine)
23779-99-9 (Floctafenine)
25803-14-9 (Clometacin)
27203-92-5 (Tramadol)
42408-82-2 (Butorphanol)
51234-28-7 (Benoxaprofen)
52485-79-7 (Buprenorphine)
53648-55-8 (Dezocine)
54340-58-8 (Meptazinol)
63269-31-8 (Ciramadol)
65110-93-2 (Dihydroxycodine)
72522-13-5 (Eptazocine)
76721-89-6 (Thiorphan)
1400-61-9 (Nystatin)

11120-15-3 (Dermostatin)
26305-03-3 (Pepstatin)
73573-88-3 (Mevastatin)
75330-75-5 (Lovastatin)
81131-70-6 (Pravastatin sodium)
82009-34-5 (Cilastatin)
93957-54-1 (Fluvastatin)
134523-00-5 (Atorvastatin)
51-45-6 (Histamine)
68-88-2 (Hydroxyzine)
1159-93-9 (Clobenzepam)
5486-77-1 (Alloclamide)
13946-02-6 (Metron S)
15826-37-6 (Cromoglycate)
16110-51-3 (Cromolyn)
50679-08-8 (Terfenadine)
53237-59-5 (Urushiol)
53882-12-5 (Lodoxamide)
68302-57-8 (Amlexanox)
69049-73-6 (Nedocromil)
73080-51-0 (Repirinast)
73573-87-2 (Formoterol)
79516-68-0 (Levocabastine)
80012-43-7 (Epinastine)
83799-24-0 (Fexofenadine)
87848-99-5 (Acrivastine)
94055-76-2 (Suplatast tosylate)
112665-43-7 (Seratrodast)
158966-92-8 (Montelukast)
50-59-9 (Cephaloridine)
54-85-3 (Isoniazid)
56-75-7 (Chloramphenicol)
57-67-0 (Sulfaguanidine)
57-68-1 (Sulfamethazine)
57-92-1 (Streptomycin)
60-54-8 (Tetracycline)
61-24-5 (Cephalosporin C)
61-33-6 (Benzyl penicillinic acid)
61-72-3 (Cloxacillin)
63-74-1 (Sulfanilamide)
65-49-6 (p-Aminosalicylic acid)
66-79-5 (Oxacillin)
68-35-9 (Sulfadiazine)
68-41-7 (Cycloserine)
72-14-0 (Sulfathiazole)
74-55-5 (Ethambutol)
74-79-3 (Arginine)
79-57-2 (Oxytetracycline)
80-02-4 (2-p-Sulfanilylanilinoethanol)
80-03-5 (Acediasulfone)
80-08-0 (Dapsone)
80-32-0 (Sulfachlorpyridazine)
80-35-3 (Sulfamethoxypyridazine)
87-08-1 (Penicillin V)
87-09-2 (Penicillin O)
94-19-9 (Sulfaethidole)
103-12-8 (Sulfamidochrysoidine)
113-98-4 (Penicillin G potassium)
114-07-8 (Erythromycin)
115-68-4 (Sulfadicramide)
116-42-7 (Sulfaproxyline)
116-44-9 (Sulfapyrazine)

119-59-5 (4,4'-Sulfinyldianiline)
120-34-3 (N-Sulfanilyl-3,4-xylamide)
122-11-2 (Sulfadimethoxine)
127-33-3 (Demeclocycline)
127-69-5 (Sulfisoxazole)
127-71-9 (Sulfabenzamide)
127-79-7 (Sulfamerazine)
128-46-1 (Dihydrostreptomycin)
130-16-5 (Cloxyquin)
132-92-3 (Methicillin sodium)
132-93-4 (Phenethicillin potassium)
133-11-9 (Phenyl aminosalicylate)
138-39-6 (Mafenide)
144-80-9 (Sulfacetamide)
144-82-1 (Sulfamethizole)
144-83-2 (Sulfapyridine)
152-47-6 (Sulfalene)
153-61-7 (Cephalothin)
154-21-2 (Lincomycin)
303-81-1 (Novobiocin)
443-48-1 (Metronidazole)
473-30-3 (Thiazolsulfone)
485-41-6 (Sulfachrysoidine)
495-84-1 (Salinazid)
515-49-1 (Sulfathiourea)
515-59-3 (Sulfamethylthiazole)
515-64-0 (Sulfisomidine)
525-94-0 (Penicillin N)
526-08-9 (Sulfaphenazole)
547-44-4 (Sulfanilylurea)
547-52-4 (N4-Sulfanilylsulfanilamide)
547-53-5 (4'-(Methylsulfamoyl)sulfanilanilide)
551-27-9 (Propicillin)
599-88-2 (Sulfaperine)
651-06-9 (Sulfameter)
723-46-6 (Sulfamethoxazole)
729-99-7 (Sulfamoxole)
751-97-3 (Rolitetetracycline)
808-26-4 (Sancycline)
914-00-1 (Methacycline)
992-21-2 (Lymecycline)
1110-80-1 (Pipacycline)
1181-54-0 (Clomocycline)
1403-66-3 (Gentamicin)
1404-04-2 (Neomycin)
1596-63-0 (Quinacillin)
1614-20-6 (Nifurprazine)
1695-77-8 (Spectinomycin)
1926-49-4 (Clometocillin)
1984-94-7 (Sulfasymazine)
2013-58-3 (Meclocycline)
2030-63-9 (Clofazimine)
2315-08-4 (Salazosulfadimidine)
2447-57-6 (Sulfadoxine)
2750-76-7 (Rifamide)
2751-09-9 (Troleandomycin)
2779-55-7 (Opiniazide)
3116-76-5 (Dicloxacillin)
3485-14-1 (Cyclacillin)
3511-16-8 (Hetacillin)
3577-01-3 (Cephaloglycin)
3590-05-4 (Acetyl sulfamethoxypyrazine)

3691-74-5 (Glyconiazide)
3772-76-7 (Sulfamethomidine)
3922-90-5 (Oleandomycin)
4008-48-4 (Nitroxoline)
4393-19-5 (p-Sulfanilylbenzyl amine)
4564-87-8 (Carbomycin)
4697-36-3 (Carbenicillin)
5250-39-5 (Floxacillin)
5934-14-5 (Succisulfone)
6202-21-7 (4-Sulfanilamidosalicylic acid)
6489-97-0 (Metampicillin)
6946-29-8 (p-Aminosalicylic acid hydrazide)
6998-60-3 (Rifamycin)
7542-37-2 (Paromomycin)
8025-81-8 (Spiramycin)
10118-90-8 (Minocycline)
11003-38-6 (Capreomycin)
11006-76-1 (Virginiamycin)
12650-69-0 (Mupirocin)
13411-16-0 (Nifurpirinol)
13838-08-9 (Azidamfenicol)
13898-58-3 (Benzoylpas)
13925-12-7 (Myxin)
15599-51-6 (Apicycline)
15686-71-2 (Cephalexin)
16545-11-2 (Guamecyclyne)
16846-24-5 (Josamycin)
17243-38-8 (Azidocillin)
17784-12-2 (Sulfacytine)
18323-44-9 (Clindamycin)
19562-30-2 (Piromidic acid)
23239-41-0 (Cephacetrile sodium)
23477-98-7 (Sedecamycin)
24356-60-3 (Cephapirin sodium)
25546-65-0 (Ribostamycin)
25953-19-9 (Cefazolin)
26086-49-7 (Deoxydihydrostreptomycin)
26774-90-3 (Epicillin)
26787-78-0 (Amoxicillin)
26973-24-0 (Ceftazole)
27031-08-9 (Sulfaguanole)
28657-80-9 (Cinoxacin)
32385-11-8 (Sisomicin)
32887-01-7 (Amdinocillin)
32909-92-5 (Sulfametrole)
32986-56-4 (Tobramycin)
32988-50-4 (Viomycin)
33103-22-9 (Enviomycin)
33404-78-3 (Negamycin)
33817-20-8 (Pivampicillin)
34444-01-4 (Cefamandole)
34493-98-6 (Dibekacin)
34787-01-4 (Ticarcillin)
35457-80-8 (Midecamycin)
35531-88-5 (Carindacillin)
35607-66-0 (Cefoxitin)
35834-26-5 (Rosaramicin)
37091-66-0 (Azlocillin)
37321-09-8 (Apramycin)
37517-28-5 (Amikacin)
38129-37-2 (Bicozamycin)
38821-53-3 (Cephradine)

REGISTRY NUMBER:

41744-40-5 (Sulbenicillin)
42835-25-6 (Flumequine)
47747-56-8 (Talampicillin)
50370-12-2 (Cefadroxil)
50972-17-3 (Bacampicillin)
51025-85-5 (Arbekacin)
51481-65-3 (Mezlocillin)
51627-14-6 (Cefatrizine)
51762-05-1 (Cefroxadine)
51940-44-4 (Pipemidic acid)
52093-21-7 (Micronomicin)
53994-73-3 (Cefaclor)
55268-75-2 (Cefuroxime)
55881-07-7 (Miokamycin)
56187-47-4 (Cefazedone)
56391-56-1 (Netilmicin)
56796-20-4 (Cefmetazole)
58001-44-8 (Clavulanic acid)
60925-61-3 (Ceforanide)
61270-58-4 (Cefonicid)
61379-65-5 (Rifapentine)
61477-96-1 (Piperacillin)
61622-34-2 (Cefotiam)
62013-04-1 (Dirythromycin)
62893-19-0 (Cefoperazone)
63358-49-6 (Aspoxicillin)
63469-19-2 (Apalcillin)
63527-52-6 (Cefotaxime)
63836-75-9 (Cephalexin pivaloxymethyl ester)
64221-86-9 (Imipenem)
64952-97-2 (Moxalactam)
65052-63-3 (Cefetamet)
65085-01-0 (Cefmenoxime)
66148-78-5 (Temocillin)
68373-14-8 (Sulbactam)
68401-81-0 (Ceftizoxime)
69712-56-7 (Cefotetan)
69739-16-8 (Cefodizime)
70458-92-3 (Pefloxacin)
70458-96-7 (Norfloxacin)
70797-11-4 (Cefpiramide)
71426-83-0 (Fortimicin)
72558-82-8 (Ceftazidime)
72559-06-9 (Rifabutine)
74011-58-8 (Enoxacin)
74014-51-0 (Rokitamycin)
76470-66-1 (Loracarbef)
76497-13-7 (Sultamicillin)
76610-84-9 (Cefbuperazone)
78110-38-0 (Aztreonam)
79350-37-1 (Cefixime)
79548-73-5 (Pirlimycin)
79660-72-3 (Fleroxacin)
80370-57-6 (Ceftiofur)
80621-81-4 (Rifaximin)
81103-11-9 (Clarithromycin)
82219-78-1 (Cefuzonam)
82419-36-1 (Ofloxacin)
82547-58-8 (Cefteram)
83905-01-5 (Azithromycin)
84305-41-9 (Cefminox)
84845-57-8 (Ritipenem)

84880-03-5 (Cefpimizole)
84957-29-9 (Cefpirome)
85721-33-1 (Ciprofloxacin)
86273-18-9 (Lenampicillin)
87239-81-4 (Cefpodoxime proxetil)
87638-04-8 (Carumonam)
87726-17-8 (Panipenem)
88040-23-7 (Cefepime)
88669-04-9 (Trospectomycin)
91832-40-5 (Cefdinir)
92665-29-7 (Cefprozil)
93106-60-6 (Enrofloxacin)
96036-03-2 (Meropenem)
97519-39-6 (Ceftibuten)
98106-17-3 (Difloxacin)
99665-00-6 (Flomoxef)
100490-36-6 (Tosufloxacin)
101363-10-4 (Rufloxacin)
102507-71-1 (Tigemonam)
104145-95-1 (Cefditoren)
105239-91-6 (Cefclidin)
105889-45-0 (Cefcapene pivoxil)
105956-97-6 (Clinafloxacin)
110871-86-8 (Sparfloxacin)
113359-04-9 (Cefozopran)
119914-60-2 (Grepafloxacin)
120410-24-4 (Biapenem)
124858-35-1 (Nadifloxacin)
127045-41-4 (Pazufloxacin)
147059-72-1 (Trovafloracin)
62613-82-5 (Oxiracetam)
62732-44-9 (Ipidacrine)
90043-86-0 (Amiridine)
97205-34-0 (Nebracetam)
103878-84-8 (Lazabemide)
119386-96-8 (Mofegiline)
124027-47-0 (Velnacrine)
339-43-5 (Carbutamide)
4618-41-1 (1-Butyl-3-metanilylurea)
26944-48-9 (Glibornuride)
56180-94-0 (Acarbose)
72432-03-2 (Miglitol)
97322-87-7 (Troglitazone)
135062-02-1 (Repaglinide)
53-86-1 (Indomethacin)
61-68-7 (Mefenamic acid)
87-28-5 (Glylcol salicylate)
89-45-2 (Salicylsulfuric acid)
89-57-6 (Mesalamine)
129-20-4 (Oxyphenbutazone)
134-55-4 (Phenyl acetylsalicylate)
487-48-9 (Salacetamide)
515-69-5 (.alpha.-Bisabolol)
530-78-9 (Flufenamic acid)
552-94-3 (Salsalate)
644-62-2 (Meclofenamic acid)
959-10-4 (Xenbucin)
2055-44-9 (Perisoxal)
2316-64-5 (Bromosaligenin)
4394-00-7 (Niflumic acid)
5728-52-9 (Felbinac)
13710-19-5 (Tolfenamic acid)

13799-03-6 (Protizinic acid)
13993-65-2 (Metiazinic acid)
15307-79-6 (Sodium diclofenac)
15687-27-1 (Ibuprofen)
15722-48-2 (Olsalazine)
17969-20-9 (Fenclozic acid)
18046-21-4 (Fentiazac)
18471-20-0 (Ditazol)
20168-99-4 (Cinmetacin)
20187-55-7 (Bendazac)
21256-18-8 (Oxaprozin)
22071-15-4 (Ketoprofen)
22131-79-9 (Alclofenac)
22494-42-4 (Diflunisal)
23049-93-6 (Enfenamic acid)
24237-54-5 (Tinoridine)
25395-22-6 (Salicylamide O-acetic acid)
26171-23-3 (Tolmetin)
27470-51-5 (Suxibuzone)
29679-58-1 (Fenoprofen)
30544-47-9 (Etofenamate)
30653-83-9 (Parsalmide)
31793-07-4 (Pirprofen)
31842-01-0 (Indoprofen)
32527-55-2 (Tiaramide)
32808-51-8 (Bucloxix acid)
33005-95-7 (Tiaprofenic acid)
33369-31-2 (Zomepirac)
33996-33-7 (Oxaceprol)
34148-01-1 (Clidanac)
34552-84-6 (Isoxicam)
36322-90-4 (Piroxicam)
36330-85-5 (Fenbufen)
36981-91-6 (Fepradinol)
38677-85-9 (Flunixin)
39718-89-3 (Alminoprofen)
40828-46-4 (Suprofen)
41340-25-4 (Etodolac)
42779-82-8 (Clopirac)
50270-33-2 (Isofezolac)
~~51579-82-9~~ (Amfenac)
52443-21-7 (Glucametacin)
52549-17-4 (Pranoprofen)
53164-05-9 (Acemetacin)
53597-27-6 (Fendosal)
53648-05-8 (Ibuproxam)
53716-49-7 (Carprofen)
55453-87-7 (Isoxepac)
55837-18-8 (Butibufen)
56187-89-4 (Ximoprofen)
59804-37-4 (Tenoxicam)
65189-78-8 (Tropesin)
66934-18-7 (Flunoxaprofen)
68767-14-6 (Loxoprofen)
70374-39-9 (Lornoxicam)
71002-09-0 (Pirazolac)
71125-38-7 (Meloxicam)
74103-06-3 (Ketorolac)
74711-43-6 (Zaltoprofen)
76145-76-1 (Tomoxiprole)
78499-27-1 (Bermoprofen)
78967-07-4 (Mofezolac)

89796-99-6 (Aceclofenac)
91714-94-2 (Bromfenac)
58-32-2 (Dipyridamole)
68-90-6 (Benziodarone)
100-55-0 (Nicotinyl alcohol)
322-79-2 (Triflusal)
390-64-7 (Prenylamine)
395-28-8 (Isoxsuprine)
437-74-1 (Xanthinol niacinate)
447-41-6 (Nylidrin)
456-59-7 (Cyclandelate)
574-77-6 (Papaveroline)
987-78-0 (Citicoline)
3611-72-1 (Clobenfurol)
3703-79-5 (Bamethan)
5638-76-6 (Betahistine)
6621-47-2 (Perhexiline)
9005-49-6 (Dalteparin)
13042-18-7 (Fendiline)
14838-15-4 (Phenylpropanolamine)
22103-14-6 (Bufeniode)
23210-56-2 (Ifenprodil)
36702-83-7 (Tinofedrine)
37270-89-6 (Nadroparin calcium)
42794-76-3 (Midodrine)
54767-75-8 (Suloctidil)
57475-17-9 (Brovincamine)
57653-27-7 (Droprenilamine)
63610-08-2 (Indobufen)
74863-84-6 (Argatroban)
78919-13-8 (Iloprost)
81110-73-8 (Acetorphan)
82571-53-7 (Ozagrel)
110140-89-1 (Ridogrel)
144412-49-7 (Lamifiban)
50-44-2 (6-Mercaptopurine)
51-21-8 (Fluorouracil)
53-79-2 (Puromycin)
54-25-1 (6-Azaauridine)
57-22-7 (Vincristine)
59-05-2 (Methotrexate)
69-33-0 (Tubercidin)
84-16-2 (Hexestrol)
115-02-6 (Azaserine)
147-94-4 (Cytarabine)
148-82-3 (Melfalan)
154-42-7 (Thioguanine)
157-03-9 (6-Diazo-5-oxo-L-norleucine)
302-79-4 (Retinoic acid)
305-03-3 (Chlorambucil)
320-67-2 (Azacitidine)
477-30-5 (Demecolcine)
488-41-5 (Mitobronitol)
576-68-1 (Mannomustine)
801-52-5 (Porfiromycin)
865-21-4 (Vinblastine)
1404-15-5 (Nogalamycin)
1853-37-8 (Podophyllic acid)
2179-16-0 (Ninopterin)
2363-58-8 (Epitiostanol)
3094-09-5 (Doxifluridine)
3733-81-1 (Defosfamide)

REGISTRY NUMBER:

3930-19-6 (Streptonigrin)
4803-27-4 (Anthramycin)
5581-52-2 (Thiamiprine)
10318-26-0 (Mitolactol)
13665-88-8 (Mopidamol)
18378-89-7 (Plicamycin)
18883-66-4 (Streptozocin)
20830-81-3 (Daunorubicin)
21679-14-1 (Fludarabine)
22006-84-4 (Denopterin)
22668-01-5 (Etanidazole)
24280-93-1 (Mycophenolic acid)
27778-66-1 (Tenuazonic acid)
29767-20-2 (Teniposide)
31698-14-3 (Ancitabine)
33069-62-4 (Paclitaxel)
33419-42-0 (Etoposide)
50264-69-2 (Lonidamine)
50935-04-1 (Carubicin)
52128-35-5 (Trimetrexate)
53643-48-4 (Vindesine)
53910-25-1 (Pentostatin)
54083-22-6 (Zorubicin)
54749-90-5 (Chlorozotocin)
55726-47-1 (Enocitabine)
56420-45-2 (Epirubicin)
58957-92-9 (Idarubicin)
58970-76-6 (Ubenimex)
58994-96-0 (Ranimustine)
65271-80-9 (Mitoxantrone)
65646-68-6 (Fenretinide)
70052-12-9 (Eflornithine)
71486-22-1 (Vinorelbine)
71628-96-1 (Menogaril)
72496-41-4 (Pirarubicin)
72732-56-0 (Piritrexim)
80576-83-6 (Edatrexate)
82413-20-5 (Droloxifene)
84088-42-6 (Roquinimex)
87806-31-3 (Porfimer sodium)
90357-06-5 (Bicalutamide)
95058-81-4 (Gemcitabine)
106486-76-4 (Carzinophilin)
112887-68-0 (Tomudex)
114977-28-5 (Docetaxel)
123948-87-8 (Topotecan)
126595-07-1 (Propagermanium)
57-08-9 (.epsilon.-Acetamidocaproic acid)
33159-27-2 (Ecabet)
34675-84-8 (Cetraxate)
51481-61-9 (Cimetidine)
55028-70-1 (Arbaprostil)
56695-65-9 (Rosaprostol)
57381-26-7 (Irsogladine)
59122-46-2 (Misoprostol)
64204-55-3 (Esomeprazole)
64218-02-6 (Plavix)
64506-49-6 (Sofalcone)
69900-72-7 (Trimoprostil)
73121-56-9 (Enprostil)
73590-58-6 (Omeprazole)
77287-05-9 (Rioprostil)

92071-51-7 (Rotraxate)
102625-70-7 (Pantoprazole)
50-91-9 (Floxuridine)
54-42-2 (Idoxuridine)
70-00-8 (Trifluridine)
518-28-5 (Podophyllotoxin)
768-94-5 (Amantadine)
840-50-6 (MADU)
1174-11-4 (Xenazoic acid)
3056-17-5 (Stavudine)
4097-22-7 (Dideoxyadenosine)
5536-17-4 (Vidarabine)
7481-89-2 (Zalcitabine)
13392-28-4 (Rimantadine)
15176-29-1 (Edoxudine)
27762-78-3 (Kethoxal)
30516-87-1 (Zidovudine)
36791-04-5 (Ribavirin)
39809-25-1 (Penciclovir)
69655-05-6 (Didanosine)
77181-69-2 (Sorivudine)
82410-32-0 (Ganciclovir)
104227-87-4 (Famciclovir)
113852-37-2 (Cidofovir)
127779-20-8 (Saquinavir)
134678-17-4 (Lamivudine)
54-80-8 (Pronethalol)
2933-94-0 (Toliprolol)
3930-20-9 (Sotalol)
5741-22-0 (Moprolol)
6452-71-7 (Oxprenolol)
6673-35-4 (Practolol)
7413-36-7 (Nifenalol)
13655-52-2 (Alprenolol)
14556-46-8 (Bupranolol)
22664-55-7 (Metipranolol)
23694-81-7 (Mepindolol)
26839-75-8 (Timolol)
29122-68-7 (Atenolol)
30187-90-7 (Xibenolol)
34915-68-9 (Bunitrolol)
34919-98-7 (Cetamolol)
36894-69-6 (Labetalol)
37517-30-9 (Acebutolol)
38363-40-5 (Penbutolol)
42200-33-9 (Nadolol)
51384-51-1 (Metoprolol)
51781-06-7 (Carteolol)
53684-49-4 (Bufetolol)
54063-51-3 (Nadoxolol)
54340-62-4 (Bufuralol)
56980-93-9 (Celiprolol)
57460-41-0 (Talinolol)
57775-29-8 (Carazolol)
58409-59-9 (Bucumolol)
58930-32-8 (Butofilolol)
59170-23-9 (Bevantolol)
60607-68-3 (Indenolol)
63659-18-7 (Betaxolol)
66264-77-5 (Sulfinalol)
68377-92-4 (Arotinolol)
72956-09-3 (Carvedilol)

75659-07-3 (Dilevalol)
81147-92-4 (Esmolol)
83688-84-0 (Tertatolol)
85136-71-6 (Tilisolol)
85320-68-9 (Amosulalol)
86880-51-5 (Epanolol)
118457-14-0 (Nebivolol)
2809-21-4 (Etidronic acid)
15468-10-7 (Oxidronic acid)
40391-99-9 (Pamidronic acid)
51395-42-7 (Butedronic acid)
105462-24-6 (Risedronic acid)
51-43-4 (Epinephrine)
136-70-9 (Protokylol)
299-42-3 (Ephedrine)
497-75-6 (Dioxethedrine)
519-37-9 (Etophylline)
530-08-5 (Isoetharine)
536-24-3 (Ethylnorepinephrine)
586-06-1 (Metaproterenol)
603-00-9 (Proxiphylline)
652-37-9 (Acefylline)
2016-63-9 (Bamifylline)
3215-70-1 (Hexoprenaline)
5205-82-3 (Bevonium methyl sulfate)
5614-56-2 (1-Theobromineacetic acid)
5633-20-5 (Oxybutynin)
7683-59-2 (Isoproterenol)
13392-18-2 (Fenoterol)
13642-52-9 (Soterenol)
20267-87-2 (Diphylline)
22254-24-6 (Ipratropium bromide)
23031-25-6 (Terbutaline)
30286-75-0 (Oxitropium bromide)
30392-40-6 (Bitolterol)
30418-38-3 (Tretioquinol)
32665-36-4 (Eprozinol)
32953-89-2 (Rimiterol)
34866-47-2 (Carbuterol)
37148-27-9 (Clenbuterol)
37762-06-4 (Zaprinast)
38677-81-5 (Pirbuterol)
41570-61-0 (Tulobuterol)
48141-64-6 (Etafedrine)
54063-54-6 (Reproterol)
56341-08-3 (Mabuterol)
63516-07-4 (Flutropium bromide)
72332-33-3 (Procaterol)
81732-65-2 (Bambuterol)
89365-50-4 (Salmeterol)
129927-33-9 (NS-21)
136310-93-5 (Tiotropium bromide)
80-53-5 (Terpin)
93-14-1 (Guaifenesin)
498-71-5 (Sobrerol)
1953-02-2 (Tiopronin)
3572-43-8 (Bromhexine)
19767-45-4 (Mesna)
53943-88-7 (Letosteine)
61869-07-6 (Domiodol)
72324-18-6 (Stepronin)
84611-23-4 (Erdosteine)

9041-08-1 (Reviparin sodium)
69-53-4 (Ampicillin)
105-59-9 (N-Methyldiethanolamine)
110-63-4 (1,4-Butanediol)
111-46-6 (Diethylene glycol)
321-64-2 (Tacrine)
479-18-5 (Diphylline)
525-66-6 (Propranolol)
591-81-1 (4-Hydroxybutanoic acid)
1135-24-6 (Ferulic acid)
1191-25-9 (6-Hydroxyhexanoic acid)
6007-86-9 (Thiophene-2,5-dimethanol)
15307-86-5 (Diclofenac)
18559-94-9 (Salbutamol)
18683-91-5 (Ambroxol)
23214-92-8 (Doxorubicin)
38194-50-2 (Sulindac)
54120-69-3 (1,4-Dioxane-2,6-dimethanol)
59277-89-3 (Aciclovir)
66376-36-1 (Alendronic acid)
75847-73-3 (Enalapril)
79902-63-9 (Simvastatin)
82964-04-3 (Tolrestat)
83881-51-0 (Cetirizine)
REGISTRY NUMBER: 113665-84-2 (Clopidogrel)
326850-59-3 (1,4-Dithiane-2,6-dimethanol)
326850-60-6 (3-Cyclohexene-1,3-dimethanol)
326850-61-7 (2,5-Thiazoledimethanol)
326850-62-8 (2,5-Oxazoledimethanol)
REGISTRY NUMBER: 65-45-2; 1503-53-3; 57-62-5; 389-08-2; 52152-93-9;
73384-59-5; 98079-51-7; 99450-52-9; 89667-40-3;
70667-26-4; 13523-86-9; 3811-25-4; 52109-93-0;
153196-03-3; 90-05-1; 5634-39-9; 326850-30-0; 326850-31-1;
326850-32-2; 326850-33-3; 326850-34-4; 326850-35-5;
326850-36-6; 326850-37-7; 326850-38-8; 326850-39-9;
326850-40-2; 326850-41-3; 326850-42-4; 326850-43-5;
326850-44-6; 326850-45-7; 326850-46-8; 326850-47-9;
326850-94-6; 103-90-2; 111-48-8; 1005-72-7; 3447-95-8;
301669-82-9; 326850-58-2; 41683-29-8; 301669-90-9;
326850-48-0; 326850-49-1; 326850-50-4; 326850-51-5;
326850-52-6; 326850-53-7; 326850-54-8; 326850-55-9;
326850-56-0; 326850-57-1

L82 ANSWER 46 OF 49 TOXCENTER COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:204448 TOXCENTER
COPYRIGHT: Copyright 2004 ACS
DOCUMENT NUMBER: CA13322309791M
TITLE: Synthesis, activity and formulations of pharmaceutical
compounds for treatment of oxidative stress and/or
endothelial dysfunction
AUTHOR(S): Del Soldato, Piero
CORPORATE SOURCE: ASSIGNEE: Nicox S.A.
PATENT INFORMATION: WO 2000061541 A2 19 Oct 2000
SOURCE: (2000) PCT Int. Appl., 140 pp.
CODEN: PIXXD2.
COUNTRY: FRANCE
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2000:742057
LANGUAGE: English
ENTRY DATE: Entered STN: 20011116
Last Updated on STN: 20030819

ABSTRACT:

Synthesis, activity and formulations of pharmaceutical compds. for treatment of oxidative stress and/or endothelial dysfunction are disclosed. The precursors are such as to meet the pharmacol. test reported in the description.

CLASSIFICATION CODE: 26-1

SUPPLEMENTARY TERMS: Miscellaneous Descriptors

pharmaceutical compd prepn oxidative stress treatment;
endothelial dysfunction treatment pharmaceutical compd
prepn; precursor antiinflammatory analgesic bronchodilator
expectorant; antiasthmatic antihistaminic ACE inhibitor
beta blocker precursor; antithrombotic vasodilator
antidiabetic **antitumor** antiulcer precursor;
antihyperlipidemic antibiotic antiviral antidementia
precursor; bone resorption inhibitor precursor

REGISTRY NUMBER:

34661-75-1 (Urapidil)
62571-86-2 (Captopril)
74258-86-9 (Alacepril)
76420-72-9 (Enalaprilat)
76547-98-3 (Lisinopril)
82834-16-0 (Perindopril)
83435-66-9 (Delapril)
83647-97-6 (Spirapril)
85441-61-8 (Quinapril)
85856-54-8 (Moveltipril)
86541-75-5 (Benazepril)
87333-19-5 (Ramipril)
87679-37-6 (Trandolapril)
88768-40-5 (Cilazapril)
89371-37-9 (Imidapril)
98048-97-6 (Fosinopril)
111223-26-8 (Ceronapril)
111902-57-9 (Temocapril)
114798-26-4 (Losartan)
50-33-9 (Phenylbutazone)
57-27-2 (Morphine)
76-41-5 (Oxymorphone)
76-42-6 (Oxycodone)
76-57-3 (Codeine)
76-58-4 (Ethylmorphine)
77-07-6 (Levorphanol)
94-10-0 (Ethoxazene)
97-53-0 (Eugenol)
103-97-9 (Phenocoll)
118-55-8 (Phenyl salicylate)
118-57-0 (Acetaminosalol)
125-29-1 (Hydrocodone)
127-35-5 (Phenazocine)
132-60-5 (Cinchophen)
138-52-3 (Salicin)
143-52-2 (Metopon)
144-14-9 (Anileridine)
326-43-2 (Phenylramidol hydrochloride)
359-83-1 (Pentazocine)
404-86-4 (Capsaicine)
427-00-9 (Desomorphine)
466-97-7 (Normorphine)
466-99-9 (Hydromorphone)
468-56-4 (Hydroxypethidine)
486-79-3 (Dipyrrocetyl)
509-60-4 (Dihydromorphine)
530-75-6 (Acetylsalicylsalicylic acid)
539-08-2 (p-Lactophenetide)

545-90-4 (Dimepheptanol)
562-26-5 (Phenoperidine)
639-48-5 (Nicomorphine)
1083-57-4 (Bucetin)
1531-12-0 (Norlevorphanol)
1553-60-2 (Ibufenac)
3567-76-8 (Aminochlorthenoxazin)
3734-52-9 (Metazocine)
3820-67-5 (Glafenine)
6064-83-1 (Fosfosal)
13739-02-1 (Diacerein)
17737-65-4 (Clonixin)
18699-02-0 (Actarit)
20594-83-6 (Nalbuphine)
23779-99-9 (Floctafenine)
25803-14-9 (Clometacin)
27203-92-5 (Tramadol)
42408-82-2 (Butorphanol)
51234-28-7 (Benoxaprofen)
52485-79-7 (Buprenorphine)
53648-55-8 (Dezocine)
54340-58-8 (Meptazinol)
63269-31-8 (Ciramadol)
65110-93-2 (Dihydroxycodine)
72522-13-5 (Eptazocine)
76721-89-6 (Thiorphan)
1400-61-9 (Nystatin)
11120-15-3 (Dermostatin)
26305-03-3 (Pepstatin)
73573-88-3 (Mevastatin)
75330-75-5 (Lovastatin)
81131-70-6 (Pravastatin sodium)
82009-34-5 (Cilastatin)
93957-54-1 (Fluvastatin)
134523-00-5 (Atorvastatin)
51-45-6 (Histamine)
68-88-2 (Hydroxyzine)
1159-93-9 (Clobenzepam)
5486-77-1 (Alloclamide)
13946-02-6 (Metron S)
15826-37-6 (Cromoglycate)
16110-51-3 (Cromolyn)
50679-08-8 (Terfenadine)
53237-59-5 (Urushiol)
53882-12-5 (Lodoxamide)
68302-57-8 (Amlexanox)
69049-73-6 (Nedocromil)
73080-51-0 (Repirinast)
73573-87-2 (Formoterol)
79516-68-0 (Levocabastine)
80012-43-7 (Epinastine)
83799-24-0 (Fexofenadine)
87848-99-5 (Acrivastine)
94055-76-2 (Suplatast tosylate)
112665-43-7 (Seratrodast)
158966-92-8 (Montelukast)
50-59-9 (Cephaloridine)
54-85-3 (Isoniazid)
56-75-7 (Chloramphenicol)
57-67-0 (Sulfaguanidine)
57-68-1 (Sulfamethazine)
57-92-1 (Streptomycin)

60-54-8 (Tetracycline)
61-24-5 (Cephalosporin C)
61-33-6 (Benzyl penicillinic acid)
61-72-3 (Cloxacillin)
63-74-1 (Sulfanilamide)
65-49-6 (p-Aminosalicylic acid)
66-79-5 (Oxacillin)
68-35-9 (Sulfadiazine)
68-41-7 (Cycloserine)
72-14-0 (Sulfathiazole)
74-55-5 (Ethambutol)
74-79-3 (Arginine)
79-57-2 (Oxytetracycline)
80-02-4 (2-p-Sulfanilylanilinoethanol)
80-03-5 (Acediasulfone)
80-08-0 (Dapsone)
80-32-0 (Sulfachlorpyridazine)
80-35-3 (Sulfamethoxypyridazine)
87-08-1 (Penicillin V)
87-09-2 (Penicillin O)
94-19-9 (Sulfaethidole)
103-12-8 (Sulfamidochrysoidine)
113-98-4 (Penicillin G potassium)
114-07-8 (Erythromycin)
115-68-4 (Sulfadiazine)
116-42-7 (Sulfaproxyline)
116-44-9 (Sulfapyrazine)
119-59-5 (4,4'-Sulfinyldianiline)
120-34-3 (N-Sulfanilyl-3,4-xylamide)
122-11-2 (Sulfadimethoxine)
127-33-3 (Demeclocycline)
127-69-5 (Sulfisoxazole)
127-71-9 (Sulfabenzamide)
127-79-7 (Sulfamerazine)
128-46-1 (Dihydrostreptomycin)
130-16-5 (Cloxyquin)
132-92-3 (Methicillin sodium)
132-93-4 (Phenethicillin potassium)
133-11-9 (Phenyl aminosalicylate)
138-39-6 (Mafenide)
144-80-9 (Sulfacetamide)
144-82-1 (Sulfamethizole)
144-83-2 (Sulfapyridine)
152-47-6 (Sulfalene)
153-61-7 (Cephalothin)
154-21-2 (Lincomycin)
303-81-1 (Novobiocin)
443-48-1 (Metronidazole)
473-30-3 (Thiazolsulfone)
485-41-6 (Sulfachrysoidine)
495-84-1 (Salinazid)
515-49-1 (Sulfathiourea)
515-59-3 (Sulfamethylthiazole)
515-64-0 (Sulfisomidine)
525-94-0 (Penicillin N)
526-08-9 (Sulfaphenazole)
547-44-4 (Sulfanilylurea)
547-52-4 (N4-Sulfanilylsulfanilamide)
547-53-5 (4'-(Methylsulfamoyl)sulfanilanilide)
551-27-9 (Propicillin)
599-88-2 (Sulfaperine)
651-06-9 (Sulfameter)

723-46-6 (Sulfamethoxazole)
729-99-7 (Sulfamoxole)
751-97-3 (Rolitetetracycline)
808-26-4 (Sancycline)
914-00-1 (Methacycline)
992-21-2 (Lymecycline)
1110-80-1 (Pipacycline)
1181-54-0 (Clomocycline)
1403-66-3 (Gentamicin)
1404-04-2 (Neomycin)
1596-63-0 (Quinacillin)
1614-20-6 (Nifurprazine)
1695-77-8 (Spectinomycin)
1926-49-4 (Clometocillin)
1984-94-7 (Sulfasymazine)
2013-58-3 (Meclocycline)
2030-63-9 (Clofazimine)
2315-08-4 (Salazosulfadimidine)
2447-57-6 (Sulfadoxine)
2750-76-7 (Rifamide)
2751-09-9 (Troleandomycin)
2779-55-7 (Opiniazone)
3116-76-5 (Dicloxacillin)
3485-14-1 (Cyclacillin)
3511-16-8 (Hetacillin)
3577-01-3 (Cephaloglycin)
3590-05-4 (Acetyl sulfamethoxypyrazine)
3691-74-5 (Glyconiazide)
3772-76-7 (Sulfamethomidine)
3922-90-5 (Oleandomycin)
4008-48-4 (Nitroxoline)
4393-19-5 (p-Sulfanilylbenzyl amine)
4564-87-8 (Carbomycin)
4697-36-3 (Carbenicillin)
5250-39-5 (Floxacin)
5934-14-5 (Succisulfone)
6202-21-7 (4-Sulfanilamidosalicylic acid)
6489-97-0 (Metampicillin)
6946-29-8 (p-Aminosalicylic acid hydrazide)
6998-60-3 (Rifamycin)
7542-37-2 (Paromomycin)
8025-81-8 (Spiramycin)
10118-90-8 (Minocycline)
11003-38-6 (Capreomycin)
11006-76-1 (Virginiamycin)
12650-69-0 (Mupirocin)
13411-16-0 (Nifurpirinol)
13838-08-9 (Azidamfenicol)
13898-58-3 (Benzoylpas)
13925-12-7 (Myxin)
15599-51-6 (Apicycline)
15686-71-2 (Cephalexin)
16545-11-2 (Guamecycline)
16846-24-5 (Josamycin)
17243-38-8 (Azidocillin)
17784-12-2 (Sulfacycline)
18323-44-9 (Clindamycin)
19562-30-2 (Piromidic acid)
23239-41-0 (Cephacetrile sodium)
23477-98-7 (Sedecamycin)
24356-60-3 (Cephapirin sodium)
25546-65-0 (Ribostamycin)

REGISTRY NUMBER:

25953-19-9 (Cefazolin)
26086-49-7 (Deoxydihydrostreptomycin)
26774-90-3 (Epicillin)
26787-78-0 (Amoxicillin)
26973-24-0 (Ceftezole)
27031-08-9 (Sulfaguanole)
28657-80-9 (Cinoxacin)
32385-11-8 (Sisomicin)
32887-01-7 (Amdinocillin)
32909-92-5 (Sulfametrole)
32986-56-4 (Tobramycin)
32988-50-4 (Viomycin)
33103-22-9 (Enviomycin)
33404-78-3 (Negamycin)
33817-20-8 (Pivampicillin)
34444-01-4 (Cefamandole)
34493-98-6 (Dibekacin)
34787-01-4 (Ticarcillin)
35457-80-8 (Midecamycin)
35531-88-5 (Carindacillin)
35607-66-0 (Cefoxitin)
35834-26-5 (Rosaramicin)
37091-66-0 (Azlocillin)
37321-09-8 (Apramycin)
37517-28-5 (Amikacin)
38129-37-2 (Bicozamycin)
38821-53-3 (Cephradine)
41744-40-5 (Sulbenicillin)
42835-25-6 (Flumequine)
47747-56-8 (Talampicillin)
50370-12-2 (Cefadroxil)
50972-17-3 (Bacampicillin)
51025-85-5 (Arbekacin)
51481-65-3 (Mezlocillin)
51627-14-6 (Cefatrizine)
51762-05-1 (Cefroxadine)
51940-44-4 (Pipemidic acid)
52093-21-7 (Micronomicin)
53994-73-3 (Cefaclor)
55268-75-2 (Cefuroxime)
55881-07-7 (Miokamycin)
56187-47-4 (Cefazedone)
56391-56-1 (Netilmicin)
56796-20-4 (Cefmetazole)
58001-44-8 (Clavulanic acid)
60925-61-3 (Ceforanide)
61270-58-4 (Cefonicid)
61379-65-5 (Rifapentine)
61477-96-1 (Piperacillin)
61622-34-2 (Cefotiam)
62013-04-1 (Dirythromycin)
62893-19-0 (Cefoperazone)
63358-49-6 (Aspoxicillin)
63469-19-2 (Apalcillin)
63527-52-6 (Cefotaxime)
63836-75-9 (Cephalexin pivaloxymethyl ester)
64221-86-9 (Imipenem)
64952-97-2 (Moxalactam)
65052-63-3 (Cefetamet)
65085-01-0 (Cefmenoxime)
66148-78-5 (Temocillin)
68373-14-8 (Sulbactam)

68401-81-0 (Ceftizoxime)
69712-56-7 (Cefotetan)
69739-16-8 (Cefodizime)
70458-92-3 (Pefloxacin)
70458-96-7 (Norfloxacin)
70797-11-4 (Cefpiramide)
71426-83-0 (Fortimicin)
72558-82-8 (Ceftazidime)
72559-06-9 (Rifabutine)
74011-58-8 (Enoxacin)
74014-51-0 (Rokitamycin)
76470-66-1 (Loracarbef)
76497-13-7 (Sultamicillin)
76610-84-9 (Cefbuperazone)
78110-38-0 (Aztreonam)
79350-37-1 (Cefixime)
79548-73-5 (Pirlimycin)
79660-72-3 (Fleroxacin)
80370-57-6 (Ceftiofur)
80621-81-4 (Rifaximin)
81103-11-9 (Clarithromycin)
82219-78-1 (Cefuzonam)
82419-36-1 (Ofloxacin)
82547-58-8 (Cefteram)
83905-01-5 (Azithromycin)
84305-41-9 (Cefminox)
84845-57-8 (Ritipenem)
84880-03-5 (Cefpimizole)
84957-29-9 (Cefpirome)
85721-33-1 (Ciprofloxacin)
86273-18-9 (Lenampicillin)
87239-81-4 (Cefpodoxime proxetil)
87638-04-8 (Carumonam)
87726-17-8 (Panipenem)
88040-23-7 (Cefepime)
88669-04-9 (Trospectomycin)
91832-40-5 (Cefdinir)
92665-29-7 (Cefprozil)
93106-60-6 (Enrofloxacin)
96036-03-2 (Meropenem)
97519-39-6 (Ceftibuten)
98106-17-3 (Difloxacin)
99665-00-6 (Flomoxef)
100490-36-6 (Tosufloxacin)
101363-10-4 (Rufloxacin)
102507-71-1 (Tigemonam)
104145-95-1 (Cefditoren)
105239-91-6 (Cefclidin)
105889-45-0 (Cefcapene pivoxil)
105956-97-6 (Clinafloxacin)
110871-86-8 (Sparfloxacin)
113359-04-9 (Cefozopran)
119914-60-2 (Grepafloxacin)
120410-24-4 (Biapenem)
124858-35-1 (Nadifloxacin)
127045-41-4 (Pazufloxacin)
147059-72-1 (Trovafoxacin)
62613-82-5 (Oxiracetam)
62732-44-9 (Ipidacrine)
90043-86-0 (Amiridine)
97205-34-0 (Nebracetam)
103878-84-8 (Lazabemide)

119386-96-8 (Mofegiline)
124027-47-0 (Velnacrine)
339-43-5 (Carbutamide)
4618-41-1 (1-Butyl-3-metanilylurea)
26944-48-9 (Glibornuride)
56180-94-0 (Acarbose)
72432-03-2 (Miglitol)
82964-04-3 (Tolrestat)
97322-87-7 (Troglitazone)
135062-02-1 (Repaglinide)
53-86-1 (Indomethacin)
61-68-7 (Mefenamic acid)
87-28-5 (Glylcol salicylate)
89-45-2 (Salicylsulfuric acid)
89-57-6 (Mesalamine)
129-20-4 (Oxyphenbutazone)
134-55-4 (Phenyl acetylsalicylate)
487-48-9 (Salacetamide)
515-69-5 (.alpha.-Bisabolol)
530-78-9 (Flufenamic acid)
552-94-3 (Salsalate)
644-62-2 (Meclofenamic acid)
959-10-4 (Xenbucin)
2055-44-9 (Perisoxal)
2316-64-5 (Bromosaligenin)
4394-00-7 (Niflumic acid)
5728-52-9 (Felbinac)
13710-19-5 (Tolfenamic acid)
13799-03-6 (Protizinic acid)
13993-65-2 (Metiazinic acid)
15307-79-6 (Sodium diclofenac)
15687-27-1 (Ibuprofen)
15722-48-2 (Olsalazine)
17969-20-9 (Fenclozic acid)
18046-21-4 (Fentiazac)
18471-20-0 (Ditazol)
20168-99-4 (Cinmetacin)
20187-55-7 (Bendazac)
21256-18-8 (Oxaprozin)
22071-15-4 (Ketoprofen)
22131-79-9 (Alclofenac)
22494-42-4 (Diflunisal)
23049-93-6 (Enfenamic acid)
24237-54-5 (Tinoridine)
25395-22-6 (Salicylamide O-acetic acid)
26171-23-3 (Tolmetin)
27470-51-5 (Suxibuzone)
29679-58-1 (Fenoprofen)
30544-47-9 (Etofenamate)
30653-83-9 (Parsalmide)
31793-07-4 (Pirprofen)
31842-01-0 (Indoprofen)
32527-55-2 (Tiaramide)
32808-51-8 (Bucloxic acid)
33005-95-7 (Tiaprofenic acid)
33369-31-2 (Zomepirac)
33996-33-7 (Oxaceprol)
34148-01-1 (Clidanac)
34552-84-6 (Isoxicam)
36322-90-4 (Piroxicam)
36330-85-5 (Fenbufen)
36981-91-6 (Fepradinol)

38194-50-2 (Sulindac)
38677-85-9 (Flunixin)
39718-89-3 (Alminoprofen)
40828-46-4 (Suprofen)
41340-25-4 (Etodolac)
42779-82-8 (Clopirac)
50270-33-2 (Isofezolac)
~~51579-82-9~~ (Amfenac)
52443-21-7 (Glucametacin)
52549-17-4 (Pranoprofen)
53164-05-9 (Acemetacin)
53597-27-6 (Fendosal)
53648-05-8 (Ibuproxam)
53716-49-7 (Carprofen)
55453-87-7 (Isoxepac)
55837-18-8 (Butibufen)
56187-89-4 (Ximoprofen)
59804-37-4 (Tenoxicam)
65189-78-8 (Tropesin)
66934-18-7 (Flunoxaprofen)
68767-14-6 (Loxoprofen)
70374-39-9 (Lornoxicam)
71002-09-0 (Pirazolac)
71125-38-7 (Meloxicam)
74103-06-3 (Ketorolac)
74711-43-6 (Zaltoprofen)
76145-76-1 (Tomoxiprole)
78499-27-1 (Bermoprofen)
78967-07-4 (Mofezolac)
89796-99-6 (Aceclofenac)
~~91714-94-2~~ (Bromfenac)
58-32-2 (Dipyridamole)
68-90-6 (Benziodarone)
100-55-0 (Nicotiny alcohol)
322-79-2 (Triflusal)
390-64-7 (Prenylamine)
395-28-8 (Isoxsuprine)
437-74-1 (Xanthinol niacinate)
447-41-6 (Nylidrin)
456-59-7 (Cyclandelate)
574-77-6 (Papaveroline)
987-78-0 (Citicoline)
3611-72-1 (Clobenfurol)
3703-79-5 (Bamethan)
5638-76-6 (Betahistine)
6621-47-2 (Perhexiline)
9005-49-6 (Dalteparin)
13042-18-7 (Fendiline)
14838-15-4 (Phenylpropanolamine)
22103-14-6 (Bufenioder)
23210-56-2 (Ifenprodil)
36702-83-7 (Tinofedrine)
37270-89-6 (Nadroparin calcium)
42794-76-3 (Midodrine)
54767-75-8 (Suloctidil)
57475-17-9 (Brovincamine)
57653-27-7 (Droprenilamine)
63610-08-2 (Indobufen)
74863-84-6 (Argatroban)
78919-13-8 (Iloprost)
81110-73-8 (Acetorphan)
82571-53-7 (Ozagrel)

REGISTRY NUMBER:

110140-89-1 (Ridogrel)
144412-49-7 (Lamifiban)
50-44-2 (6-Mercaptopurine)
51-21-8 (Fluorouracil)
53-79-2 (Puromycin)
54-25-1 (6-Azaauridine)
57-22-7 (Vincristine)
59-05-2 (Methotrexate)
69-33-0 (Tubercidin)
84-16-2 (Hexestrol)
115-02-6 (Azaserine)
147-94-4 (Cytarabine)
148-82-3 (Melphalan)
154-42-7 (Thioguanine)
157-03-9 (6-Diazo-5-oxo-L-norleucine)
302-79-4 (Retinoic acid)
305-03-3 (Chlorambucil)
320-67-2 (Azacitidine)
477-30-5 (Demecolcine)
488-41-5 (Mitobronitol)
576-68-1 (Mannomustine)
801-52-5 (Porfiromycin)
865-21-4 (Vinblastine)
1404-15-5 (Nogalamycin)
1853-37-8 (Podophyllic acid)
2179-16-0 (Ninopterin)
2363-58-8 (Epitiostanol)
3094-09-5 (Doxifluridine)
3733-81-1 (Defosfamide)
3930-19-6 (Streptonigrin)
4803-27-4 (Anthramycin)
5581-52-2 (Thiamiprine)
10318-26-0 (Mitolactol)
13665-88-8 (Mopidamol)
18378-89-7 (Plicamycin)
18883-66-4 (Streptozocin)
20830-81-3 (Daunorubicin)
21679-14-1 (Fludarabine)
22006-84-4 (Denopterin)
22668-01-5 (Etanidazole)
24280-93-1 (Mycophenolic acid)
27778-66-1 (Tenuazonic acid)
29767-20-2 (Teniposide)
31698-14-3 (Ancitabine)
33069-62-4 (Paclitaxel)
33419-42-0 (Etoposide)
50264-69-2 (Lonidamine)
50935-04-1 (Carubicin)
52128-35-5 (Trimetrexate)
53643-48-4 (Vindesine)
53910-25-1 (Pentostatin)
54083-22-6 (Zorubicin)
54749-90-5 (Chlorozotocin)
55726-47-1 (Enocitabine)
56420-45-2 (Epirubicin)
58957-92-9 (Idarubicin)
58970-76-6 (Ubenimex)
58994-96-0 (Ranimustine)
65271-80-9 (Mitoxantrone)
65646-68-6 (Fenretinide)
70052-12-9 (Eflornithine)
71486-22-1 (Vinorelbine)

71628-96-1 (Menogaril)
72496-41-4 (Pirarubicin)
72732-56-0 (Piritrexim)
80576-83-6 (Edatrexate)
82413-20-5 (Droloxifene)
84088-42-6 (Roquinimex)
87806-31-3 (Porfimer sodium)
90357-06-5 (Bicalutamide)
106486-76-4 (Carzinophilin)
112887-68-0 (Tomudex)
114977-28-5 (Docetaxel)
123948-87-8 (Topotecan)
126595-07-1 (Propagermanium)
57-08-9 (.epsilon.-Acetamidocaproic acid)
33159-27-2 (Ecabet)
34675-84-8 (Cetraxate)
51481-61-9 (Cimetidine)
55028-70-1 (Arbaprostil)
56695-65-9 (Rosaprostol)
57381-26-7 (Irsogladine)
59122-46-2 (Misoprostol)
64204-55-3 (Esomeprazole)
64218-02-6 (Plavix)
64506-49-6 (Sofalcone)
69900-72-7 (Trimoprostil)
73121-56-9 (Enprostil)
73590-58-6 (Omeprazole)
77287-05-9 (Rioprostil)
92071-51-7 (Rotraxate)
102625-70-7 (Pantoprazole)
50-91-9 (Floxuridine)
54-42-2 (Idoxuridine)
70-00-8 (Trifluridine)
518-28-5 (Podophyllotoxin)
768-94-5 (Amantadine)
840-50-6 (MADU)
1174-11-4 (Xenazoic acid)
3056-17-5 (Stavudine)
4097-22-7 (Dideoxyadenosine)
5536-17-4 (Vidarabine)
7481-89-2 (Zalcitabine)
13392-28-4 (Rimantadine)
15176-29-1 (Edoxudine)
27762-78-3 (Kethoxal)
30516-87-1 (Zidovudine)
36791-04-5 (Ribavirin)
39809-25-1 (Penciclovir)
69655-05-6 (Didanosine)
77181-69-2 (Sorivudine)
82410-32-0 (Ganciclovir)
104227-87-4 (Famciclovir)
113852-37-2 (Cidofovir)
127779-20-8 (Saquinavir)
134678-17-4 (Lamivudine)
54-80-8 (Pronethalol)
2933-94-0 (Toliprolol)
3930-20-9 (Sotalol)
5741-22-0 (Moprolol)
6452-71-7 (Oxprenolol)
6673-35-4 (Practolol)
7413-36-7 (Nifenalol)
13655-52-2 (Alprenolol)

14556-46-8 (Bupranolol)
22664-55-7 (Metipranolol)
23694-81-7 (Mepindolol)
26839-75-8 (Timolol)
29122-68-7 (Atenolol)
30187-90-7 (Xibenolol)
34915-68-9 (Bunitrolol)
34919-98-7 (Cetamolol)
36894-69-6 (Labetalol)
37517-30-9 (Acebutolol)
38363-40-5 (Penbutolol)
42200-33-9 (Nadolol)
51384-51-1 (Metoprolol)
51781-06-7 (Carteolol)
53684-49-4 (Bufetolol)
54063-51-3 (Nadoxolol)
54340-62-4 (Bufuralol)
56980-93-9 (Celiprolol)
57460-41-0 (Talinolol)
57775-29-8 (Carazolol)
58409-59-9 (Bucumolol)
58930-32-8 (Butofilolol)
59170-23-9 (Bevantolol)
60607-68-3 (Indenolol)
63659-18-7 (Betaxolol)
66264-77-5 (Sulfinalol)
68377-92-4 (Arotinolol)
72956-09-3 (Carvedilol)
75659-07-3 (Dilevalol)
81147-92-4 (Esmolol)
83688-84-0 (Tertatolol)
85136-71-6 (Tilisolol)
85320-68-9 (Amosulalol)
86880-51-5 (Epanolol)
118457-14-0 (Nebivolol)
2809-21-4 (Etidronic acid)
15468-10-7 (Oxidronic acid)
40391-99-9 (Pamidronic acid)
51395-42-7 (Butedronic acid)
105462-24-6 (Risedronic acid)
51-43-4 (Epinephrine)
136-70-9 (Protokylol)
299-42-3 (Ephedrine)
497-75-6 (Dioxethedrine)
519-37-9 (Etophylline)
530-08-5 (Isoetharine)
536-24-3 (Ethylnorepinephrine)
586-06-1 (Metaproterenol)
603-00-9 (Proxyphylline)
652-37-9 (Acefylline)
2016-63-9 (Bamifylline)
3215-70-1 (Hexoprenaline)
5205-82-3 (Bevonium methyl sulfate)
5614-56-2 (1-Theobromineacetic acid)
5633-20-5 (Oxybutynin)
7683-59-2 (Isoproterenol)
13392-18-2 (Fenoterol)
13642-52-9 (Soteranol)
20267-87-2 (Diphylline)
22254-24-6 (Ipratropium bromide)
23031-25-6 (Terbutaline)
30286-75-0 (Oxitropium bromide)

30392-40-6 (Bitolterol)
30418-38-3 (Tretoquinol)
32665-36-4 (Eprozinol)
32953-89-2 (Rimiterol)
34866-47-2 (Carbuterol)
37148-27-9 (Clenbuterol)
37762-06-4 (Zaprinast)
38677-81-5 (Pirbuterol)
41570-61-0 (Tulobuterol)
48141-64-6 (Etafedrine)
54063-54-6 (Reproterol)
56341-08-3 (Mabuterol)
63516-07-4 (Flutropium bromide)
72332-33-3 (Procaterol)
81732-65-2 (Bambuterol)
89365-50-4 (Salmeterol)
129927-33-9 (NS-21)
136310-93-5 (Tiotropium bromide)
80-53-5 (Terpin)
93-14-1 (Guaifenesin)
498-71-5 (Sobrerol)
1953-02-2 (Tiopronin)
3572-43-8 (Bromhexine)
19767-45-4 (Mesna)
53943-88-7 (Letosteine)
61869-07-6 (Domiodol)
72324-18-6 (Stepronin)
84611-23-4 (Erdosteine)
9041-08-1 (Reviparin sodium)
302356-14-5 (NO-Naproxene)
302356-15-6 (NO-Flurbiprofen)
69-53-4 (Ampicillin)
71-00-1 (L-Histidine)
98-92-0 (Nicotinamide)
110-15-6 (Butanedioic acid)
321-64-2 (Tacrine)
535-65-9 (Glybuthiazole)
3447-95-8 (Benfurodil hemisuccinate)
5104-49-4 (Flurbiprofen)
14297-87-1 (Benzyl morphine)
15307-86-5 (Diclofenac)
18559-94-9 (Salbutamol)
18683-91-5 (Ambroxol)
19771-63-2 ((L)-2-Oxo-4-thiazolidinecarboxylic acid)
23214-92-8 (Doxorubicin)
34592-47-7 ((L)-Thiazolidine-4-carboxylic acid)
52081-33-1 (Mitomycins)
59277-89-3 (Acyclovir)
66376-36-1 (Alendronic acid)
75847-73-3 (Enalapril)
79902-63-9 (Simvastatin)
83881-51-0 (Cetirizine)
113665-84-2 (Clopidogrel)
124832-26-4 (Valacyclovir)
65-45-2; 103-90-2; 1503-53-3; 57-62-5; 389-08-2;
52152-93-9; 73384-59-5; 98079-51-7; 99450-52-9;
89667-40-3; 66004-77-1; 70667-26-4; 13523-86-9; 3811-25-4;
52109-93-0; 153196-03-3; 90-05-1; 5634-39-9; 9015-82-1;
301669-67-0; 301669-68-1; 301669-70-5; 301669-71-6;
301669-72-7; 301669-73-8; 301669-74-9; 301669-75-0;
301669-76-1; 301669-77-2; 301669-78-3; 301669-79-4;
301669-80-7; 301669-93-2; 301669-94-3; 301669-95-4;

REGISTRY NUMBER:

REGISTRY NUMBER:

301669-96-5; 301670-01-9; 50-78-2; 525-66-6; 22204-53-1;
301669-82-9; 301669-83-0; 301669-84-1; 301669-85-2;
301669-87-4; 301669-88-5; 301669-89-6; 301669-90-9;
301669-91-0; 301669-92-1; 301669-97-6; 301669-98-7;
301669-99-8; 301670-00-8

L82 ANSWER 47 OF 49 TOXCENTER COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:204447 TOXCENTER

COPYRIGHT: Copyright 2004 ACS

DOCUMENT NUMBER: CA13322310142G

TITLE: Synthesis, activity and formulations of pharmaceutical compounds for treatment of oxidative stress and/or endothelial dysfunction

AUTHOR(S): Del Soldato, Piero

CORPORATE SOURCE: ASSIGNEE: Nicox S.A.

PATENT INFORMATION: WO 2000061537 A2 19 Oct 2000

SOURCE: (2000) PCT Int. Appl., 159 pp.

CODEN: PIXXD2.

COUNTRY: FRANCE

DOCUMENT TYPE: Patent

FILE SEGMENT: CAPLUS

OTHER SOURCE: CAPLUS 2000:742053

LANGUAGE: English

ENTRY DATE: Entered STN: 20011116

Last Updated on STN: 20030819

ABSTRACT:

Compds. A-B-C-N(O)s and A-Cl[N(O)s]-B1 or their salts [s is an integer 1 or 2, preferably s = 2; A is the radical of a drug and is such as to meet the pharmacol. tests reported in the description; C and Cl are two bivalent radicals; the precursors of the radicals B and B1 are such as to meet the pharmacol. test reported in the description] were prepd. for use as pharmaceuticals. Thus, (S,S)-N-acetyl-S-(6-methoxy-.alpha.-methyl-2-naphthalenylacetyl)cysteine 4-nitroxybutyl ester was prepd. (NCX 2101) from naproxene and N-acetylcysteine in the first of 28 synthetic examples given. Pharmacol. test examples and tabular data are also given.

CLASSIFICATION CODE: 34-3

SUPPLEMENTARY TERMS: Miscellaneous Descriptors .

pharmaceutical compd prepn oxidative stress treatment;
endothelial function treatment pharmaceutical compd prepn;
antiinflammatory precursor; analgesic precursor;
bronchodilator precursor; expectorant precursor; mucolytic
precursor; antiasthmatic precursor; antihistaminic
precursor; ACE inhibitor precursor; beta blocker
precursor; antithrombotic precursor; vasodilator
precursor; antidiabetic precursor; **antitumor**
precursor; antiulcer precursor; antihyperlipidemic
precursor; antibiologic precursor; antiviral precursor;
bone readorption drug precursor; antidementia drug
precursor

REGISTRY NUMBER: 50-33-9 (Phenylbutazone)
50-44-2 (Mercaptopurine)
50-59-9 (Cephaloridine)
50-91-9 (Floxuridine)
51-21-8 (Fluorouracil)
51-43-4 (Epinephrine)
51-45-6 (Histamine)
53-79-2 (Puromycin)
54-25-1 (Azauridine)
54-42-2 (Idoxuridine)
54-80-8 (Pronethalol)
54-85-3 (Isoniazid)
56-75-7 (Chloramphenicol)

56-81-5Q (Glycerol, iodo deriv.)
57-08-9 (.epsilon.-Acetamidocaproic acid)
57-22-7 (Vincristine)
57-27-2 (Morphine)
57-67-0 (Sulfaguanidine)
57-68-1 (Sulfamethazine)
57-92-1 (Streptomycin)
58-32-2 (Dipyridamole)
59-05-2 (Methotrexate)
60-00-4 (Edetic acid)
60-54-8 (Tetracycline)
61-24-5 (CephalosporinC)
61-33-6 (Benzylpenicillinicacid)
61-68-7 (Mefenamicacid)
61-72-3 (Cloxacillin)
63-74-1 (Sulfanilamide)
65-49-6 (p-Aminosalicylic acid)
66-79-5 (Oxacillin)
68-26-8 (Vitamin A)
68-35-9 (Sulfadiazine)
68-41-7 (Cycloserine)
68-88-2 (Hydroxyzine)
68-90-6 (Benziodarone)
69-33-0 (Tubercidin)
70-00-8 (Trifluridine)
72-14-0 (Sulfathiazole)
74-31-7 (N,N'-Diphenyl-p-phenylenediamine)
74-55-5 (Ethambutol)
74-79-3 (Arginine)
76-41-5 (Oxymorphone)
76-42-6 (Oxycodone)
76-57-3 (Codeine)
76-58-4 (Ethylmorphine)
77-07-6 (Levorphanol)
79-57-2 (Oxytetracycline)
80-02-4 (2-p-Sulfanilylanilinoethanol)
80-03-5 (Acediasulfone)
80-08-0 (4,4'-Sulfonyldianiline)
80-32-0 (Sulfachlorpyridazine)
80-35-3 (Sulfamethoxypyridazine)
80-53-5 (Terpin)
84-16-2 (Hexestrol)
87-08-1 (Penicillin V)
87-09-2 (Penicillin O)
87-28-5 (Glycolsalicylate)
89-45-2 (Salicylsulfuricacid)
90-05-1 (Guaiacol)
91-53-2 (Ethoxyquin)
93-14-1 (Guaifenesin)
94-10-0 (Ethoxazene)
94-19-9 (Sulfaethidole)
97-53-0 (Eugenol)
97-54-1 (Isoeugenol)
98-92-0 (Nicotinamide)
100-55-0 (Nicotiny alcohol)
101-91-7 (4'-Hydroxybutyranilide)
103-12-8 (Sulfamidochrysoidine)
103-97-9 (Phenocoll)
110-17-8 (Fumaric acid)
111-17-1 (3,3'-Thiodipropionic acid)
113-98-4 (Penicillin G potassiumsalt)
114-07-8 (Erythromycin)

115-02-6 (Azaserine)
115-68-4 (Sulfadicramide)
116-42-7 (Sulfaproxyline)
116-44-9 (Sulfapyrazine)
118-55-8 (Phenyl salicylate)
118-57-0 (Acetaminosalol)
119-98-2 (Tocol)
120-34-3 (n-Sulfanilyl-3,4-xylamide)
121-00-6 (3-tert-Butyl-4-hydroxyanisole)
121-79-9 (Propyl gallate)
122-11-2 (Sulfadimethoxine)
125-28-0 (Dihydrocodeine)
125-29-1 (Hydrocodone)
127-07-1 (Hydroxyurea)
127-33-3 (Demeclocycline)
127-35-5 (Phenazocine)
127-69-5 (Sulfisoxazole)
127-71-9 (Sulfabenzamide)
127-79-7 (Sulfamerazine)
128-37-0 (3,5-Di-tert-Butyl-4-hydroxytoluene)
128-46-1 (Dihydrostreptomycin)
129-20-4 (Oxyphenbutazone)
130-16-5 (Cloxyquin)
132-60-5 (Cinchophen)
132-92-3 (Methicillinsodium salt)
132-93-4 (Phenethicillin potassium salt)
133-11-9 (Phenylaminosalicylate)
134-55-4 (Phenylacetylsalicylate)
136-70-9 (Protokylol)
138-52-3 (Salicin)
143-52-2 (Metopon)
144-14-9 (Anileridine)
144-80-9 (Sulfacetamide)
144-82-1 (Sulfamethizole)
144-83-2 (Sulfapyridine)
147-94-4 (Cytarabine)
148-24-3 (8-Quinolinol)
148-82-3 (Melphalan)
152-47-6 (Sulfalene)
153-61-7 (Cephalothin)
154-21-2 (Lincomycin)
154-42-7 (Thioguanine)
157-03-9 (6-Diazo-5-oxo-L-norleucine)
299-42-3 (Ephedrine)
302-79-4 (Retinoic acid)
303-81-1 (Novobiocin)
305-03-3 (Chlorambucil)
315-30-0 (Allopurinol)
320-67-2 (Azacitidine)
322-79-2 (Triflusal)
339-43-5 (Carbutamide)
359-83-1 (Pentazocine)
390-64-7 (Prenylamine)
395-28-8 (Isoxsuprine)
404-86-4 (Capsaicine)
427-00-9 (Desomorphine)
437-74-1 (Xanthinol niacinate)
443-48-1 (Metronidazole)
447-41-6 (Nylidrin)
456-59-7 (Cyclandelate)
458-37-7 (Curcumin)
466-97-7 (Normorphine)

466-99-9 (Hydromorphone)
468-56-4 (Hydroxypethidine)
473-30-3 (Thiazolsulfone)
477-30-5 (Demecolcine)
485-41-6 (Sulfachrysoidine)
486-79-3 (Dipyracetyl)
487-48-9 (Salacetamide)
488-41-5 (Mitobronitol)
495-76-1 (Piperonyl alcohol)
495-84-1 (Salinazid)
498-71-5 (Sobrerol)
501-94-0 (4-Hydroxyphenethyl alcohol)
509-60-4 (Dihydromorphine)
515-49-1 (Sulfathiourea)
515-59-3 (Sulfamethylthiazole)
515-64-0 (Sulfisomidine)
515-69-5 (Bisabolol)
518-28-5 (Podophyllotoxin)
519-37-9 (Etofylline)
525-94-0 (Penicillin N)
526-08-9 (Sulfaphenazole)
526-84-1 (Dihydroxymaleic acid)
530-08-5 (Isoetharine)
530-75-6 (Acetylsalicylsalicylicacid)
530-78-9 (Flufenamicacid)
533-73-3 (Hydroxyhydroquinone)
536-24-3 (Ethylnorepinephrine)
539-08-2 (p-Lactophenetide)
545-90-4 (Dimepheptanol)
547-44-4 (Sulfanilylurea)
547-52-4 (Sulfanilylsulfanilamide)
551-27-9 (Propicillin)
552-94-3 (Salsalate)
553-69-5 (Benzenemethanol, ..alpha..-[(2-pyridinylamino)methyl]-)
562-26-5 (Phenoperidine)
574-77-6 (Papaveroline)
576-68-1 (Mannomustine)
577-85-5 (3-Hydroxyflavone)
581-64-6 (Thionine)
586-06-1 (Metaproterenol)
599-88-2 (Sulfaperine)
603-00-9 (Proxiphylline)
632-00-8 (Sulfasomizole)
635-65-4 (Bilirubin)
639-48-5 (Nicomorphine)
644-62-2 (Meclofenamicacid)
651-06-9 (Sulfameter)
652-37-9 (Acefylline)
723-46-6 (Sulfamethoxazole)
729-99-7 (Sulfamoxole)
751-97-3 (Rolitetetracycline)
768-94-5 (Amantadine)
801-52-5 (Porfiromycin)
808-26-4 (Sancycline)
824-46-4 (Methoxyhydroquinone)
840-50-6 (MADU)
865-21-4 (Vinblastine)
959-10-4 (Xenbucin)
987-78-0 (Citicoline)
992-21-2 (Lymecycline)
1077-28-7 (Thioctic acid)

1083-57-4 (Bucetin)
1110-80-1 (Pipacycline)
1159-93-9 (Clobenzepam)
1174-11-4 (Xenazoic acid)
1181-54-0 (Clomocycline)
1400-61-9 (Nystatin)
1403-66-3 (Gentamicin)
1404-04-2 (Neomycin)
1404-15-5 (Nogalamycin)
1406-18-4 (Vitamin E)
1503-53-3 (5-Bromosalicylic acid acetate)
1531-12-0 (Norlevorphanol)
1553-60-2 (Ibufenac)
1596-63-0 (Quinacillin)
1614-20-6 (Nifurprazine)
1695-77-8 (Spectinomycin)
1853-37-8 (Podophyllicacid)
1926-49-4 (Clometocillin)
1953-02-2 (Tiopronin)
1984-94-7 (Sulfasymazine)
2013-58-3 (Meclocycline)
2016-63-9 (Bamifylline)
2030-63-9 (Clofazimine)
2055-44-9 (Perisoxal)
2179-16-0 (Ninopterin)
2315-08-4 (Salazosulfadimidine)
2316-64-5 (Bromosaligenin)
2363-58-8 (Epitiostanol)
2373-80-0 (3,4-Methylenedioxycinnamic acid)
2447-57-6 (Sulfadoxine)
2750-76-7 (Rifamide)
2751-09-9 (Troleandomycin)
2779-55-7 (Opiniazide)
2809-21-4 (Etidronicacid)
2933-94-0 (Toliprolol)
3056-17-5 (Stavudine)
3094-09-5 (Doxifluridine)
3116-76-5 (Dicloxacillin)
3215-70-1 (Hexoprenaline)
3485-14-1 (Cyclacillin)
3511-16-8 (Hetacillin)
3572-43-8 (Bromhexine)
3577-01-3 (Cephaloglycin)
3590-05-4 (Acetylsulfamethoxypyrazine)
3611-72-1 (Clobenfurol)
3690-05-9 (p-Coumaric alcohol)
3691-74-5 (Glyconiazide)
3703-79-5 (Bamethan)
3733-81-1 (Defosfamide)
3734-52-9 (Metazocine)
3772-76-7 (Sulfamethomidine)
3820-67-5 (Glafenine)
3922-90-5 (Oleandomycin)
3930-19-6 (Streptonigrin)
3930-20-9 (Sotalol)
4008-48-4 (Nitroxoline)
4097-22-7 (Dideoxyadenosine)
4394-00-7 (Niflumicacid)
4564-87-8 (Carbomycin)
4697-36-3 (Carbenicillin)
4803-27-4 (Anthramycin)
5205-82-3 (Bevoniummethylsulfate)

REGISTRY NUMBER:

5250-39-5 (Floxacillin)
5486-77-1 (Alloclamide)
5536-17-4 (Vidarabine)
5581-52-2 (Thiamiprine)
5633-20-5 (Oxybutynin)
5638-76-6 (Betahistine)
5728-52-9 (Felbinac)
5741-22-0 (Moprolol)
5934-14-5 (Succisulfone)
6064-83-1 (Fosfosal)
6135-36-0 (1-Butyl-3-methylurea)
6202-21-7 (4-Sulfanilamidosalicylic acid)
6452-71-7 (Oxprenolol)
6489-97-0 (Metampicillin)
6621-47-2 (Perhexiline)
6673-35-4 (Practolol)
6946-29-8 (P-Aminosalicylicacidhydrazide)
6998-60-3 (Rifamycin)
7413-36-7 (Nifenalol)
7481-89-2 (Zalcitabine)
7542-37-2 (Paromomycin)
8025-81-8 (Spiramycin)
9005-49-6 (Dalteparin)
9041-08-1 (Reviparin sodium)
10118-90-8 (Minocycline)
10318-26-0 (Mitolactol)
11003-38-6 (Capreomycin)
11006-76-1 (Virginiamycin)
11120-15-3 (Dermostatin)
12650-69-0 (Mupirocin)
13042-18-7 (Fendiline)
13292-46-1 (Rifampin)
13392-18-2 (Fenoterol)
13392-28-4 (Rimantadine)
13411-16-0 (Nifurpirinol)
13642-52-9 (Soterenol)
13655-52-2 (Alprenolol)
13665-88-8 (Mopidamol)
13710-19-5 (Tolfenamicacid)
13739-02-1 (Diacerein)
13741-18-9 (Xibornol)
13799-03-6 (Protizinicacid)
13838-08-9 (Azidamfenicol)
13898-58-3 (Benzoylpas)
13925-12-7 (Myxin)
13946-02-6 (Metron S)
13993-65-2 (Metiazinicacid)
14556-46-8 (Bupranolol)
14838-15-4 (Phenylpropanolamine)
15176-29-1 (Edoxudine)
15307-79-6 (Sodium diclofenac)
15468-10-7 (Oxidronic acid)
15599-51-6 (Apicycline)
15686-71-2 (Cephalexin)
15722-48-2 (Olsalazine)
16545-11-2 (Guamecycline)
16846-24-5 (Josamycin)
17243-38-8 (Azidocillin)
17737-65-4 (Clonixin)
17784-12-2 (Sulfacytine)
17969-20-9 (Fenclozicacid)
18046-21-4 (Fentiazac)

18323-44-9 (Clindamycin)
18378-89-7 (Plicamycin)
18471-20-0 (Ditazol)
18699-02-0 (Actarit)
18883-66-4 (Streptozocin)
19562-30-2 (Piromidicacid)
19767-45-4 (Mesna)
20168-99-4 (Cinmetacin)
20187-55-7 (Bendazac)
20594-83-6 (Nalbuphine)
20830-81-3 (Daunorubicin)
21256-18-8 (Oxaprozin)
21679-14-1 (Fludarabine)
22006-84-4 (Denopterin)
22071-15-4 (Ketoprofen)
22103-14-6 (Bufeniode)
22131-79-9 (Alclofenac)
22254-24-6 (Ipratropiumbromide)
22494-42-4 (Diflunisal)
22664-55-7 (Metipranolol)
22668-01-5 (Etanidazole)
23031-25-6 (Terbutaline)
23049-93-6 (Enfenamic acid)
23210-56-2 (Ifenprodil)
23239-41-0 (Cephacetrilesodium)
23477-98-7 (Sedecamycin)
23694-81-7 (Mepindolol)
23779-99-9 (Floctafenine)
24237-54-5 (Tinoridine)
24280-93-1 (Mycophenolic acid)
24356-60-3 (Cephapirinsodium)
25395-22-6 (Salicylamide O acetic acid)
25546-65-0 (Ribostamycin)
25803-14-9 (Clometacin)
25953-19-9 (Cefazolin)
26086-49-7 (Deoxydihydrostreptomycin)
26171-23-3 (Tolmetin)
26774-90-3 (Epicillin)
26787-78-0 (Amoxicillin)
26839-75-8 (Timolol)
26973-24-0 (Ceftazole)
27031-08-9 (Sulfaguanole)
27203-92-5 (Tramadol)
27470-51-5 (Suxibuzone)
27726-31-4 (Pivcephalexin)
27762-78-3 (Kethoxal)
28657-80-9 (Cinoxacin)
29122-68-7 (Atenolol)
29679-58-1 (Fenoprofen)
29767-20-2 (Teniposide)
30187-90-7 (Xibenolol)
30286-75-0 (Oxitropium bromide)
30392-40-6 (Bitolterol)
30418-38-3 (Tretoquinol)
30516-87-1 (Zidovudine)
30544-47-9 (Etofenamate)
30653-83-9 (Parsalmide)
31127-82-9 (Iodoxamide)
31698-14-3 (Ancitabine)
31793-07-4 (Pirprofen)
31842-01-0 (Indoprofen)
32385-11-8 (Sisomicin)

32527-55-2 (Tiaramide)
32665-36-4 (Eprozinol)
32808-51-8 (Bucloxic acid)
32887-01-7 (Amdinocillin)
32909-92-5 (Sulfametrole)
32953-89-2 (Rimiterol)
32986-56-4 (Tobramycin)
32988-50-4 (Viomycin)
33005-95-7 (Tiaprofenicacid)
33069-62-4 (Paclitaxel)
33103-22-9 (Enviomycin)
33159-27-2 (Ecabet)
33369-31-2 (Zomepirac)
33404-78-3 (Negamycin)
33419-42-0 (Etoposide)
33817-20-8 (Pivampicillin)
33996-33-7 (Oxaceprol)
34148-01-1 (Clidanac)
34444-01-4 (Cefamandole)
34493-98-6 (Dibekacin)
34552-84-6 (Isoxicam)
34661-75-1 (Urapidil)
34675-84-8 (Cetraxate)
34787-01-4 (Ticarcillin)
34866-47-2 (Carbuterol)
34915-68-9 (Bunitrolol)
34919-98-7 (Cetamolol)
35457-80-8 (Midecamycin)
35531-88-5 (Carindacillin)
35607-66-0 (Cefoxitin)
36330-85-5 (Fenbufen)
36702-83-7 (Tinofedrine)
36791-04-5 (Ribavirin)
36894-69-6 (Labetalol)
36981-91-6 (Fepradinol)
37091-66-0 (Azlocillin)
37148-27-9 (Clenbuterol)
37321-09-8 (Apramycin)
37517-28-5 (Amikacin)
37517-30-9 (Acebutolol)
37762-06-4 (Zaprinast)
38129-37-2 (Bicozamycin)
38194-50-2 (Sulindac)
38363-40-5 (Penbutolol)
38677-81-5 (Pirbuterol)
38677-85-9 (Flunixin)
38821-53-3 (Cephradine)
39324-30-6 (Pepstatin)
39718-89-3 (Alminoprofen)
39809-25-1 (Penciclovir)
40391-99-9 (Pamidronicacid)
40828-46-4 (Suprofen)
41340-25-4 (Etodolac)
41570-61-0 (Tulobuterol)
41744-40-5 (Sulbenicillin)
42200-33-9 (Nadolol)
42408-82-2 (Butorphanol)
42779-82-8 (Clopiprac)
42794-76-3 (Midodrine)
42835-25-6 (Flumequine)
47747-56-8 (Talampicillin)
50264-69-2 (Lonidamine)

50270-33-2 (Isofezolac)
50370-12-2 (Cefadroxil)
50679-08-8 (Terfenadine)
50935-04-1 (Carubicin)
50972-17-3 (Bacampicillin)
51025-85-5 (Arbekacin)
51384-51-1 (Metoprolol)
51395-42-7 (Butedronic acid)
51481-61-9 (Cimetidine)
51481-65-3 (Mezlocillin)
~~51579-82-9~~ (Amfenac)
51627-14-6 (Cefatrizine)
51762-05-1 (Cefroxadine)
51781-06-7 (Carteolol)
51940-44-4 (Pipemidicacid)
52081-33-1 (Mitomycins)
52093-21-7 (Micronomicin)
52128-35-5 (Trimetrexate)
52443-21-7 (Glucametacin)
52485-79-7 (Buprenorphine)
52549-17-4 (Pranoprofen)
53164-05-9 (Acemetacin)
53237-59-5 (Urushiol)
53597-27-6 (Fendosal)
53643-48-4 (Vindesine)
53648-05-8 (Ibuproxam)
53648-55-8 (Dezocine)
53684-49-4 (Bufetolol)
53716-49-7 (Carprofen)
53910-25-1 (Pentostatin)
53943-88-7 (Letosteine)
53994-73-3 (Cefaclor)
54063-51-3 (Nadoxolol)
54063-54-6 (Reproterol)
54083-22-6 (Zorubicin)
54340-58-8 (Meptazinol)
54340-62-4 (Bufuralol)
54749-90-5 (Chlorozotocin)
54767-75-8 (Suloctidil)
55028-70-1 (Arbaprostil)
55268-75-2 (Cefuroxime)
55453-87-7 (Isoxepac)
55726-47-1 (Enocitabine)
55837-18-8 (Butibufen)
55881-07-7 (Miokamycin)
56180-94-0 (Acarbose)
56187-47-4 (Cefazedone)
56187-89-4 (Ximoprofen)
56341-08-3 (Mabuterol)
56391-56-1 (Netilmicin)
56420-45-2 (Epirubicin)
56695-65-9 (Rosaprostol)
56796-20-4 (Cefmetazole)
56980-93-9 (Celiprolol)
57381-26-7 (Irsogladine)
57460-41-0 (Talinolol)
57475-17-9 (Brovincamine)
57653-27-7 (Droprenilamine)
57775-29-8 (Carazolol)
58001-44-8 (Clavulanicacid)
58409-59-9 (Bucumolol)
58930-32-8 (Butofilolol)

REGISTRY NUMBER:

58957-92-9 (Idarubicin)
58970-76-6 (Ubenimex)
58994-96-0 (Ranimustine)
59170-23-9 (Bevantolol)
59804-37-4 (Tenoxicam)
60607-68-3 (Indenolol)
60925-61-3 (Ceforanide)
61270-58-4 (Cefonicid)
61379-65-5 (Rifapentine)
61477-96-1 (Piperacillin)
61622-34-2 (Cefotiam)
61869-07-6 (Domiodol)
62013-04-1 (Dirithromycin)
62571-86-2 (Captopril)
62613-82-5 (Oxiracetam)
62732-44-9 (Ipidacrine)
62893-19-0 (Cefoperazone)
63147-28-4 (Acetic acid, mercapto-, [3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl ester)
63269-31-8 (Ciramadol)
63358-49-6 (Aspoxicillin)
63469-19-2 (Apalcillin)
63527-52-6 (Cefotaxime)
63610-08-2 (Indobufen)
63659-18-7 (Betaxolol)
64204-55-3 (Esomeprazole)
64218-02-6 (Plaunotol)
64221-86-9 (Imipenem)
64506-49-6 (Sofalcone)
64952-97-2 (Moxalactam)
65052-63-3 (Cefetamet)
65085-01-0 (Cefmenoxime)
65189-78-8 (Tropesin)
65271-80-9 (Mitoxantrone)
65646-68-6 (Fenretinide)
66148-78-5 (Temocillin)
66264-77-5 (Sulfinalol)
66934-18-7 (Flunoxaprofen)
68302-57-8 (Amlexanox)
68373-14-8 (Sulbactam)
68377-92-4 (Arotinolol)
68401-81-0 (Ceftizoxime)
68767-14-6 (Loxoprofen)
69049-73-6 (Nedocromil)
69655-05-6 (Didanosine)
69712-56-7 (Cefotetan)
69739-16-8 (Cefodizime)
69900-72-7 (Trimoprostil)
70052-12-9 (Eflornithine)
70374-39-9 (Lornoxicam)
70458-92-3 (Pefloxacin)
70458-96-7 (Norfloxacin)
70797-11-4 (Cefpiramide)
71002-09-0 (Pirazolac)
71125-38-7 (Meloxicam)
71426-83-0 (Fortimicin)
71486-22-1 (Vinorelbine)
71628-96-1 (Menogaril)
72324-18-6 (Stepronin)
72332-33-3 (Procaterol)
72432-03-2 (Miglitol)
72496-41-4 (Pirarubicin)

72522-13-5 (Eptazocine)
72558-82-8 (Ceftazidime)
72559-06-9 (Rifabutin)
72732-56-0 (Piritrexim)
72956-09-3 (Carvedilol)
73080-51-0 (Repirinast)
73121-56-9 (Enprostil)
73384-59-5 (Ceftriaxone)
73573-87-2 (Formoterol)
73573-88-3 (Mevastatin)
74011-58-8 (Enoxacin)
74014-51-0 (Rokitamycin)
74103-06-3 (Ketorolac)
74258-86-9 (Alacepril)
74711-43-6 (Zaltoprofen)
74863-84-6 (Argatroban)
75330-75-5 (Lovastatin)
75659-07-3 (Dilevalol)
76145-76-1 (Tomoxiprole)
76420-72-9 (Enalaprilat)
76470-66-1 (Loracarbef)
76497-13-7 (Sultamicillin)
76547-98-3 (Lisinopril)
76610-84-9 (Cefbuperazone)
77181-69-2 (Sorivudine)
77287-05-9 (Rioprostil)
78110-38-0 (Aztreonam)
78499-27-1 (Bermoprofen)
78919-13-8 (Iloprost)
78967-07-4 (Mofezolac)
79350-37-1 (Cefixime)
79516-68-0 (Levocabastine)
79548-73-5 (Pirlimycin)
79660-72-3 (Fleroxacin)
80012-43-7 (Epinastine)
80370-57-6 (Ceftiofur)
80576-83-6 (Edatrexate)
80621-81-4 (Rifaximin)
81103-11-9 (Clarithromycin)
81110-73-8 (Acetorphan)
81147-92-4 (Esmolol)
81732-65-2 (Bambuterol)
82009-34-5 (Cilastatin)
82219-78-1 (Cefuzonam)
82410-32-0 (Ganciclovir)
82413-20-5 (Droloxifene)
82419-36-1 (Ofloxacin)
82547-58-8 (Cefteram)
82571-53-7 (Ozagrel)
82834-16-0 (Perindopril)
82964-04-3 (Tolrestat)
83435-66-9 (Delapril)
83647-97-6 (Spirapril)
83688-84-0 (Tertatolol)
83799-24-0 (Fexofenadine)
83905-01-5 (Azithromycin)
84088-42-6 (Roquinimex)
84305-41-9 (Cefminox)
84611-23-4 (Erdosteine)
84845-57-8 (Ritipenem)
84880-03-5 (Cefpimizole)
84957-29-9 (Cefpirome)

85136-71-6 (Tilisolol)
85320-68-9 (Amosulalol)
85441-61-8 (Quinapril)
85721-33-1 (Ciprofloxacin)
85856-54-8 (Moveltipril)
86273-18-9 (Lenampicillin)
86541-75-5 (Benazepril)
86880-51-5 (Epanolol)
87239-81-4 (Cefpodoxime proxetil)
87333-19-5 (Ramipril)
87638-04-8 (Carumonam)
87679-37-6 (Trandolapril)
87806-31-3 (Porfimersodium)
87848-99-5 (Acrivastine)
88040-23-7 (Cefepime)
88669-04-9 (Trospectomycin)
88768-40-5 (Cilazapril)
89365-50-4 (Salmeterol)
89371-37-9 (Imidapril)
89796-99-6 (Aceclofenac)
90043-86-0 (Amiridine)
90357-06-5 (Bicalutamide)
91714-94-2 (Bromfenac)
91832-40-5 (Cefdinir)
92071-51-7 (Rotraxate)
92665-29-7 (Cefprozil)
93106-60-6 (Enrofloxacin)
93957-54-1 (Fluvastatin)
94055-76-2 (Suplatast tosylate)
95058-81-4 (Gemcitabine)
96036-03-2 (Meropenem)
97205-34-0 (Nebracetam)
97322-87-7 (Troglitazone)
97519-39-6 (Ceftibuten)
98048-97-6 (Fosinopril)
98106-17-3 (Difloxacin)
99665-00-6 (Flomoxef)
100490-36-6 (Tosufloxacin)
101363-10-4Q (Rufloxacin, iodo deriv.)
102507-71-1 (Tigemonam)
102625-70-7 (Pantoprazole)
103878-84-8 (Lazabemide)
104145-95-1 (Cefditoren)
104227-87-4 (Famciclovir)
105239-91-6 (Cefclidin)
105462-24-6 (Risedronic acid)
105889-45-0 (Cefcapene pivoxil)
105956-97-6 (Clinafloxacin)
106486-76-4 (Carzinophilin)
110140-89-1 (Ridogrel)
110871-86-8 (Sparfloxacin)
111223-26-8 (Ceronapril)
111902-57-9 (Temocapril)
112665-43-7 (Seratrodist)
112887-68-0 (Tomudex)
113359-04-9 (Cefozopran)
113852-37-2 (Cidofovir)
114798-26-4 (Losartan)
114977-28-5 (Docetaxel)
118457-14-0 (Nebivolol)
119386-96-8 (Mofegiline)
119914-60-2 (Grepafloxacin)

120410-24-4 (Biapenem)
123948-87-8 (Topotecan)
124027-47-0 (Velnacrine)
124832-26-4 (Valacyclovir)
124858-35-1 (Nadifloxacin)
126595-07-1 (Propagermanium)
127045-41-4 (Pazufloxacin)
127779-20-8 (Saquinavir)
129927-33-9 (NS21)
134523-00-5 (Atorvastatin)
134678-17-4 (Lamivudine)
135062-02-1 (Repaglinide)
135889-00-8 (Cefcapene)
136310-93-5 (Tiotropiumbromide)
144412-49-7 (Lamifiban)
147059-72-1 (Trovafloracin)
158966-92-8 (Montelukast)
80-72-8 (Reductic acid)
94-53-1 (Piperonylic acid)
138-39-6 (Mafenide)
87726-17-8 (Panipenem)
301838-00-6 (NCX 2164)
301838-28-8 (NCX 2121)
302543-75-5 (NCX 2101)
302543-76-6 (NCX 2111)
302543-77-7 (NCX 2131)
302543-78-8 (NCX 2210)
302543-79-9 (NCX 2216)
302543-80-2 (NCX 2160)
302543-81-3 (NCX 2136)
302543-82-4 (NCX 2161)
302543-83-5 (NCX 2211)
302543-84-6 (NCX 2060)
302543-85-7 (NCX 2134)
302543-86-8 (NCX 2080)
302543-87-9 (NCX 2135)
302543-88-0 (NCX 2212)
302543-89-1 (NCX 2163)
302543-90-4 (NCX 2214)
302543-91-5 (NCX 2062)
302543-92-6 (NCX 2073)
302543-93-7 (NCX 2132)
302543-94-8 (NCX 2133)
302543-95-9 (NCX 2213)
302543-96-0 (NCX 2138)
302543-97-1 (NCX 2215)
302543-98-2 (NCX 2061)
52-90-4 (L-Cysteine)
53-86-1 (Indomethacin)
89-57-6 (Mesalamine)
103-90-2 (Paracetamol)
321-64-2 (Tacrine)
18683-91-5 (Ambroxol)
59122-46-2 (Misoprostol)
66376-36-1 (Alendronic acid)
73590-58-6 (Omeprazole)
50-81-7 (Ascorbic acid)
70-18-8 (Glutathione)
89-65-6 (Isoascorbic acid)
117-39-5 (Quercetin)
120-05-8 (Sulphuretin)
121-34-6 (Vanillic acid)

REGISTRY NUMBER:

123-31-9 (1,4-Benzenediol)
149-91-7 (Gallic acid)
154-23-4 (Catechin)
303-45-7 (Gossypol)
327-97-9 (Chlorogenic acid)
331-39-5 (Caffeic acid)
492-27-3 (Kynurenic acid)
500-38-9 (Nordihydroguaiaretic acid)
520-18-3 (Kaempferol)
530-57-4 (Syringic acid)
584-85-0 (Anserine)
1078-61-1 (Hydrocaffeic acid)
3211-76-5 (Selenomethionine)
3614-08-2 (Selenocysteine)
7400-08-0 (p-Coumaric acid)
92614-59-0 (Glutathione ethyl ester)
97451-46-2 (Glutathione isopropyl ester)
2623-87-2 (4-Bromobutyric acid)
52-67-5 (Penicillamine)
59-67-6 (Nicotinic acid)
69-53-4 (Ampicillin)
110-52-1 (1,4-Dibromobutane)
305-84-0 (L-Carnosine)
479-18-5 (Diphylline)
490-79-9 (Gentisic acid)
914-00-1 (Methacycline)
927-58-2 (4-Bromobutyryl chloride)
1135-24-6 (Ferulic acid)
3447-95-8 (Benfurodil hemisuccinate)
5104-49-4 (Flurbiprofen)
15307-86-5 (Diclofenac)
15537-71-0 (n-Acetylpenicillamine)
15687-27-1 (Ibuprofen)
18559-94-9 (Salbutamol)
23214-92-8 (Doxorubicin)
26117-28-2 (n-Acetyl-D-cysteine)
36322-90-4 (Piroxicam)
59277-89-3 (Aciclovir)
75847-73-3 (Enalapril)
79902-63-9 (Simvastatin)
83881-51-0 (Cetirizine)
113665-84-2 (Clopidogrel)
REGISTRY NUMBER: 57-50-1; 57-62-5; 65-45-2; 98-54-4; 389-08-2; 458-35-5;
497-75-6; 547-53-5; 610-88-8; 3567-76-8; 3811-25-4;
4393-19-5; 13523-86-9; 16110-51-3; 52109-93-0; 52152-93-9;
70667-26-4; 89667-40-3; 98079-51-7; 153196-03-3;
7683-59-2; 99450-52-9; 9015-82-1; 301838-02-8;
301838-03-9; 164790-49-2; 77-92-9; 301669-90-9;
301838-04-0; 301838-05-1; 301838-06-2; 301838-07-3;
301838-08-4; 301838-09-5; 301838-10-8; 301838-11-9;
301838-12-0; 301838-14-2; 301838-15-3; 301838-16-4;
301838-17-5; 301838-18-6; 301838-19-7; 301838-20-0;
301838-21-1; 301838-23-3; 301838-24-4; 301838-25-5;
301838-27-7; 50-78-2; 525-66-6; 22204-53-1; 119222-62-7;
301669-82-9

L82 ANSWER 48 OF 49 TOXCENTER COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:492470 TOXCENTER
DOCUMENT NUMBER: ETICBACK-38342
TITLE: REPRODUCTION STUDIES OF AMFENAC SODIUM. 1.FERTILITY STUDY
IN RATS TREATED ORALLY WITH AMFENAC SODIUM
AUTHOR(S): KUREBE M; ASAOKA H; MORIGUCHI M; HATA T; YAMAMOTO A;

SOURCE: MYOJIN S; TAKEDA U; KOEDA T
Oyo Yakuri, (1985) (30) 117-126.
CODEN: OYYAA.
DOCUMENT TYPE: Journal
FILE SEGMENT: ETIC
LANGUAGE: Japanese; English
ENTRY DATE: Entered STN: 20021200
Last Updated on STN: 20021200
SUPPLEMENTARY TERMS: Miscellaneous Descriptors
Taxonomic Name: RATTUS, WISTAR-SLC
Test Object: MAMMAL, RAT
Assay Method: GROWTH; MUSCULOSKELETAL SYSTEM; VIABILITY,
FERTILITY AND MORTALITY; SENSE ORGANS; SEX RATIO
Experimental Conditions: PRECONCEPTION+; PRECONCEPTION
Maternal Effects: MATERNAL FERTILITY; MATERNAL WEIGHT
CHANGES; MATERNAL NUTRITION; MATERNAL HEMIC AND LYMPHATIC
SYSTEMS; MATERNAL UROGENITAL SYSTEM; MATERNAL DIGESTIVE
SYSTEM; MATERNAL DEATH; MATERNAL NEOPLASMS
REGISTRY NUMBER: 61618-27-7 (AMFENAC SODIUM)

L82 ANSWER 49 OF 49 TOXCENTER COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1979:94659 TOXCENTER
COPYRIGHT: Copyright 2004 ACS
DOCUMENT NUMBER: CA09105032550Z
TITLE: Comparative effects of antiarthritic and other
pharmacological agents in the 18-hour arthritis and
carrageenan edema tests in rats
AUTHOR(S): Sofia, R. Duane; Danielsen, Lisa; Vassar, Heidi B.
CORPORATE SOURCE: Wallace Lab., Biol. Res., Cranbury, NJ, 08512, USA.
SOURCE: Pharmacological Research Communications, (1979) Vol. 11,
No. 2, pp. 179-93.
CODEN: PLRCAT. ISSN: 0031-6989.
COUNTRY: UNITED STATES
DOCUMENT TYPE: Journal
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 1979:432550
LANGUAGE: English
ENTRY DATE: Entered STN: 20011116
Last Updated on STN: 20021203

ABSTRACT:

Fifty-three antiarthritics, antimalarials, immunosuppressives, analgesics,
antineoplastics, antifungals, antihelminthics, serotonin antagonists,
antihistamines, and misc. substances were tested for their comparative
effectiveness in the 18-h arthritis and carrageenan edema tests in rats. No
false-pos. compds. were detected, and among the 15 nonsteroidal
antiinflammatory agents, mg/kg potency was greatest in the carrageenan test.
Two compds. which may be considered as false-neg. responders were methotrexate
[59-05-2] and clotrimazole [23593-75-1]. Apparently, the 18-h arthritis test
in rats is a more reliable screening procedure than carrageenan-induced edema
for specific detection of clin. useful antiarthritic agents.

CLASSIFICATION CODE: 1-1

SUPPLEMENTARY TERMS: Miscellaneous Descriptors

arthritis inhibitors screening

REGISTRY NUMBER: 50-44-2; 50-76-0; 50-78-2; 52-24-4; 52-52-8; 53-79-2;
53-86-1; 54-25-1; 56-75-7; 58-14-0; 58-22-0; 58-33-3;
58-55-9; 59-05-2; 59-33-6; 63-45-6; 66-75-1; 66-81-9;
80-08-0; 82-92-8; 83-89-6; 86-42-0; 118-42-3; 127-07-1;
129-49-7; 147-94-4; 148-64-1; 154-42-7; 477-30-5;
523-87-5; 804-63-7; 865-21-4; 1166-34-3; 1972-08-3;
3562-84-3; 13669-70-0; 14769-73-4; 15687-27-1; 21256-18-8;
21626-89-1; 22494-42-4; 23593-75-1; 27302-90-5;
27591-97-5; 33369-31-2; 34031-32-8; 36505-82-5;

36616-52-1; 38194-50-2; 42461-84-7; 53716-49-7;
55300-29-3; **61618-27-7**

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:36:18 ON 13 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAY 2004 HIGHEST RN 681425-81-0
DICTIONARY FILE UPDATES: 12 MAY 2004 HIGHEST RN 681425-81-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> s 61618-27-7 or 91714-94-2 or 51579-82-9 or 78281-72-8 or 120638-55-3 or 8
61941-56-8

1 61618-27-7
(61618-27-7/RN)

1 91714-94-2
(91714-94-2/RN)

1 51579-82-9
(51579-82-9/RN)

1 78281-72-8
(78281-72-8/RN)

1 120638-55-3
(120638-55-3/RN)

1 61941-56-8
(61941-56-8/RN)

L83 6 61618-27-7 OR 91714-94-2 OR 51579-82-9 OR 78281-72-8 OR
120638-55-3 OR 61941-56-8

=> d ide 1-6

L83 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN

RN 120638-55-3 REGISTRY

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt, hydrate
(2:3) (9CI) (CA INDEX NAME)

MF C15 H12 Br N O3 . 3/2 H2 O . Na


SR CAS Client Services

LC STN Files: ADISINSIGHT, IPA, MRCK*, PROUSDDR, PS, SYNTHLINE, TOXCENTER,
USAN

(*File contains numerically searchable property data)

CRN (91714-94-2)

*structures
for hits
from Biotechno,
IPA, Embase, Bidsis,
Toxcenter*



● Na

● 3/2 H₂O

L83 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN

RN 91714-94-2 REGISTRY

CN Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN AHR 10282

CN Bromfenac

FS 3D CONCORD


MF C15 H12 Br N O3

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CIN, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

84 REFERENCES IN FILE CA (1907 TO DATE)

13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

84 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L83 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN

RN 78281-72-8 REGISTRY

CN Benzeneacetamide, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN AHR 9434

CN AL 6515

CN Nepafenac


FS 3D CONCORD

MF C15 H14 N2 O2

CI COM

LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMINFORMRX, DDFU,


DRUGU, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

20 REFERENCES IN FILE CA (1907 TO DATE)
 20 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L83 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 61941-56-8 REGISTRY
 CN Benzeneacetic acid, 2-amino-3-benzoyl-, monosodium salt (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN AHR 5850
 CN AHR 5850D
 CN Amfenac sodium
 CN Phenazox
 CN Sodium (2-amino-3-benzoylphenyl)acetate
 CN Sodium 2-amino-3-benzoylbenzeneacetate
 MF C15 H13 N O3 . Na
 LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, PROMT, PS, RTECS*, TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)
 CRN (51579-82-9)



● Na


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

39 REFERENCES IN FILE CA (1907 TO DATE)
 39 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L83 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 61618-27-7 REGISTRY
 CN Benzeneacetic acid, 2-amino-3-benzoyl-, monosodium salt, monohydrate (9CI) (CA INDEX NAME)
 MF C15 H13 N O3 . H2 O . Na
 LC STN Files: ANABSTR, CA, CAPLUS, IMSPATENTS, IPA, MRCK*, PHAR, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN

(*File contains numerically searchable property data)

CRN (51579-82-9)



● Na

● H₂O

2 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L83 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN

RN 51579-82-9 REGISTRY

CN Benzeneacetic acid, 2-amino-3-benzoyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (2-Amino-3-benzoylphenyl)acetic acid

CN Amfenac

CN NSC 309467

FS 3D CONCORD


MF C15 H13 N O3

CI COM

LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CIN, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

77 REFERENCES IN FILE CA (1907 TO DATE)

15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

77 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil medl

FILE 'MEDLINE' ENTERED AT 11:07:39 ON 14 MAY 2004

FILE LAST UPDATED: 13 MAY 2004 (20040513/UP). FILE COVERS 1951 TO DATE.

On February 29, 2004, the 2004 MeSH terms were loaded. See HELP RLOAD for details. OLD MEDLINE now back to 1951.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2004 vocabulary. See <http://www.nlm.nih.gov/mesh/> and http://www.nlm.nih.gov/pubs/techbull/nd03/nd03_mesh.html for a description of changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> e angiogenesis inhibitors+all/ct

E1	0	BT5	D Chemicals and Drugs/CT
E2	0	BT8	D Chemicals and Drugs/CT
E3	0	BT7	Chemical Actions and Uses/CT
E4	0	BT6	Pharmacologic Actions/CT
E5	0	BT5	Physiological Effects of Drugs/CT
E6	0	BT4	Immunologic and Biological Factors/CT
E7	3261	BT3	Biological Factors/CT
E8	0	BT6	D Chemicals and Drugs/CT
E9	0	BT9	D Chemicals and Drugs/CT
E10	0	BT8	Chemical Actions and Uses/CT
E11	0	BT7	Pharmacologic Actions/CT
E12	0	BT6	Physiological Effects of Drugs/CT
E13	0	BT5	Immunologic and Biological Factors/CT
E14	156	BT4	Immunologic and Biological Factors/CT
E15	41125	BT3	Cytokines/CT
E16	0	BT4	D Chemicals and Drugs/CT
E17	0	BT3	Growth Substances, Pigments, and Vitamins/CT
E18	0	BT4	D Chemicals and Drugs/CT
E19	0	BT7	D Chemicals and Drugs/CT
E20	0	BT6	Chemical Actions and Uses/CT
E21	0	BT5	Pharmacologic Actions/CT
E22	0	BT4	Physiological Effects of Drugs/CT
E23	0	BT3	Immunologic and Biological Factors/CT
E24	0	BT6	D Chemicals and Drugs/CT
E25	0	BT5	Chemical Actions and Uses/CT
E26	0	BT4	Pharmacologic Actions/CT
E27	0	BT3	Physiological Effects of Drugs/CT
E28	20454	BT2	Growth Substances/CT
E29	3	BT1	Angiogenesis Modulating Agents/CT
E30	0	BT3	D Chemicals and Drugs/CT
E31	0	BT6	D Chemicals and Drugs/CT
E32	0	BT5	Chemical Actions and Uses/CT
E33	0	BT4	Pharmacologic Actions/CT
E34	1	BT3	Therapeutic Uses/CT
E35	0	BT2	Antineoplastic and Immunosuppressive Agents/CT
E36	83948	BT1	Antineoplastic Agents/CT
E37	0	BT5	D Chemicals and Drugs/CT
E38	0	BT8	D Chemicals and Drugs/CT
E39	0	BT7	Chemical Actions and Uses/CT
E40	0	BT6	Pharmacologic Actions/CT
E41	0	BT5	Physiological Effects of Drugs/CT
E42	0	BT4	Immunologic and Biological Factors/CT
E43	3261	BT3	Biological Factors/CT
E44	0	BT6	D Chemicals and Drugs/CT

E45	0	BT9	D Chemicals and Drugs/CT
E46	0	BT8	Chemical Actions and Uses/CT
E47	0	BT7	Pharmacologic Actions/CT
E48	0	BT6	Physiological Effects of Drugs/CT
E49	0	BT5	Immunologic and Biological Factors/CT
E50	156	BT4	Immunologic Factors/CT
E51	41125	BT3	Cytokines/CT
E52	0	BT4	D Chemicals and Drugs/CT
E53	0	BT3	Growth Substances, Pigments, and Vitamins/CT
E54	0	BT4	D Chemicals and Drugs/CT
E55	0	BT7	D Chemicals and Drugs/CT
E56	0	BT6	Chemical Actions and Uses/CT
E57	0	BT5	Pharmacologic Actions/CT
E58	0	BT4	Physiological Effects of Drugs/CT
E59	0	BT3	Immunologic and Biological Factors/CT
E60	0	BT6	D Chemicals and Drugs/CT
E61	0	BT5	Chemical Actions and Uses/CT
E62	0	BT4	Pharmacologic Actions/CT
E63	0	BT3	Physiological Effects of Drugs/CT
E64	20454	BT2	Growth Substances/CT
E65	6639	BT1	Growth Inhibitors/CT
E66	2324	-->	Angiogenesis Inhibitors/CT
E67	2324	MN	D11.303.450.100./CT
E68	2324	MN	D22.204.25./CT
E69	2324	MN	D24.185.348.402.100./CT
E70	2324	MN	D27.505.696.377.450.100./CT
E71	2324	MN	D27.505.696.377.77.99./CT
E72	2324	MN	D27.505.696.444.348.402.100./CT
E73	2324	MN	D27.505.954.266.204.25./CT
		DC	an INDEX MEDICUS major descriptor
		NOTE	Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
		AQ	AD AE AG AI AN BI BL CF CH CL CS CT DF DU EC GE HI IM IP ME PD PH PK PO RESD SE ST TO TU UR
		PNTE	Neovascularization, Pathologic (1980-1999)
		HNTE	2004(2000); for ANGIOGENESIS FACTOR INHIBITORS use ANGIOGENESIS INHIBITORS (NM) 1981-2003
		MHTH	NLM (2000)
E74	0	UF	ANGIOGENESIS INHIB/CT
E75	0	UF	Agents, Angiostatic/CT
E76	0	UF	Agents, Anti-Angiogenetic/CT
E77	0	UF	Agents, Antiangiogenic/CT
E78	0	UF	Angiogenesis Factor Inhibitors/CT
E79	0	UF	Angiogenetic Antagonists/CT
E80	0	UF	Angiogenetic Inhibitors/CT
E81	0	UF	Angiogenic Antagonists/CT
E82	0	UF	Angiogenic Inhibitors/CT
E83	0	UF	Angiostatic Agents/CT
E84	0	UF	Antagonists, Angiogenetic/CT
E85	0	UF	Antagonists, Angiogenic/CT
E86	0	UF	Anti Angiogenetic Agents/CT
E87	0	UF	Anti Angiogenic Drugs/CT
E88	0	UF	Anti-Angiogenetic Agents/CT
E89	0	UF	Anti-Angiogenic Drugs/CT
E90	0	UF	Antiangiogenic Agents/CT
E91	0	UF	Drugs, Anti-Angiogenic/CT
E92	0	UF	Factor Inhibitors, Angiogenesis/CT
E93	0	UF	Inhibitors, Angiogenesis/CT
E94	0	UF	Inhibitors, Angiogenesis Factor/CT
E95	0	UF	Inhibitors, Angiogenetic/CT

E96	0	UF	Inhibitors, Angiogenic/CT
E97	0	UF	Inhibitors, Neovascularization/CT
E98	0	UF	Neovascularization Inhibitors/CT
E99	0	NT1	Angiostatic Proteins/CT
E100	335	NT2	Angiostatins/CT
E101	426	NT2	Endostatins/CT
E102	335	NT1	Angiostatins/CT
E103	426	NT1	Endostatins/CT
E104	1911	NT1	Interferon Alfa-2a/CT
E105	2857	NT1	Interferon Alfa-2b/CT
E106	9	NT1	Interferon Alfa-2c/CT
E107	2338	NT1	Interferon Type I, Recombinant/CT
E108	1911	NT2	Interferon Alfa-2a/CT
E109	2857	NT2	Interferon Alfa-2b/CT
E110	9	NT2	Interferon Alfa-2c/CT
E111	8208	NT1	Interferon-alpha/CT
E112	1911	NT2	Interferon Alfa-2a/CT
E113	2857	NT2	Interferon Alfa-2b/CT
E114	9	NT2	Interferon Alfa-2c/CT
E115	3025	NT1	Interferon-beta/CT
E116	5577	NT1	Interleukin-12/CT
E117	2572	NT1	Thalidomide/CT

***** END *****

*medline considers
all of these to
be angiogenesis
inhibitors*

=> d que 124; d que 127; d que 131; d que 132; d que 133; d que 136; d que 139; d que 140; d que 143

L4	771	SEA	FILE=MEDLINE	ABB=ON	IRITIS/CT
L16	27050	SEA	FILE=MEDLINE	ABB=ON	ANGIOGENESIS INHIBITORS+NT/CT
L18	18915	SEA	FILE=MEDLINE	ABB=ON	L16 (L) (TU OR AD OR PD OR PK) /CT
L19	12389	SEA	FILE=MEDLINE	ABB=ON	L18/MAJ
L24	1	SEA	FILE=MEDLINE	ABB=ON	L19 AND L4

*TU - therapeutic use
AD - administration & dosage
PD - pharmacology
PK - pharmacokinetics*

*angiogenesis
inhibitors
+
claim 7
diseases*

L7	2182	SEA	FILE=MEDLINE	ABB=ON	"RETINOPATHY OF PREMATURITY"/CT
L16	27050	SEA	FILE=MEDLINE	ABB=ON	ANGIOGENESIS INHIBITORS+NT/CT
L18	18915	SEA	FILE=MEDLINE	ABB=ON	L16 (L) (TU OR AD OR PD OR PK) /CT
L19	12389	SEA	FILE=MEDLINE	ABB=ON	L18/MAJ
L27	3	SEA	FILE=MEDLINE	ABB=ON	L19 AND L7

L12	168	SEA	FILE=MEDLINE	ABB=ON	ISCHEMI? (2A) RETINOPATH?
L16	27050	SEA	FILE=MEDLINE	ABB=ON	ANGIOGENESIS INHIBITORS+NT/CT
L18	18915	SEA	FILE=MEDLINE	ABB=ON	L16 (L) (TU OR AD OR PD OR PK) /CT
L19	12389	SEA	FILE=MEDLINE	ABB=ON	L18/MAJ
L31	4	SEA	FILE=MEDLINE	ABB=ON	L19 AND L12

L9	53987	SEA	FILE=MEDLINE	ABB=ON	RETINAL DISEASES+NT/CT
L13	29783	SEA	FILE=MEDLINE	ABB=ON	ISCHEMIA/CT
L14	69029	SEA	FILE=MEDLINE	ABB=ON	RETINA+NT/CT
L15	10436	SEA	FILE=MEDLINE	ABB=ON	RETINAL VESSELS+NT/CT
L16	27050	SEA	FILE=MEDLINE	ABB=ON	ANGIOGENESIS INHIBITORS+NT/CT
L18	18915	SEA	FILE=MEDLINE	ABB=ON	L16 (L) (TU OR AD OR PD OR PK) /CT
L19	12389	SEA	FILE=MEDLINE	ABB=ON	L18/MAJ
L32	3	SEA	FILE=MEDLINE	ABB=ON	L19 AND ((L13 AND (L9 OR (L14 OR L15))))

L3 1026 SEA FILE=MEDLINE ABB=ON PTERYGIUM/CT
 L5 300 SEA FILE=MEDLINE ABB=ON IRIDOCYCLITIS/CT
 L6 195 SEA FILE=MEDLINE ABB=ON UVEITIS, INTERMEDIATE+NT/CT
 L8 11253 SEA FILE=MEDLINE ABB=ON ANEMIA, SICKLE CELL+NT/CT
 L9 53987 SEA FILE=MEDLINE ABB=ON RETINAL DISEASES+NT/CT
 L16 27050 SEA FILE=MEDLINE ABB=ON ANGIOGENESIS INHIBITORS+NT/CT
 L33 1 SEA FILE=MEDLINE ABB=ON (L3 OR L5 OR L6 OR (L8 AND L9)) AND L16

L1 5548 SEA FILE=MEDLINE ABB=ON MACULAR DEGENERATION+NT/CT
 L2 11417 SEA FILE=MEDLINE ABB=ON DIABETIC RETINOPATHY/CT
 L10 288 SEA FILE=MEDLINE ABB=ON CORNEAL NEOVASCULARIZATION/CT
 L16 27050 SEA FILE=MEDLINE ABB=ON ANGIOGENESIS INHIBITORS+NT/CT
 L18 18915 SEA FILE=MEDLINE ABB=ON L16(L) (TU OR AD OR PD OR PK)/CT
 L19 12389 SEA FILE=MEDLINE ABB=ON L18/MAJ
 L35 574 SEA FILE=MEDLINE ABB=ON (L1 AND (L2 OR L10)) OR (L2 AND L10)
 L36 3 SEA FILE=MEDLINE ABB=ON L35 AND L19

L2 11417 SEA FILE=MEDLINE ABB=ON DIABETIC RETINOPATHY/CT
 L16 27050 SEA FILE=MEDLINE ABB=ON ANGIOGENESIS INHIBITORS+NT/CT
 L18 18915 SEA FILE=MEDLINE ABB=ON L16(L) (TU OR AD OR PD OR PK)/CT
 L19 12389 SEA FILE=MEDLINE ABB=ON L18/MAJ
 L22 11 SEA FILE=MEDLINE ABB=ON L19 AND L2
 L37 1010732 SEA FILE=MEDLINE ABB=ON GENERAL REVIEW/DT
 L39 3 SEA FILE=MEDLINE ABB=ON L37 AND L22

L10 288 SEA FILE=MEDLINE ABB=ON CORNEAL NEOVASCULARIZATION/CT
 L16 27050 SEA FILE=MEDLINE ABB=ON ANGIOGENESIS INHIBITORS+NT/CT
 L18 18915 SEA FILE=MEDLINE ABB=ON L16(L) (TU OR AD OR PD OR PK)/CT
 L19 12389 SEA FILE=MEDLINE ABB=ON L18/MAJ
 L29 19 SEA FILE=MEDLINE ABB=ON L19 AND L10
 L37 1010732 SEA FILE=MEDLINE ABB=ON GENERAL REVIEW/DT
 L40 3 SEA FILE=MEDLINE ABB=ON L37 AND L29

L1 5548 SEA FILE=MEDLINE ABB=ON MACULAR DEGENERATION+NT/CT
 L16 27050 SEA FILE=MEDLINE ABB=ON ANGIOGENESIS INHIBITORS+NT/CT
 L18 18915 SEA FILE=MEDLINE ABB=ON L16(L) (TU OR AD OR PD OR PK)/CT
 L19 12389 SEA FILE=MEDLINE ABB=ON L18/MAJ
 L37 1010732 SEA FILE=MEDLINE ABB=ON GENERAL REVIEW/DT
 L41 666 SEA FILE=MEDLINE ABB=ON L1(L) (DT OR PC)/CT
 L42 389 SEA FILE=MEDLINE ABB=ON L41/MAJ
 L43 4 SEA FILE=MEDLINE ABB=ON L42 AND L19 AND L37

*DT - drug therapy
 PC - prevention & control*

=> s l24 or l27 or l31 or l32 or l33 or l36 or l39 or l40 or l43
 L64 23 L24 OR L27 OR L31 OR L32 OR L33 OR L36 OR L39 OR L40 OR L43

=> d iall 1-23

L64 ANSWER 1 OF 23 MEDLINE on STN
 ACCESSION NUMBER: 2004134081 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 15026379
 TITLE: Scientists take aim at angiogenesis to treat degenerative eye diseases.

AUTHOR: Hampton Tracy
SOURCE: JAMA : journal of the American Medical Association, (2004
Mar 17) 291 (11) 1309-10.
Journal code: 7501160. ISSN: 1538-3598.
PUB. COUNTRY: United States
DOCUMENT TYPE: News Announcement
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200403
ENTRY DATE: Entered STN: 20040318
Last Updated on STN: 20040323
Entered Medline: 20040322
CONTROLLED TERM: Check Tags: Human
*Angiogenesis Inhibitors: TU, therapeutic use
Animals
*Diabetic Retinopathy: DT, drug therapy
*Eye: BS, blood supply
*Macular Degeneration: DT, drug therapy
*Neovascularization, Pathologic
CHEMICAL NAME: 0 (Angiogenesis Inhibitors)

L64 ANSWER 2 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2004049190 MEDLINE
DOCUMENT NUMBER: PubMed ID: 14749498
TITLE: Angiostatin and anti-angiogenic therapy in human disease.
AUTHOR: Wahl Miriam L; Moser Tammy L; Pizzo Salvatore V
CORPORATE SOURCE: Department of Pathology, Duke University Medical Center,
Durham, North Carolina 27710, USA.
CONTRACT NUMBER: CA-59960 (NCI)
CA86344 (NCI)
SOURCE: Recent progress in hormone research, (2004) 59 73-104.
Ref: 190
Journal code: 0404471. ISSN: 0079-9963.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200404
ENTRY DATE: Entered STN: 20040130
Last Updated on STN: 20040430
Entered Medline: 20040429

ABSTRACT:

Many diseases have abnormal quality and/or quantity of vascularization as a characteristic feature. Cancer cells elicit the growth of new capillaries during neovascularization in a process termed angiogenesis. In diabetics, pathologic angiogenesis in various tissues is a clinical feature of many common complications. Therefore, the diabetic cancer patient warrants special consideration and extra care in the design of anti-angiogenic treatments without adverse side effects. Some treatment regimens that look promising in vitro, in animal models, or in early clinical trials may be contra-indicated for diabetics. This chapter will review the common complications of diabetes, with emphasis on the angiogenic pathology. Recent research related to the mechanism of action and basis for specificity of the anti-angiogenic peptide, angiostatin, will be the focus. The aim is to shed light on areas in which more research is needed with respect to angiostatin and other anti-angiogenic agents and the microenvironmental conditions that affect their activities, in order to develop improved therapeutic strategies for diabetic cancer patients.

CONTROLLED TERM: Check Tags: Human; Support, U.S. Gov't, P.H.S.
Angiostatins: CH, chemistry
Angiostatins: ME, metabolism

***Angiostatsins: TU, therapeutic use**
 Animals
***Diabetes Mellitus: CO, complications**
 Diabetic Retinopathy
 Disease Models, Animal
 Endothelium, Vascular: DE, drug effects
 Endothelium, Vascular: PP, physiopathology
***Neoplasms: BS, blood supply**
***Neoplasms: CO, complications**
***Neovascularization, Pathologic: DT, drug therapy**
 Neovascularization, Pathologic: PP, physiopathology
 CAS REGISTRY NO.: 86090-08-6 (Angiostatsins)

L64 ANSWER 3 OF 23 MEDLINE on STN
 ACCESSION NUMBER: 2004007927 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 14704828
 TITLE: [Bilateral uveitis intermedia. A 15-year clinical course].
 Bilaterale Uveitis intermedia. Ein klinischer Verlauf uber
 15 Jahre.
 AUTHOR: Ayertey H D; Jordan J F; Walter P; Brunner R
 CORPORATE SOURCE: Zentrum fur Augenheilkunde, Universitat zu Koln..
 helen.ayertey@gmx.de
 SOURCE: Der Ophthalmologe : Zeitschrift der Deutschen
 Ophthalmologischen Gesellschaft, (2003 Dec) 100 (12)
 1106-8.
 Journal code: 9206148. ISSN: 0941-293X.
 PUB. COUNTRY: Germany: Germany, Federal Republic of
 DOCUMENT TYPE: (CASE REPORTS)
 Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: German
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200404
 ENTRY DATE: Entered STN: 20040106
 Last Updated on STN: 20040403
 Entered Medline: 20040402
 CONTROLLED TERM: Check Tags: Female; Human
 Adult
 Age Factors
 Anti-Inflammatory Agents: AD, administration & dosage
 Anti-Inflammatory Agents: TU, therapeutic use
 Azathioprine: AD, administration & dosage
 Azathioprine: TU, therapeutic use
 Child
 Drug Therapy, Combination
 Fluocortolone: AD, administration & dosage
 Fluocortolone: TU, therapeutic use
 Fluorescein Angiography
 Follow-Up Studies
 Fundus Oculi
 Immunosuppressive Agents: AD, administration & dosage
 Immunosuppressive Agents: TU, therapeutic use
 Interferon-beta: TU, therapeutic use
***Multiple Sclerosis: CO, complications**
 Multiple Sclerosis: DI, diagnosis
 Multiple Sclerosis: DT, drug therapy
 Time Factors
 ***Uveitis, Intermediate**
 Uveitis, Intermediate: DI, diagnosis
 Uveitis, Intermediate: DT, drug therapy
 Uveitis, Intermediate: SU, surgery
 Visual Acuity
 Vitreotomy

CAS REGISTRY NO.: 152-97-6 (Fluocortolone); 446-86-6 (Azathioprine);
77238-31-4 (Interferon-beta)
CHEMICAL NAME: 0 (Anti-Inflammatory Agents); 0 (Immunosuppressive Agents)

L64 ANSWER 4 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2003532917 MEDLINE
DOCUMENT NUMBER: PubMed ID: 14610924
TITLE: Pharmacologic therapy for diabetic retinopathy.
AUTHOR: Speicher Matthew A; Danis Ronald P; Criswell Mark; Pratt
Linda
CORPORATE SOURCE: Department of Ophthalmology, Indiana University School of
Medicine, 702 Rotary Circle, Indianapolis, IN 46202, USA.
SOURCE: Expert opinion on emerging drugs, (2003 May) 8 (1) 239-50.
Ref: 109
Journal code: 101135662. ISSN: 1472-8214.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200401
ENTRY DATE: Entered STN: 20031113
Last Updated on STN: 20040107
Entered Medline: 20040106

ABSTRACT:

Diabetic retinopathy remains one of the major causes of acquired blindness in developed nations. This is true despite the development of laser treatment, which can prevent blindness in the majority of those who develop macular oedema (ME) or proliferative diabetic retinopathy (PDR). ME is manifest by retinal vascular leakage and thickening of the retina. The hallmark of PDR is neovascularisation (NV)--abnormal angiogenesis that may ultimately cause severe vitreous cavity bleeding and/or retinal detachment. Pharmacologic therapy aimed specifically at preventing vascular leakage and NV would be a welcome addition to the armamentarium. PDR and ME could be prevented by improved metabolic control or by pharmacologically blunting the biochemical consequences of hyperglycaemia (e.g., with aldose reductase inhibitors, inhibitors of non-enzymatic glycation or by protein kinase C [PKC] inhibition). The angiogenesis in PDR could be treated via growth factor (e.g., vascular endothelial growth factor [VEGF], insulin like growth factor-1 [IGF-1]) blockade, integrin (e.g., alpha-v beta-3) blockade, extracellular matrix alteration (e.g., with steroid compounds) or interference with intracellular signal transduction pathways (e.g., PKC and mitogen activated protein kinase [MAPK] pathway proteins). Some of these antiangiogenic agents may also prove useful for treating or preventing ME. Numerous potentially useful antiangiogenic compounds are in development; two drugs are presently in clinical trials for treatment of the preproliferative stage of PDR, while two are in clinical trials for treatment of ME.

CONTROLLED TERM: Check Tags: Human
***Angiogenesis Inhibitors: TU, therapeutic use**
Animals
***Diabetic Retinopathy: DT, drug therapy**
Diabetic Retinopathy: ME, metabolism
Diabetic Retinopathy: SU, surgery
Neovascularization, Pathologic: DT, drug therapy
Neovascularization, Pathologic: ME, metabolism
Neovascularization, Pathologic: SU, surgery
CHEMICAL NAME: 0 (Angiogenesis Inhibitors)

L64 ANSWER 5 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2003440172 MEDLINE
DOCUMENT NUMBER: PubMed ID: 14502056

TITLE: Retinopathy of prematurity.
AUTHOR: Hutcheson Kelly A
CORPORATE SOURCE: Department of Ophthalmology, Childrens National Medical Center, Washington, DC 20010, USA.
SOURCE: Current opinion in ophthalmology, (2003 Oct) 14 (5) 286-90.
Ref: 30
Journal code: 9011108. ISSN: 1040-8738.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals; Health Technology
ENTRY MONTH: 200312
ENTRY DATE: Entered STN: 20030923
Last Updated on STN: 20031218
Entered Medline: 20031204

ABSTRACT:

PURPOSE OF REVIEW: This review highlights recent advances in basic science and clinical research on retinopathy of prematurity (ROP). RECENT FINDINGS: The modern concept of ROP pathophysiology is discussed, as are studies investigating anti-angiogenic agents for treatment. Results of the largest clinical trials are summarized. Current screening criteria, potential modifications to them, and telephotoscreening are discussed. SUMMARY: ROP is a challenging and involving area of pediatric ophthalmology.

CONTROLLED TERM: Check Tags: Human

***Angiogenesis Inhibitors: TU, therapeutic use**

Clinical Trials

Infant, Newborn

Mass Screening: MT, methods

Retinopathy of Prematurity: DI, diagnosis

***Retinopathy of Prematurity: DT, drug therapy**

Retinopathy of Prematurity: ET, etiology

***Retinopathy of Prematurity: PP, physiopathology**

Telemedicine

CHEMICAL NAME: 0 (Angiogenesis Inhibitors)

L64 ANSWER 6 OF 23 MEDLINE on STN

ACCESSION NUMBER: 2003301948 MEDLINE

DOCUMENT NUMBER: PubMed ID: 12830391

TITLE: [Treatment of oedematous, proliferative and neovascular diseases by intravitreal triamcinolone acetate]. Therapie intraokularer, oedematoser, proliferativer und neovaskularer Erkrankungen durch intravitreales Triamcinolon-Acetonid.

COMMENT: Comment in: Klin Monatsbl Augenheilkd. 2003 Jun;220(6):383. PubMed ID: 12830390

AUTHOR: Jonas Jost B; Kreissig Ingrid; Degenring Robert F

CORPORATE SOURCE: Universitäts-Augenklinik, Fakultät für Klinische Medizin Mannheim der Ruprecht-Karls-Universität Heidelberg.. Jost.Jonas@augen.ma.uni-heidelberg.de

SOURCE: Klinische Monatsblätter für Augenheilkunde, (2003 Jun) 220 (6) 384-90. Ref: 69

Journal code: 0014133. ISSN: 0023-2165.

PUB. COUNTRY: Germany: Germany, Federal Republic of

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, ACADEMIC)

LANGUAGE: German

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200401

ENTRY DATE: Entered STN: 20030628

Last Updated on STN: 20040129

Entered Medline: 20040128

ABSTRACT:

BACKGROUND: Recent studies have suggested that intravitreal triamcinolone acetonide may be a therapeutical possibility for treating of various intraocular neovascular, oedematous and proliferative diseases. **METHODS AND RESULTS:** Gain in visual acuity was relatively highest for eyes with intraretinal oedematous diseases such as diffuse diabetic macular oedema and various types of cystoid macular oedema due to reasons such as retinal venous occlusions and uveitis. Intravitreal triamcinolone may be useful as angiostatic therapy in eyes with iris neovascularisation and proliferative ischaemic retinopathies. Possibly, intravitreal triamcinolone may be helpful for exudative age-related macular degeneration. In eyes with chronic therapy resistant ocular hypotony, intravitreal triamcinolone can induce an increase in intraocular pressure. The role of intravitreal triamcinolone as adjunctive treatment of proliferative vitreoretinopathy has not been determined so far. Complications of intravitreal triamcinolone include secondary ocular hypertension in about 50 % of the eyes injected, with one per cent of the eyes necessitating antiglaucomatous filtering surgery; a cataractogenic effect; and postoperative infectious endophthalmitis. Long-term studies of more than 3 years follow-up have been missing so far, so that there is no reliable information on long-term complications. The injection can be combined with cataract surgery. Cataract surgery performed some months after the injection did not show a markedly elevated rate of complications. If vision increases after the intravitreal triamcinolone injection, the injection can be repeated. The duration of the effect of a single intravitreal injection of triamcinolone ranges between 2 and 9 months. Triamcinolone acetonide was detected in the aqueous humour nine months after an intravitreal injection of 25 mg. **CONCLUSIONS:** Intravitreal triamcinolone acetonide may offer a possibility for adjunctive treatment of intraocular oedematous, neovascular and proliferative diseases.

CONTROLLED TERM: Check Tags: Human***Angiogenesis Inhibitors: AD, administration & dosage**

Angiogenesis Inhibitors: AE, adverse effects

***Anti-Inflammatory Agents: AD, administration & dosage**

Anti-Inflammatory Agents: AE, adverse effects

Clinical Trials

English Abstract

***Glucocorticoids: AD, administration & dosage**

Glucocorticoids: AE, adverse effects

Injections

***Macular Degeneration: DT, drug therapy**

Macular Degeneration: ET, etiology

***Macular Edema, Cystoid: DT, drug therapy**

Macular Edema, Cystoid: ET, etiology

***Retinal Neovascularization: DT, drug therapy**

Retinal Neovascularization: ET, etiology

***Triamcinolone Acetonide: AD, administration & dosage**

Triamcinolone Acetonide: AE, adverse effects

***Vitreoretinopathy, Proliferative: DT, drug therapy**

Vitreoretinopathy, Proliferative: ET, etiology

Vitreous Body

CAS REGISTRY NO.: 76-25-5 (Triamcinolone Acetonide)**CHEMICAL NAME:** 0 (Angiogenesis Inhibitors); 0 (Anti-Inflammatory Agents); 0 (Glucocorticoids)

L64 ANSWER 7 OF 23

MEDLINE on STN

ACCESSION NUMBER: 2003178350 MEDLINE**DOCUMENT NUMBER:** PubMed ID: 12696477**TITLE:** Using thalidomide against pathological neovascularization.**AUTHOR:** Eisenkraft Arik; Luria Shai; Robenshtok Eyal; Hourvitz

SOURCE: Ariel
Harefuah, (2003 Mar) 142 (3) 212-6, 237. Ref: 39
Journal code: 0034351. ISSN: 0017-7768.
PUB. COUNTRY: Israel
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: Hebrew
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200305
ENTRY DATE: Entered STN: 20030417
Last Updated on STN: 20030514
Entered Medline: 20030513

ABSTRACT:

Thalidomide was first used during the 50's-60's, especially for morning sickness in pregnant women. It was found to be a powerful teratogen only years later and was banned from use. At the same time it was found to have anti-inflammatory and anti-angiogenic properties and was approved as treatment for leprosy. As such, thalidomide might be used against pathological neovascularization, as seen in mustard gas exposure. From past experience we know that the eyes are the most vulnerable organ to mustard gas exposure. In some of the casualties there is a late sequella including pathological corneal neovascularization. So far there is no specific effective treatment against this neovascularization. The purpose of this review is to examine current research about the potential use of thalidomide as an anti-angiogenic agent, including potential role in treating mustard gas eye injury.

CONTROLLED TERM: Check Tags: Human
***Angiogenesis Inhibitors: TU, therapeutic use**
Corneal Neovascularization: DT, drug therapy
English Abstract
***Neovascularization, Pathologic: DT, drug therapy**
***Thalidomide: TU, therapeutic use**
CAS REGISTRY NO.: 50-35-1 (Thalidomide)
CHEMICAL NAME: 0 (Angiogenesis Inhibitors)

L64 ANSWER 8 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2003165139 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12682760
TITLE: [Molecular mechanisms of vasculogenesis and angiogenesis.
What regulates vascular growth?].
Molekulare Mechanismen der Vaskulogenese und Angiogenese.
Möglichkeiten antiangiogener Therapie.
AUTHOR: Joussen A M; Kirchhof B; Gottstein C
CORPORATE SOURCE: Abteilung für Netzhaut- und Glaskörperchirurgie und Zentrum
für Molekulare Medizin, Universität zu Köln, Cologne..
JoussenA@aol.com
SOURCE: Der Ophthalmologe : Zeitschrift der Deutschen
Ophthalmologischen Gesellschaft, (2003 Apr) 100 (4) 284-91.
Journal code: 9206148. ISSN: 0941-293X.
PUB. COUNTRY: Germany: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: German
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200306
ENTRY DATE: Entered STN: 20030409
Last Updated on STN: 20030610
Entered Medline: 20030609

ABSTRACT:

The basic mechanisms governing how endothelial cells, periendothelial cells, matrix molecules and blood constituents interact with each other are discussed. The many insights gained from this basic knowledge are being extended to further understand physiological and pathological features of vascular

sprouting and maintenance. Understanding these basic principles that drive angiogenesis and vasculogenesis will lead to a more specific therapy of many disorders in ophthalmology and other fields, such as arteriosclerosis, tumor growth, myocardial ischemia and tissue repair.

CONTROLLED TERM: Check Tags: Comparative Study; Human
 Adult
 Angiogenesis Inducing Agents: PH, physiology
 Angiogenesis Inhibitors: PH, physiology
 *Angiogenesis Inhibitors: TU, therapeutic use
 Animals
 Arteriosclerosis: PP, physiopathology
 Blood Vessels: GD, growth & development
 Diabetic Retinopathy: PP, physiopathology
 Endothelial Growth Factors: PH, physiology
 Endothelium, Vascular: CY, cytology
 English Abstract
 Extracellular Matrix: PH, physiology
 *Eye Diseases: PP, physiopathology
 Eye Neoplasms: PP, physiopathology
 Growth Substances: PH, physiology
 Infant, Newborn
 Intercellular Signaling Peptides and Proteins: PH, physiology
 Lymphokines: PH, physiology
 Melanoma: PA, pathology
 Melanoma: PP, physiopathology
 Mice
 Morphogenesis
 Neoplasms: BS, blood supply
 Neoplasms: PP, physiopathology
 *Neovascularization, Pathologic
 Neovascularization, Pathologic: DT, drug therapy
 Neovascularization, Pathologic: PP, physiopathology
 *Neovascularization, Physiologic
 Pericytes
 Receptors, Vascular Endothelial Growth Factor: PH, physiology
 Retinal Neovascularization: PP, physiopathology
 Retinopathy of Prematurity: PP, physiopathology
 Stem Cells
 Vascular Endothelial Growth Factor A
 Vascular Endothelial Growth Factors
 CHEMICAL NAME: 0 (Angiogenesis Inducing Agents); 0 (Angiogenesis Inhibitors); 0 (Endothelial Growth Factors); 0 (Growth Substances); 0 (Intercellular Signaling Peptides and Proteins); 0 (Lymphokines); 0 (Vascular Endothelial Growth Factor A); 0 (Vascular Endothelial Growth Factors); EC 2.7.1.112 (Receptors, Vascular Endothelial Growth Factor)

L64 ANSWER 9 OF 23 MEDLINE on STN
 ACCESSION NUMBER: 2003009232 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 12515077
 TITLE: Antiangiogenesis agents.
 AUTHOR: Ciardella Antonio P; Donsoff Irene M; Guyer David R; Adamis Anthony; Yannuzzi Lawrence A
 CORPORATE SOURCE: LuEsther T. Mertz Retinal Research Laboratory, Manhattan Eye, Ear and Throat Hospital, 210 E. 64th Street, New York, NY 10021, USA.. aciardella@yahoo.com
 SOURCE: Ophthalmology clinics of North America, (2002 Dec) 15 (4) 453-8. Ref: 69
 Journal code: 8905383. ISSN: 0896-1549.
 PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, TUTORIAL)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200302

ENTRY DATE: Entered STN: 20030108

Last Updated on STN: 20030205

Entered Medline: 20030204

ABSTRACT:

Although these preliminary results on the use of antiangiogenesis drugs for the treatment of neovascular AMD appear promising, double-masked, placebo-controlled, multicenter clinical trials are needed to demonstrate the therapeutic efficacy of such treatments. For example, the first antiangiogenesis drug tested in AMD, interferon alpha-2a, raised great enthusiasm. Indeed, interferon alpha-2a had been shown to be antiangiogenic in animal and in vitro models. It proved to be ineffective, however, in halting the progression of neovascular AMD in a double-masked, placebo-controlled clinical trial [28]. Another antiangiogenesis drug tested in a phase 3 clinical trial is thalidomide [67]. Although the enrollment of patients is finished, the results are not yet known.

CONTROLLED TERM: Check Tags: Human; Support, Non-U.S. Gov't

*Angiogenesis Inhibitors: TU, therapeutic use

*Choroidal Neovascularization: DT, drug therapy

Choroidal Neovascularization: ET, etiology

Clinical Trials

Interferon Alfa-2a: TU, therapeutic use

Macular Degeneration: CO, complications

*Macular Degeneration: DT, drug therapy

Thalidomide: TU, therapeutic use

CAS REGISTRY NO.: 50-35-1 (Thalidomide); 76543-88-9 (Interferon Alfa-2a)

CHEMICAL NAME: 0 (Angiogenesis Inhibitors)

L64 ANSWER 10 OF 23 MEDLINE on STN

ACCESSION NUMBER: 2002639368 MEDLINE

DOCUMENT NUMBER: PubMed ID: 12399735

TITLE: [Age related macular degeneration: a review of anti-angiogenic treatments].

Traitements anti-angiogeniques au cours de la degenerescence maculaire liee a l'age.

AUTHOR: Razavi S; Coscas G; Soubrane G

CORPORATE SOURCE: Service Universitaire d'Ophtalmologie de Creteil, Centre Hospitalier Intercommunal de Creteil, 40 avenue de Verdun, 94010 Creteil, France.

SOURCE: Journal francais d'ophtalmologie, (2002 Sep) 25 (7) 747-52.

Ref: 42

Journal code: 7804128. ISSN: 0181-5512.

PUB. COUNTRY: France

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, TUTORIAL)

LANGUAGE: French

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200212

ENTRY DATE: Entered STN: 20021026

Last Updated on STN: 20021217

Entered Medline: 20021204

ABSTRACT:

In Western countries, age-related macular degeneration is the leading cause of visual loss in people aged 65 and over. Laser photocoagulation has been shown to be beneficial in patients with extra- or juxta-foveal classic choroidal neovascularization (CNV), but the majority of patients with exudative

maculopathy have occult or subfoveal CNV. Laser photocoagulation is plagued by recurrences, which occur in more than 50% of cases. Because of the limited efficacy of laser photocoagulation and the small number of patients who are eligible for treatment, investigators are attempting to develop new modalities to treat CNV. These modalities can be classified into three major categories: surgery, photodynamic and pharmacological treatments. The general mechanism, the regulation of ocular angiogenesis, and current anti-angiogenic treatments are the subject of this review of the recent literature.

CONTROLLED TERM: Check Tags: Human
 Adrenal Cortex Hormones: TU, therapeutic use
 Aged
 Aging: PH, physiology
 *Angiogenesis Inhibitors: TU, therapeutic use
 English Abstract
 *Macular Degeneration: DT, drug therapy
 Macular Degeneration: PP, physiopathology
 CHEMICAL NAME: 0 (Adrenal Cortex Hormones); 0 (Angiogenesis Inhibitors)

L64 ANSWER 11 OF 23 MEDLINE on STN
 ACCESSION NUMBER: 2002434559 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 12192207
 TITLE: Recombinant interferon alfa 2b therapy in a patient with metastatic hepatocellular carcinoma.
 AUTHOR: Yuen Man-Fung; Hon Charmaine; Hui Chee-Kin; Siu Chung-Wah; Lai Ching-Lung
 CORPORATE SOURCE: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
 SOURCE: Journal of clinical gastroenterology, (2002 Sep) 35 (3) 272-5.
 Journal code: 7910017. ISSN: 0192-0790.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: (CASE REPORTS)
 Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200210
 ENTRY DATE: Entered STN: 20020823
 Last Updated on STN: 20021026
 Entered Medline: 20021024

ABSTRACT:

At present, there is no effective treatment of metastatic hepatocellular carcinoma (HCC). Systemic interferon alfa (IFN-alpha) was found to be of some use in patients with inoperable HCC in two randomized trials. We report a case in which metastatic HCC was cured by systemic IFN-alpha 2b in combination with surgery. A patient developed two bilateral pulmonary metastatic HCC nodules 5 months after the resection of the primary HCC. He was treated with systemic IFN-alpha 2b. One lesion completely disappeared. The other lesion showed an initial response but became resistant to the IFN-alpha 2b therapy after reduction in dosage because of the side effects. This was resected in view of the absence of new metastases after 9 months of IFN-alpha 2b therapy. He remained free from recurrence at 59 months of follow-up. A rare, but reversible, complication of retinal cotton wool spots caused by IFN-alpha 2b occurred in this patient. IFN-alpha 2b is partially effective in treating metastatic HCC. The time for its administration can also serve as an observation period, which is vital in deciding whether definitive surgical treatment of any residual lesions is indicated.

CONTROLLED TERM: Check Tags: Human; Male
 *Antineoplastic Agents: TU, therapeutic use
 *Carcinoma, Hepatocellular: DT, drug therapy
 Carcinoma, Hepatocellular: SC, secondary
 Carcinoma, Hepatocellular: SU, surgery
 Hepatectomy

*Interferon Alfa-2b: TU, therapeutic use

Ischemia: CI, chemically induced

*Liver Neoplasms: DT, drug therapy

Liver Neoplasms: PA, pathology

Liver Neoplasms: SU, surgery

*Lung Neoplasms: DT, drug therapy

Lung Neoplasms: SC, secondary

Lung Neoplasms: SU, surgery

Middle Aged

Pneumonectomy

Retina

Retinal Vessels: DE, drug effects

alpha-Fetoproteins: AN, analysis

CAS REGISTRY NO.: 99210-65-8 (Interferon Alfa-2b)

CHEMICAL NAME: 0 (Antineoplastic Agents); 0 (alpha-Fetoproteins)

L64 ANSWER 12 OF 23 MEDLINE on STN

ACCESSION NUMBER: 2002159436 MEDLINE

DOCUMENT NUMBER: PubMed ID: 11891206

TITLE: Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4.

AUTHOR: Griggs Jeremy; Skepper Jeremy N; Smith Gerry A; Brindle Kevin M; Metcalfe James C; Hesketh Robin

CORPORATE SOURCE: Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom.

SOURCE: American journal of pathology, (2002 Mar) 160 (3) 1097-103. Journal code: 0370502. ISSN: 0002-9440.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 200204

ENTRY DATE: Entered STN: 20020314

Last Updated on STN: 20020404

Entered Medline: 20020402

ABSTRACT:

Retinal neovascularization occurs in a variety of diseases including diabetic retinopathy, the most common cause of blindness in the developed world. There is accordingly considerable incentive to develop drugs that target the aberrant angiogenesis associated with these conditions. Previous studies have shown that a number of anti-angiogenic agents can inhibit retinal neovascularization in a well-characterized murine model of ischemia-induced proliferative retinopathy. Combretastatin-A4 (CA-4) is an anti-vascular tubulin-binding agent currently undergoing clinical evaluation for the treatment of solid tumors. We have recently shown that CA-4 is not tumor-specific but elicits anti-vascular effects in nonneoplastic angiogenic vessels. In this study we have examined the capacity of CA-4 to inhibit retinal neovascularization in vivo. CA-4 caused a dose-dependent inhibition of neovascularization with no apparent side effects. The absence of vascular abnormalities or remnants of disrupted neovessels in retinas of CA-4-treated mice suggests an anti-angiogenic mechanism in this model, in contrast to the anti-vascular effects observed against established tumor vessels. Importantly, histological and immunohistochemical analyses indicated that CA-4 permitted the development of normal retinal vasculature while inhibiting aberrant neovascularization. These data are consistent with CA-4 eliciting tissue-dependent anti-angiogenic effects and suggest that CA-4 has potential in the treatment of nonneoplastic diseases with an angiogenic component.

CONTROLLED TERM: Check Tags: Support, Non-U.S. Gov't

*Angiogenesis Inhibitors: PD, pharmacology

Angiogenesis Inhibitors: TU, therapeutic use

Animals

*Antineoplastic Agents, Phytogenic: PD, pharmacology

Antineoplastic Agents, Phytogenic: TU, therapeutic use
 Dose-Response Relationship, Drug
 Endothelium, Vascular: DE, drug effects
 Endothelium, Vascular: PA, pathology
 Mice
 Mice, Inbred C57BL
 *Neovascularization, Pathologic: DT, drug therapy
 *Retinal Diseases: DT, drug therapy
 Retinal Diseases: PA, pathology
 *Stilbenes: PD, pharmacology
 Stilbenes: TU, therapeutic use
 CAS REGISTRY NO.: 117048-59-6 (combretastatin A-4)
 CHEMICAL NAME: 0 (Angiogenesis Inhibitors); 0 (Antineoplastic Agents,
 Phytogenic); 0 (Stilbenes)

L64 ANSWER 13 OF 23 MEDLINE on STN
 ACCESSION NUMBER: 2002154749 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 11782462
 TITLE: Down-regulation of vascular endothelial growth factor and
 up-regulation of pigment epithelium-derived factor: a
 possible mechanism for the anti-angiogenic activity of
 plasminogen kringle 5.
 AUTHOR: Gao Guoquan; Li Yan; Gee Stephen; Dudley Andrew; Fant
 James; Crosson Craig; Ma Jian-xing
 CORPORATE SOURCE: Department of Ophthalmology, Medical University of South
 Carolina, Charleston, South Carolina 29403, USA.
 CONTRACT NUMBER: EY09741 (NEI)
 EY12231 (NEI)
 EY12600 (NEI)
 SOURCE: Journal of biological chemistry, (2002 Mar 15) 277 (11)
 9492-7.
 Journal code: 2985121R. ISSN: 0021-9258.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200204
 ENTRY DATE: Entered STN: 20020312
 Last Updated on STN: 20030105
 Entered Medline: 20020405

ABSTRACT:

We have previously shown that intravitreal injection of plasminogen kringle 5 (K5), a potent angiogenic inhibitor, inhibits ischemia-induced retinal neovascularization in a rat model. Here we report that K5 down-regulates an endogenous angiogenic stimulator, vascular endothelial growth factor (VEGF) and up-regulates an angiogenic inhibitor, pigment epithelium-derived factor (PEDF) in a dose-dependent manner in vascular cells and in the retina. The regulation of VEGF and PEDF by K5 in the retina correlates with its anti-angiogenic effect in a rat model of **ischemia-induced retinopathy**. Retinal RNA levels of VEGF and PEDF are also changed by K5. K5 inhibits the p42/p44 MAP kinase activation and nuclear translocation of hypoxia-inducible factor-1alpha, which may be responsible for the down-regulation of VEGF. Down-regulation of endogenous angiogenic stimulators and up-regulation of endogenous angiogenic inhibitors, thus leading toward restoration of the balance in angiogenic control, may represent a mechanism for the anti-angiogenic activity of K5.

CONTROLLED TERM: Check Tags: Support, Non-U.S. Gov't; Support, U.S. Gov't,
 P.H.S.
 Active Transport, Cell Nucleus: DE, drug effects
 *Angiogenesis Inhibitors: PD, pharmacology
 Down-Regulation
 *Endothelial Growth Factors: AI, antagonists & inhibitors

Endothelial Growth Factors: GE, genetics
 Kringles
 *Lymphokines: AI, antagonists & inhibitors
 Lymphokines: GE, genetics
 Mitogen-Activated Protein Kinases: ME, metabolism
 Phosphorylation
 *Plasminogen: PD, pharmacology
 *Proteins: BI, biosynthesis
 Proteins: GE, genetics
 RNA, Messenger: AN, analysis
 Retina: ME, metabolism
 Retinal Neovascularization
 *Serpins: BI, biosynthesis
 Serpins: GE, genetics
 Transcription Factors: ME, metabolism
 Up-Regulation
 Vascular Endothelial Growth Factor A
 Vascular Endothelial Growth Factors
 CAS REGISTRY NO.: 9001-91-6 (Plasminogen)
 CHEMICAL NAME: 0 (Angiogenesis Inhibitors); 0 (Endothelial Growth Factors); 0 (HIF1alpha protein); 0 (Lymphokines); 0 (Proteins); 0 (RNA, Messenger); 0 (Serpins); 0 (Transcription Factors); 0 (Vascular Endothelial Growth Factor A); 0 (Vascular Endothelial Growth Factors); 0 (pigment epithelium-derived factor); EC 2.7.1.37 (Mitogen-Activated Protein Kinases)

L64 ANSWER 14 OF 23 MEDLINE on STN
 ACCESSION NUMBER: 2002009496 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 11336594
 TITLE: Anti-angiogenic therapy of proliferative diabetic retinopathy.
 COMMENT: Erratum in: Expert Opin Pharmacother 2001 Apr;2(4):727
 AUTHOR: Danis R P; Ciulla T A; Criswell M; Pratt L
 CORPORATE SOURCE: Department of Ophthalmology, Indiana University School of Medicine, 702 Rotary Circle, Indianapolis, IN 46202, USA.. rdanis@iupui.edu
 SOURCE: Expert opinion on pharmacotherapy, (2001 Mar) 2 (3) 395-407. Ref: 84
 Journal code: 100897346. ISSN: 1465-6566.
 PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200209
 ENTRY DATE: Entered STN: 20020121
 Last Updated on STN: 20020921
 Entered Medline: 20020919

ABSTRACT:

Proliferative diabetic retinopathy (PDR) remains one of the major causes of acquired blindness in developed nations. This is true despite the development of laser treatment, which can prevent blindness in the majority of those who develop this complication. The hallmark of PDR is neovascularisation (NV), abnormal angiogenesis that may ultimately cause severe vitreous cavity bleeding and/or retinal detachment. Pharmacologic therapy aimed at preventing NV, as an adjunct to laser treatment, or as an alternative to laser treatment, would be a welcome addition to the armamentarium. PDR could be prevented by improved metabolic control or by pharmacologically blunting the biochemical consequences of hyperglycaemia (e.g., with aldose reductase inhibitors, inhibitors of non-enzymatic glycation or by protein kinase C (PKC) inhibition). The

angiogenesis in PDR could be treated via growth factor (e.g., vascular endothelial growth factor (VEGF), insulin like growth factor-1) blockade, integrin (e.g., alpha-v beta-3) blockade or extracellular matrix alteration (e.g., with steroid compounds), or interference with intracellular signal transduction pathways (e.g., PKC and mitogen activated protein kinase pathway proteins). Numerous potentially useful anti-angiogenic compounds are in development, but two drugs are presently in clinical trials for the treatment of the preproliferative stage of PDR.

CONTROLLED TERM: Check Tags: Human; Support, Non-U.S. Gov't
Aldehyde Reductase: AI, antagonists & inhibitors
*Angiogenesis Inhibitors: TU, therapeutic use
Blood Glucose: AN, analysis
*Diabetic Retinopathy: DT, drug therapy
Endothelial Growth Factors: AI, antagonists & inhibitors
Glycosylation End Products, Advanced: PH, physiology
Insulin-Like Growth Factor I: AI, antagonists & inhibitors
Lasers: TU, therapeutic use
Lymphokines: AI, antagonists & inhibitors
Microsurgery
Mitogen-Activated Protein Kinases: AI, antagonists & inhibitors
Protein Kinase C: AI, antagonists & inhibitors
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
CAS REGISTRY NO.: 67763-96-6 (Insulin-Like Growth Factor I)
CHEMICAL NAME: 0 (Angiogenesis Inhibitors); 0 (Blood Glucose); 0 (Endothelial Growth Factors); 0 (Glycosylation End Products, Advanced); 0 (Lymphokines); 0 (Vascular Endothelial Growth Factor A); 0 (Vascular Endothelial Growth Factors); EC 1.1.1.21 (Aldehyde Reductase); EC 2.7.1.37 (Mitogen-Activated Protein Kinases); EC 2.7.1.37 (Protein Kinase C)

L64 ANSWER 15 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2001463146 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11508321
TITLE: Study of antiangiogenic agents with possible therapeutic applications in neoplastic disorders and macular degeneration.
AUTHOR: Ambrus J L; Toumbis C A; Karakousis C P; Kulaylat M; Akhter S; Plavsic L
CORPORATE SOURCE: Department of Internal Medicine, State University of NY at Buffalo Medical School-Kaleida Health Systems, 14203, USA.
SOURCE: Journal of medicine, (2000) 31 (5-6) 278-82.
Journal code: 7505566. ISSN: 0025-7850.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200111
ENTRY DATE: Entered STN: 20010820
Last Updated on STN: 20011105
Entered Medline: 20011101

ABSTRACT:

Using a previously developed method (Ambrus, et al., 1991), we found that pentoxifylline and thalidomide potentiate each others antiangiogenic effect induced by human malignant melanoma cells in the cornea of Macaca arctoides monkeys.

CONTROLLED TERM: Check Tags: Human; Support, Non-U.S. Gov't
*Angiogenesis Inhibitors: PD, pharmacology
Angiogenesis Inhibitors: TU, therapeutic use
Animals

Cells, Cultured
*Cornea: DE, drug effects
 *Corneal Neovascularization: DT, drug therapy
 Corneal Neovascularization: PA, pathology
Drug Combinations
Enzyme Inhibitors: PD, pharmacology
Keratinocytes
Macaca
 Macular Degeneration: DT, drug therapy
*Melanoma: PA, pathology
*Pentoxifylline: PD, pharmacology
 *Thalidomide: PD, pharmacology
CAS REGISTRY NO.: 50-35-1 (Thalidomide); 6493-05-6 (Pentoxifylline)
CHEMICAL NAME: 0 (Angiogenesis Inhibitors); 0 (Drug Combinations); 0
(Enzyme Inhibitors)

L64 ANSWER 16 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2001458672 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11226284
TITLE: Prevention of ischemia-induced
retinopathy by the natural ocular antiangiogenic
agent pigment epithelium-derived factor.
COMMENT: Comment in: Proc Natl Acad Sci U S A. 2001 Feb
27;98(5):2122-4. PubMed ID: 11226201
AUTHOR: Stellmach V; Crawford S E; Zhou W; Bouck N
CORPORATE SOURCE: Department of Microbiology-Immunology, Robert H. Lurie
Comprehensive Cancer Center, Northwestern University
Medical School, 320 East Superior Street, Chicago, IL
60611, USA.
CONTRACT NUMBER: CA52750 (NCI)
CA64239 (NCI)
SOURCE: Proceedings of the National Academy of Sciences of the
United States of America, (2001 Feb 27) 98 (5) 2593-7.
Journal code: 7505876. ISSN: 0027-8424.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200109
ENTRY DATE: Entered STN: 20010816
Last Updated on STN: 20030105
Entered Medline: 20010913

ABSTRACT:

Aberrant blood vessel growth in the retina that underlies the pathology of proliferative diabetic retinopathy and retinopathy of prematurity is the result of the ischemia-driven disruption of the normally antiangiogenic environment of the retina. In this study, we show that a potent inhibitor of angiogenesis found naturally in the normal eye, pigment epithelium-derived growth factor (PEDF), inhibits such aberrant blood vessel growth in a murine model of ***ischemia*** -induced retinopathy. Inhibition was proportional to dose and systemic delivery of recombinant protein at daily doses as low as 2.2 mg/kg could prevent aberrant endothelial cells from crossing the inner limiting membrane. PEDF appeared to inhibit angiogenesis by causing apoptosis of activated endothelial cells, because it induced apoptosis in cultured endothelial cells and an 8-fold increase in apoptotic endothelial cells could be detected in situ when the ischemic retinas of PEDF-treated animals were compared with vehicle-treated controls. The ability of low doses of PEDF to curtail aberrant growth of ocular endothelial cells without overt harm to retinal morphology suggests that this natural protein may be beneficial in the treatment of a variety of retinal vasculopathies.

CONTROLLED TERM: Check Tags: Female; Human; Support, U.S. Gov't, P.H.S.
 *Angiogenesis Inhibitors: PD, pharmacology

Animals
Apoptosis
Cells, Cultured
 Diabetic Retinopathy: ET, etiology
 ***Diabetic Retinopathy: PC, prevention & control**
Disease Models, Animal
Endothelium, Vascular: CY, cytology
Endothelium, Vascular: DE, drug effects
 ***Ischemia: CO, complications**
Mice
Mice, Inbred C57BL
*Proteins: PD, pharmacology
Recombinant Proteins: PD, pharmacology
 ***Retinal Vessels: DE, drug effects**
*Serpins: PD, pharmacology

CHEMICAL NAME: 0 (Angiogenesis Inhibitors); 0 (Proteins); 0 (Recombinant Proteins); 0 (Serpins); 0 (pigment epithelium-derived factor)

L64 ANSWER 17 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2001386889 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11440624
TITLE: Systemically expressed soluble Tie2 inhibits intraocular neovascularization.
AUTHOR: Hangai M; Moon Y S; Kitaya N; Chan C K; Wu D Y; Peters K G; Ryan S J; Hinton D R
CORPORATE SOURCE: Department of Ophthalmology, Keck School of Medicine at the University of Southern California, 2011 Zonal Avenue, Los Angeles, CA 90033, USA.
SOURCE: Human gene therapy, (2001 Jul 1) 12 (10) 1311-21.
Journal code: 9008950. ISSN: 1043-0342.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200109
ENTRY DATE: Entered STN: 20011001
Last Updated on STN: 20011001
Entered Medline: 20010927

ABSTRACT:

Retinal and choroidal neovascularization are the most frequent causes of severe and progressive vision loss. Studies have demonstrated that Tie2, an endothelial-specific receptor tyrosine kinase, plays a key role in angiogenesis. In this study, we determined whether adenovirus-mediated gene delivery of extracellular domain of the Tie2 receptor (ExTek) could inhibit experimental retinal and choroidal neovascularization. Immunofluorescence histochemistry with a monoclonal antibody to human Tie2 showed that Tie2 expression is prominent around and within the base of newly formed blood vessels of retinal and choroidal neovascular lesions. A single intramuscular injection of adenovirus expressing ExTek genes achieved plasma levels of ExTek exceeding 500 microg/ml in mice for 10 days (in neonates) and 7 days (in adults). This treatment inhibited retinal neovascularization by 47% ($p < 0.05$) in a murine model of **ischemia-induced retinopathy**. The same treatment reduced the incidence and extent of sodium fluorescein leakage from choroidal neovascular lesions by 52% ($p < 0.05$) and 36% ($p < 0.01$), respectively, in a laser-induced murine choroidal neovascularization model. The same mice showed a 45% ($p < 0.001$) reduction of integrated area of the choroidal neovascularization. These findings indicate that Tie2 signaling is a common component of the angiogenic pathway in both retinal and choroidal neovascularization, providing a potentially useful target in the treatment of intraocular neovascular diseases.

CONTROLLED TERM: Adenoviridae: GE, genetics

Age Factors

***Angiogenesis Inhibitors: PD, pharmacology**

Animals

Choroid: BS, blood supply**Fluorescein: PD, pharmacology*****Gene Therapy: MT, methods****Ischemia**

Mice

Microscopy, Fluorescence

Neoplasm Proteins: BL, blood

Neoplasm Proteins: CH, chemistry

Neoplasm Proteins: GE, genetics**Neovascularization, Pathologic**

Protein Structure, Tertiary

***Proto-Oncogene Proteins**

Receptor, TIE-2

***Retinal Vessels: ME, metabolism**

Signal Transduction

Time Factors

CAS REGISTRY NO.: 2321-07-5 (Fluorescein)
CHEMICAL NAME: 0 (Angiogenesis Inhibitors); 0 (MEN1 protein, human); 0
(Neoplasm Proteins); 0 (Proto-Oncogene Proteins); EC
2.7.1.112 (Receptor, TIE-2)

L64 ANSWER 18 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2001367970 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11245278
TITLE: Local anti-angiogenic brain tumor therapies.
AUTHOR: Sipos E P; Brem H
CORPORATE SOURCE: Division of Neurosurgery, Walter Reed Army Medical Center
Washington D.C., USA.
CONTRACT NUMBER: CA52857 (NCI)
SOURCE: Journal of neuro-oncology, (2000 Oct-Nov) 50 (1-2) 181-8.
Ref: 93
Journal code: 8309335. ISSN: 0167-594X.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200106
ENTRY DATE: Entered STN: 20010702
Last Updated on STN: 20010702
Entered Medline: 20010628

ABSTRACT:

The critical role of angiogenesis in the growth of solid tumors, including neoplasms of the central nervous system, has provided the impetus for research leading to the discovery of inhibitors of tumor neovascularization. The therapeutic potential of systemically administered antiangiogenic drugs for brain tumors, however, is limited by a variety of anatomic and physiologic barriers to drug delivery. Implantable controlled-release polymers for local drug administration directly into the tumor parenchyma have therefore been developed to achieve therapeutic concentrations of these drugs within the brain while minimizing systemic toxicity. With use of these polymers, successful antiangiogenic therapy for treatment of experimental intracranial malignancies has been achieved. This has been demonstrated with a variety of otherwise unrelated drugs -- including the angiostatic steroids, tetracycline derivatives, and amiloride -- which modulate collagenase activity, and thus, basement membrane and interstitial matrix metabolism. Controlled-release polymers provide a clinically practicable method of achieving sustained antiangiogenic therapy which can be readily used in combination with other

treatment modalities such as cytoreductive surgery, radiation, and cytotoxic chemotherapy.

CONTROLLED TERM: Check Tags: Human; Support, U.S. Gov't, P.H.S.
Amiloride: TU, therapeutic use
***Angiogenesis Inhibitors: TU, therapeutic use**
Animals
Antibiotics, Antineoplastic: TU, therapeutic use
Biological Factors: IP, isolation & purification
Biological Factors: TU, therapeutic use
Blood-Brain Barrier
Brain Neoplasms: BS, blood supply
*Brain Neoplasms: DT, drug therapy
Brain Neoplasms: PA, pathology
Cartilage: CH, chemistry
Corneal Neovascularization: DT, drug therapy
Delayed-Action Preparations
Forecasting
Glioma: BS, blood supply
Glioma: DT, drug therapy
Glioma: PA, pathology
Heparin: TU, therapeutic use
Hydrocortisone: TU, therapeutic use
Mice
Mice, Nude
*Neovascularization, Pathologic: DT, drug therapy
Polymers
Rabbits
Tetracyclines: TU, therapeutic use
Thalidomide: TU, therapeutic use
CAS REGISTRY NO.: 2609-46-3 (Amiloride); 50-23-7 (Hydrocortisone); 50-35-1 (Thalidomide); 9005-49-6 (Heparin)
CHEMICAL NAME: 0 (Angiogenesis Inhibitors); 0 (Antibiotics, Antineoplastic); 0 (Biological Factors); 0 (Delayed-Action Preparations); 0 (Polymers); 0 (Tetracyclines)

L64 ANSWER 19 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2001218632 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11309996
TITLE: Inhibitors of neovascularization.
AUTHOR: York J; Glaser B; Murphy R
CORPORATE SOURCE: Glaser Murphy Retina Treatment Center, 901 Dulaney Valley Road, Suite 200, Baltimore, MD 21204, USA.
SOURCE: Journal of ophthalmic nursing & technology, (2000 Jul-Aug) 19 (4) 194-7. Ref: 11
Journal code: 8219658. ISSN: 0744-7132.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Nursing Journals
ENTRY MONTH: 200106
ENTRY DATE: Entered STN: 20010611
Last Updated on STN: 20010611
Entered Medline: 20010607

ABSTRACT:
The use of neovascular inhibitors in the treatment of CNV will no doubt have a profound impact in the future. However, complex issues surround the use of these agents. Careful clinical trials will be necessary to determine the optimal parameters for their use. Furthermore, it must be determined whether these inhibitors will be most efficacious as primary agents or as agents used to augment the efficacy of photoreactive laser treatment or feeder vessel

treatment.

CONTROLLED TERM: Check Tags: Human
*Angiogenesis Inhibitors: TU, therapeutic use
*Macular Degeneration: DT, drug therapy
*Macular Degeneration: PP, physiopathology
*Neovascularization, Pathologic: PP, physiopathology
CHEMICAL NAME: 0 (Angiogenesis Inhibitors)

L64 ANSWER 20 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2001087920 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11133880
TITLE: The effect of an angiostatic steroid on neovascularization
in a rat model of retinopathy of prematurity.
AUTHOR: Penn J S; Rajaratnam V S; Collier R J; Clark A F
CORPORATE SOURCE: Department of Ophthalmology and Visual Sciences, Vanderbilt
University School of Medicine, Nashville, Tennessee
37232-8808, USA.. john.penn@mcmail.vanderbilt.edu
CONTRACT NUMBER: EY07533 (NEI)
SOURCE: Investigative ophthalmology & visual science, (2001 Jan) 42
(1) 283-90.
Journal code: 7703701. ISSN: 0146-0404.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200101
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20010118

ABSTRACT:

PURPOSE: The inhibition of angiogenesis by angiostatic steroids has been demonstrated in a variety of systems, including rabbit and rat cornea. There is considerable interest in the therapeutic potential of this class of compounds for angiogenic ocular conditions such as diabetic retinopathy, macular degeneration, and retinopathy of prematurity (ROP). This study was designed to test the capacity of an angiostatic steroid, anecortave acetate, to inhibit retinal neovascularization using a rat model of ROP and to investigate the mechanism of the effect. METHODS: At birth, rats were placed in an atmosphere of varying oxygen that produces retinal neovascular changes that approximate human ROP. The rats then received intravitreal injections of either anecortave acetate or vehicle at varying times, and all were subsequently placed in room air. Retinas were assessed for plasminogen activator inhibitor (PAI)-1 mRNA level by RNase protection assay at 1, 2, and 3 days after injection and for normal and abnormal blood vessel growth 3 days later. RESULTS: A significant reduction in the severity of abnormal retinal neovascularization was observed in the steroid-treated eyes compared with vehicle-injected eyes in ROP rats, yet the extent of normal total retinal vascular area was not significantly different. The drug had no effect on either retinal vascular area or neovascularization when tested in room air-raised control rats. Drug-injected eyes demonstrated a six- to ninefold increase in PAI-1 mRNA at 1 to 3 days after injection. CONCLUSIONS: This study represents the first therapeutic effect of an angiostatic steroid in an animal model of neovascular retinopathy. Additionally, the induction of PAI-1 indicates a mechanism of action for this class of compounds, and this is a novel finding in vivo. Because anecortave acetate significantly inhibited pathologic retinal angiogenesis in this model, while not significantly affecting normal intraretinal vessels, it holds therapeutic potential for a number of human ocular conditions in which angiogenesis plays a critical pathologic role.

CONTROLLED TERM: Check Tags: Female; Human; Male; Support, Non-U.S. Gov't;
Support, U.S. Gov't, P.H.S.
*Angiogenesis Inhibitors: TU, therapeutic use

Animals
Animals, Newborn
Blotting, Northern
Disease Models, Animal
Infant, Newborn
Injections
Nuclease Protection Assays
Plasminogen Activator Inhibitor 1: BI, biosynthesis
Plasminogen Activator Inhibitor 1: GE, genetics
*Pregnadienediols: TU, therapeutic use
RNA Probes
RNA, Messenger: BI, biosynthesis
Random Allocation
Rats
Rats, Sprague-Dawley
Retinal Neovascularization: ME, metabolism
Retinal Neovascularization: PA, pathology
*Retinal Neovascularization: PC, prevention & control
 *Retinopathy of Prematurity: DT, drug therapy
 Retinopathy of Prematurity: ME, metabolism
 Retinopathy of Prematurity: PA, pathology
Vitreous Body
CHEMICAL NAME: 0 (Angiogenesis Inhibitors); 0 (Plasminogen Activator
Inhibitor 1); 0 (Pregnadienediols); 0 (RNA Probes); 0 (RNA,
Messenger); 0 (anecortave acetate)

L64 ANSWER 21 OF 23 MEDLINE on STN
ACCESSION NUMBER: 95320558 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7541149
TITLE: An inside job. IL-12 attacks tumors on two fronts, but can
it win the battle?
AUTHOR: Leutwyler K
SOURCE: Scientific American, (1995 Jul) 273 (1) 24. Ref: 0
Journal code: 0404400. ISSN: 0036-8733.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199508
ENTRY DATE: Entered STN: 19950817
Last Updated on STN: 19960129
Entered Medline: 19950803
CONTROLLED TERM: Check Tags: Human
Animals
Clinical Trials
Corneal Neovascularization: DT, drug therapy
*Interleukin-12: PD, pharmacology
Mice
*Neoplasms, Experimental: BS, blood supply
*Neoplasms, Experimental: DT, drug therapy
*Neovascularization, Pathologic: DT, drug therapy
CAS REGISTRY NO.: 187348-17-0 (Interleukin-12)

L64 ANSWER 22 OF 23 MEDLINE on STN
ACCESSION NUMBER: 95255149 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7537655
TITLE: Rethinking thalidomide.
AUTHOR: Anonymous
SOURCE: Environmental health perspectives, (1995 Feb) 103 (2) 132.
Journal code: 0330411. ISSN: 0091-6765.

PUB. COUNTRY: United States
DOCUMENT TYPE: News Announcement
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199506
ENTRY DATE: Entered STN: 19950615
Last Updated on STN: 19960129
Entered Medline: 19950605
CONTROLLED TERM: Check Tags: Human
Animals
*Diabetic Retinopathy: DT, drug therapy
*Eye: BS, blood supply
*Macular Degeneration: DT, drug therapy
Neovascularization, Pathologic: DT, drug therapy
Rabbits
*Thalidomide: TU, therapeutic use
CAS REGISTRY NO.: 50-35-1 (Thalidomide)

L64 ANSWER 23 OF 23 MEDLINE on STN
ACCESSION NUMBER: 81093012 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7005131
TITLE: The treatment of lepra reaction in lepromatous leprosy.
Fifteen years' experience with thalidomide.
AUTHOR: Sheskin J
SOURCE: International journal of dermatology, (1980 Jul-Aug) 19 (6)
318-22. Ref: 67
Journal code: 0243704. ISSN: 0011-9059.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals; AIDS
ENTRY MONTH: 198103
ENTRY DATE: Entered STN: 19900316
Last Updated on STN: 19900316
Entered Medline: 19810317
CONTROLLED TERM: Check Tags: Human
Iritis: DT, drug therapy
Leprosy: CO, complications
*Leprosy: DT, drug therapy
Neuritis: DT, drug therapy
Skin Diseases: DT, drug therapy
Thalidomide: AE, adverse effects
Thalidomide: PD, pharmacology
*Thalidomide: TU, therapeutic use
Time Factors
CAS REGISTRY NO.: 50-35-1 (Thalidomide)

=> d que 157

L16 27050 SEA FILE=MEDLINE ABB=ON ANGIOGENESIS INHIBITORS+NT/CT
L18 18915 SEA FILE=MEDLINE ABB=ON L16(L) (TU OR AD OR PD OR PK)/CT
L19 12389 SEA FILE=MEDLINE ABB=ON L18/MAJ
L37 1010732 SEA FILE=MEDLINE ABB=ON GENERAL REVIEW/DT
L50 42717 SEA FILE=MEDLINE ABB=ON STOMACH NEOPLASMS/CT
L57 2 SEA FILE=MEDLINE ABB=ON L19 AND L50 AND L37

=> d iall 157 1-2

L57 ANSWER 1 OF 2 MEDLINE on STN
ACCESSION NUMBER: 95336179 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7611752
TITLE: Biomodulation of 5-fluorouracil by interferon.
AUTHOR: Aiba K
CORPORATE SOURCE: Division of Clinical Chemotherapy, Japanese Foundation for Cancer Research.
SOURCE: Gan to kagaku ryoho. Cancer & chemotherapy, (1995 Jul) 22
(8) 1018-27. Ref: 50
Journal code: 7810034. ISSN: 0385-0684.
PUB. COUNTRY: Japan
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: Japanese
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199508
ENTRY DATE: Entered STN: 19950828
Last Updated on STN: 19950828
Entered Medline: 19950815

ABSTRACT:

The biomodulation (BM) of 5-fluorouracil (5-FU) by interferon (IFN) is reviewed both preclinically and clinically, stressing clinical relevance. A number of preclinical evaluations of a combination of 5-FU and IFN were performed before Wadler et al. developed an active biomodulation therapy with a combination of 5-FU and IFN. However, extensive preclinical investigations have been performed very recently showing that IFN can enhance cytotoxic effects of 5-FU through various mechanisms, not only by increased anabolism of 5-FU to 5-fluoro 2'-deoxyuridine monophosphate (FdUMP) or 5-fluorouridine (FUR), inhibition of thymidine kinase activity, possible alternation of pharmacokinetics of 5-FU, but also by biological response modification. Since a high response rate of 76.4% in patients with previously untreated advanced metastatic colorectal cancer was reported by Wadler et al., with the combination of 5-FU and IFN, consecutive extensive phase II studies of the combination have been undertaken and shown a modest response rate ranging from 25% to 43% for colorectal cancer. An attempt to add leucovorin (LV) to the combination of 5-FU and IFN has so far appeared less successful. It showed almost the same efficacy in terms of response rate and survival, but more significant side effects. A further study is warranted to evaluate the optimal dose and schedule of IFN in combination with 5-FU or the 5-FU and LV combination chemotherapy in the proper sense of biomodulation. The role of biomodulating chemotherapy of 5-FU by IFN or IFN and LV must also be investigated in the field of head and neck cancers, esophageal cancer, biliary tract cancer, all of which are relatively sensitive to the effector of 5-FU.

CONTROLLED TERM: Check Tags: Human
Clinical Trials, Phase II
Colorectal Neoplasms: PA, pathology
*Colorectal Neoplasms: TH, therapy
Drug Synergism
Drug Therapy, Combination

*angiogenesis
inhibitors
+
diseases of
claim 9*

English Abstract

*Fluorouracil: AD, administration & dosage
 *Interferon Alfa-2b: AD, administration & dosage
 Leucovorin: AD, administration & dosage
 Stomach Neoplasms: PA, pathology
 Stomach Neoplasms: TH, therapy

CAS REGISTRY NO.: 51-21-8 (Fluorouracil); 58-05-9 (Leucovorin); 99210-65-8 (Interferon Alfa-2b)

L57 ANSWER 2 OF 2 MEDLINE on STN
 ACCESSION NUMBER: 95069606 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 7978897
 TITLE: The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors.
 AUTHOR: Oberg K; Eriksson B; Janson E T
 CORPORATE SOURCE: Department of Internal Medicine, University Hospital, Uppsala, Sweden.
 SOURCE: Annals of the New York Academy of Sciences, (1994 Sep 15) 733 471-8. Ref: 33
 Journal code: 7506858. ISSN: 0077-8923.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199412
 ENTRY DATE: Entered STN: 19950110
 Last Updated on STN: 20000303
 Entered Medline: 19941202
 CONTROLLED TERM: Check Tags: Human
 Carcinoid Tumor: TH, therapy
 Interferon Type I, Recombinant: AE, adverse effects
 *Interferon Type I, Recombinant: TU, therapeutic use
 Interferon-alpha: AE, adverse effects
 *Interferon-alpha: TU, therapeutic use
 *Neuroendocrine Tumors: TH, therapy
 *Pancreatic Neoplasms: TH, therapy
 *Stomach Neoplasms: TH, therapy
 CHEMICAL NAME: 0 (Interferon Type I, Recombinant); 0 (Interferon-alpha)

=> d que 163

L16	27050	SEA	FILE=MEDLINE	ABB=ON	ANGIOGENESIS INHIBITORS+NT/CT
L18	18915	SEA	FILE=MEDLINE	ABB=ON	L16 (L) (TU OR AD OR PD OR PK)/CT
L19	12389	SEA	FILE=MEDLINE	ABB=ON	L18/MAJ
L37	1010732	SEA	FILE=MEDLINE	ABB=ON	GENERAL REVIEW/DT
L44	41389	SEA	FILE=MEDLINE	ABB=ON	PROSTATIC NEOPLASMS/CT
L45	92936	SEA	FILE=MEDLINE	ABB=ON	LUNG NEOPLASMS+NT/CT
L46	113317	SEA	FILE=MEDLINE	ABB=ON	BREAST NEOPLASMS+NT/CT
L47	27635	SEA	FILE=MEDLINE	ABB=ON	BLADDER NEOPLASMS/CT
L48	35291	SEA	FILE=MEDLINE	ABB=ON	KIDNEY NEOPLASMS+NT/CT
L49	43037	SEA	FILE=MEDLINE	ABB=ON	COLONIC NEOPLASMS+NT/CT
L51	29803	SEA	FILE=MEDLINE	ABB=ON	PANCREATIC NEOPLASMS+NT/CT
L52	36403	SEA	FILE=MEDLINE	ABB=ON	OVARIAN NEOPLASMS+NT/CT
L53	44451	SEA	FILE=MEDLINE	ABB=ON	MELANOMA+NT/CT
L54	30544	SEA	FILE=MEDLINE	ABB=ON	CARCINOMA, HEPATOCELLULAR/CT
L55	77067	SEA	FILE=MEDLINE	ABB=ON	SARCOMA+NT/CT
L56	10559	SEA	FILE=MEDLINE	ABB=ON	LYMPHOMA, DIFFUSE+NT/CT
L58	85285	SEA	FILE=MEDLINE	ABB=ON	((L44 OR L45 OR L46 OR L47 OR L48 OR L49) OR (L51 OR L52 OR L53 OR L54 OR L55 OR L56)) (L) (DT OR

many answers with all of these, so I gave you the 15 oldest review articles

PC)/CT

L59 52129 SEA FILE=MEDLINE ABB=ON L58/MAJ
L61 90 SEA FILE=MEDLINE ABB=ON L59 AND L19 AND L37
L62 79 SEA FILE=MEDLINE ABB=ON AB/FA AND L61
L63 79 SOR L62 1- PY A

=> d iall l63 1-15; fil hom

L63 ANSWER 1 OF 79 MEDLINE on STN
ACCESSION NUMBER: 2000281872 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10822464
TITLE: Interferon treatment of renal cell carcinoma. Current status and future prospects.
AUTHOR: Krown S E
CORPORATE SOURCE: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
CONTRACT NUMBER: CA-33049 (NCI)
SOURCE: Cancer, (1987 Feb 1) 59 (3 Suppl) 647-51. Ref: 37
Journal code: 0374236. ISSN: 0008-543X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200006
ENTRY DATE: Entered STN: 20000622
Last Updated on STN: 20000622
Entered Medline: 20000614

ABSTRACT:

Studies with various interferon alpha preparations, including interferons induced in human leukocytes, interferon alfa-N1, interferon alfa-2a, and interferon alfa-2b, have all provided evidence for modest but reproducible antitumor activity in advanced renal cell carcinoma. Review of the data suggests that maximal response rates are achieved when interferon alpha is administered within a fairly restricted range of moderate to high doses, whereas extremely low or extremely high dosage regimens appear less likely to induce therapeutic response. Preliminary evidence suggests that interferons beta and gamma may also induce regression of metastatic renal cell carcinoma. Recent in vitro and animal studies have shown that combinations of interferon gamma with interferon alpha or interferon beta, produce synergistic biologic activities, suggesting that the various interferons may have different pathways of action related to agent-specific cellular receptors. Possible interactions of different interferon species given concurrently to patients with renal cell carcinoma are under investigation, as are combinations of interferon alpha with chemotherapeutic agents. Despite in vitro data suggesting enhanced antiproliferative activity for the combination of interferon alpha and vinblastine, most clinical studies of this combination have proved to be no more effective than interferon alpha alone, but they have provided evidence of increased toxicity. The recent identification and purification of other biologically active cytokines, such as tumor necrosis factor and interleukin-2, and of monoclonal antibodies that recognize unique cell surface antigens on renal carcinoma cells, provide exciting possibilities for combination regimens with various interferon species.

CONTROLLED TERM: Check Tags: Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
Animals
Antineoplastic Agents: AD, administration & dosage
*Antineoplastic Agents: TU, therapeutic use
Antineoplastic Combined Chemotherapy Protocols: TU, therapeutic use

*Carcinoma, Renal Cell: DT, drug therapy
Carcinoma, Renal Cell: SC, secondary
Drug Synergism
Forecasting
Immunotherapy
Interferon Type I, Recombinant: AD, administration & dosage
*Interferon Type I, Recombinant: TU, therapeutic use
Interferon Type II: TU, therapeutic use
Interferon-alpha: AD, administration & dosage
*Interferon-alpha: TU, therapeutic use
Interferon-beta: TU, therapeutic use
*Kidney Neoplasms: DT, drug therapy
Remission Induction

CAS REGISTRY NO.: 77238-31-4 (Interferon-beta); 82115-62-6 (Interferon Type II)
CHEMICAL NAME: 0 (Antineoplastic Agents); 0 (Antineoplastic Combined Chemotherapy Protocols); 0 (Interferon Type I, Recombinant); 0 (Interferon-alpha)

L63 ANSWER 2 OF 79 MEDLINE on STN
ACCESSION NUMBER: 91206418 MEDLINE
DOCUMENT NUMBER: PubMed ID: 2018047
TITLE: Antiretroviral therapy in combination with interferon for AIDS-related Kaposi's sarcoma.
AUTHOR: Fischl M A
CORPORATE SOURCE: Department of Medicine, University of Miami School of Medicine, Florida 33101.
SOURCE: American journal of medicine, (1991 Apr 10) 90 (4A) 2S-7S.
Ref: 36
Journal code: 0267200. ISSN: 0002-9343.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals; AIDS
ENTRY MONTH: 199105
ENTRY DATE: Entered STN: 19910607
Last Updated on STN: 20000303
Entered Medline: 19910523

ABSTRACT:

In vitro studies have shown that 3'-azido-3'-deoxythymidine (zidovudine, AZT) and interferon synergistically inhibit the replication of the human immunodeficiency virus type 1 (HIV) in peripheral blood mononuclear cells at concentrations achievable in patients. Interferon alfa can cause lesions to regress in patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma (KS). Although zidovudine has no significant effect on the regression of these lesions, it does have antiviral activity in these patients as manifested by a decline in serum HIV antigen. However, when used separately, the two drugs can have serious side effects in some patients. In addition, the development of zidovudine-resistant strains has been noted in patients with advanced HIV disease receiving zidovudine for nine months or longer. Three in vivo trials have been initiated to assess possible advantages of combination therapy with zidovudine and interferon alfa in patients with AIDS-related KS. The incidence of serious adverse reactions, therapeutic efficacy, and the rate of emergence of zidovudine-resistant strains of HIV were evaluated. Preliminary results indicate that combination therapy with interferon alfa and zidovudine can safely be administered to patients with AIDS-related KS in doses that elicit antitumor and antiviral responses and

discourage the potential emergence of zidovudine-resistant HIV strains.

CONTROLLED TERM: Check Tags: Human
*Acquired Immunodeficiency Syndrome: CO, complications
Clinical Trials
Dose-Response Relationship, Drug
Drug Therapy, Combination
HIV Antigens: IP, isolation & purification
*Interferon Type I, Recombinant: AD, administration & dosage
Interferon Type I, Recombinant: TU, therapeutic use
Sarcoma, Kaposi: CO, complications
*Sarcoma, Kaposi: DT, drug therapy
*Zidovudine: AD, administration & dosage
Zidovudine: AE, adverse effects
CAS REGISTRY NO.: 30516-87-1 (Zidovudine)
CHEMICAL NAME: 0 (HIV Antigens); 0 (Interferon Type I, Recombinant)

L63 ANSWER 3 OF 79 MEDLINE on STN
ACCESSION NUMBER: 95084211 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7992096
TITLE: Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
AUTHOR: Buzaid A C; Legha S S
CORPORATE SOURCE: Department of Melanoma/Sarcoma, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
SOURCE: Seminars in oncology, (1994 Dec) 21 (6 Suppl 14) 23-8.
Ref: 46
Journal code: 0420432. ISSN: 0093-7754.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
(CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199501
ENTRY DATE: Entered STN: 19950124
Last Updated on STN: 19990129
Entered Medline: 19950112

ABSTRACT:

The antitumor activity of available chemotherapy regimens against advanced melanoma is modest. Likewise, the results with biologic response modifiers such as interleukin-2 (IL-2) and interferon-alfa (IFN-alfa), used alone or in combination, also have been disappointing, although some patients experience very durable remissions. However, the combination of cisplatin-based chemotherapy with IL-2 plus IFN-alfa, referred to as biochemotherapy, has shown encouraging preliminary results. Investigators at M.D. Anderson Cancer Center have conducted a series of phase II studies exploring different schedules of chemotherapy administration using a regimen of cisplatin, vinblastine, and dacarbazine (CVD) and IL-2 plus IFN-alfa (biotherapy). Alternating CVD with biotherapy every 6 weeks produced a response rate similar to that obtained by using CVD alone. The administration of biotherapy immediately after CVD followed by a sandwich of biotherapy/CVD/biotherapy appears to be superior to CVD alone. Finally, the administration of biotherapy concurrently with CVD also appears to be superior to CVD alone. Similar results were observed by other investigators using a cisplatin-based regimen in combination with IL-2 plus IFN-alfa. The mechanism of antitumor effect of biochemotherapy remains unclear. Preliminary results of laboratory studies performed at M.D. Anderson Cancer Center suggest that the biotherapy may act by enhancing the cytotoxic effect of CVD, possibly by activation of

tumor-infiltrating macrophages, which release pro-oxidants that affect the DNA repair process of the tumor cells. Collectively, these clinical and laboratory findings indicate that biotherapy may be synergistic with cisplatin-based regimens and that the sequence of administration appears to be important.

CONTROLLED TERM: Check Tags: Human
Antineoplastic Combined Chemotherapy Protocols: PD,
pharmacology
*Antineoplastic Combined Chemotherapy Protocols: TU,
therapeutic use
*Cisplatin: AD, administration & dosage
Cisplatin: PD, pharmacology
Clinical Trials, Phase II
Combined Modality Therapy
Dacarbazine: AD, administration & dosage
Dacarbazine: PD, pharmacology
Drug Administration Schedule
Interferon-alpha: PD, pharmacology
*Interferon-alpha: TU, therapeutic use
Interleukin-2: PD, pharmacology
*Interleukin-2: TU, therapeutic use
*Melanoma: DT, drug therapy
*Melanoma: TH, therapy
Vinblastine: AD, administration & dosage
Vinblastine: PD, pharmacology
CAS REGISTRY NO.: 15663-27-1 (Cisplatin); 4342-03-4 (Dacarbazine); 865-21-4
(Vinblastine)
CHEMICAL NAME: 0 (Antineoplastic Combined Chemotherapy Protocols); 0
(Interferon-alpha); 0 (Interleukin-2)

L63 ANSWER 4 OF 79 MEDLINE on STN
ACCESSION NUMBER: 96001424 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7571029
TITLE: Long-lasting complete remission of pulmonary metastases
consequent to renal cell carcinoma obtained with
interferon-beta therapy: review of the literature and a
case report.
AUTHOR: Scoconi C; Torresi U; Di Giuseppe M
CORPORATE SOURCE: Department of Oncology, Hospital of Macerata, Italy.
SOURCE: Tumori, (1995 May-Jun) 81 (3) 201-3. Ref: 24
Journal code: 0111356. ISSN: 0300-8916.
PUB. COUNTRY: Italy
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW OF REPORTED CASES)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199511
ENTRY DATE: Entered STN: 19951227
Last Updated on STN: 19951227
Entered Medline: 19951106

ABSTRACT:
This case report describes a complete remission of pulmonary metastases,
consequent to renal cancer, achieved with interferon-beta therapy. After
nephrectomy (July 1990), this female patient was proposed for therapeutic
assessment: vinblastine chemotherapy was carried out for 10 cycles, whereas
concomitant immunotherapy of interferon-alpha was discontinued after 30 days
owing to lack of tolerability. In replacement, interferon-beta administration
from the 5th cycle of chemotherapy at the dose of 3 MIU 3 times a week was well
tolerated. Interferon-beta was interrupted 27 months later, due to an increase
in transaminase levels. Partial remission of pulmonary metastases was assessed
after 9 months of interferon-beta therapy, and a complete remission was

assessed after 1 and 2 years of therapy. In November 1994, the patient was still in good clinical conditions and disease-free after 37 months from the achievement of complete remission.

CONTROLLED TERM: Check Tags: Female; Human
Aged
*Antineoplastic Agents: TU, therapeutic use
***Carcinoma, Renal Cell: DT, drug therapy**
Carcinoma, Renal Cell: SC, secondary
***Interferon-beta: TU, therapeutic use**
*Kidney Neoplasms: PA, pathology
***Lung Neoplasms: DT, drug therapy**
Lung Neoplasms: SC, secondary
CAS REGISTRY NO.: 77238-31-4 (Interferon-beta)
CHEMICAL NAME: 0 (Antineoplastic Agents)

L63 ANSWER 5 OF 79 MEDLINE on STN
ACCESSION NUMBER: 95366810 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7639570
TITLE: [Clinical trial with intravesical alfa-2b interferon for the prevention of T1 transitional carcinoma of the bladder: preliminary results. Review of the bibliography].
Ensayo clinico con interferon alfa-2b endovesical en la profilaxis del carcinoma transicional de vejiga T1: resultados preliminares. Discusion de la bibliografia.
AUTHOR: Portillo Martin J A; Martin Garcia B; Hernandez Rodriguez R; Correas Gomez M A; Gutierrez Banos J L; del Valle Schaan J I; Monge Mirallas J M; Roca Edreira A
CORPORATE SOURCE: Servicio de Urologia, Hospital Universitario, Marques de Valdecilla, Santander, Espana.
SOURCE: Archivos espanoles de urologia, (1995 Jun) 48 (5) 479-88.
Ref: 67
Journal code: 0064757. ISSN: 0004-0614.
PUB. COUNTRY: Spain
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: Spanish
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199509
ENTRY DATE: Entered STN: 19950921
Last Updated on STN: 19950921
Entered Medline: 19950908

ABSTRACT:

OBJECTIVE: To assess the efficacy of 60 MU intravesical alpha-2b interferon (IFN) in preventing recurrence of transitional cell carcinoma of the bladder.
METHODS: A prospective, randomized double-blind study was conducted to assess the efficacy of 60 MU intravesical alpha-2b IFN compared to a control group. T1G2-G3 and the G1 recurrent tumors were included in the study (30 in each group). Instillation was started 2-3 weeks after complete TUR and administered once weekly for 12 weeks and once monthly thereafter for one year. **RESULTS:** The distribution according to sex and age of the patient, tumor size, grade and classification as primary or secondary was the same for both groups. Multiple tumors were prevalent in the IFN-treated group. During the first year of follow up, the tumor recurrence rate was 23.3% for the IFN-treated group and 36.6% for the control group. At 22.4 months mean follow up, the rate of recurrence was 40% for the IFN-treated group and 46.6% for the control group. Of these recurrences, 8.3% of tumors in the IFN group showed progression in grade and/or stage versus 35.7% for the control group. The disease-free interval averaged 8.5 months; 10.5 for the treated group and 6.9 months for the control group. Local or systemic toxicity was negligible. **CONCLUSIONS:**

Alpha-2b IFN is well-tolerated at a dose of 60 MU. It prolongs the disease-free interval and while throughout the follow up period the recurrence rate is similar to that of the control group, it does seem to markedly slow progression in the grade and/or stage of the tumor.

CONTROLLED TERM: Check Tags: Female; Human; Male
Administration, Intravesical
Aged
Bladder Neoplasms: PA, pathology
*Bladder Neoplasms: PC, prevention & control
Carcinoma, Transitional Cell: PA, pathology
*Carcinoma, Transitional Cell: PC, prevention & control
Double-Blind Method
English Abstract
Follow-Up Studies
*Interferon Alfa-2b: TU, therapeutic use
Middle Aged
*Neoplasm Recurrence, Local: PC, prevention & control
Neoplasm Staging
Prospective Studies
CAS REGISTRY NO.: 99210-65-8 (Interferon Alfa-2b)

L63 ANSWER 6 OF 79 MEDLINE on STN
ACCESSION NUMBER: 95251409 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7733688
TITLE: [Immunoprophylaxis of superficial tumors of the bladder with interferon alfa-2b. Our experience].
Inmunoprofilaxis de los tumores superficiales de vejiga con interferon alfa 2b. Nuestra experiencia.
AUTHOR: Moyano Calvo J L; Teba del Pino F; Sanz Sacristan J; Fernandez Arjona M; Arellano Ganan R; Rabadan Ruiz M; Herrero Torres L; Melon Rey F J; Pereira Sanz I
CORPORATE SOURCE: Hospital La Princesa de Madrid, Universidad Autonoma de Madrid, Espana.
SOURCE: Archivos espanoles de urologia, (1995 Jan-Feb) 48 (1) 55-9.
Ref: 21
Journal code: 0064757. ISSN: 0004-0614.
PUB. COUNTRY: Spain
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: Spanish
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199505
ENTRY DATE: Entered STN: 19950608
Last Updated on STN: 19950608
Entered Medline: 19950531

ABSTRACT:

OBJECTIVE: The present study was conducted to determine the usefulness of prophylactic therapy with alpha 2b interferon for superficial bladder tumors. METHOD: Following complete TUR, alpha 2b interferon was administered to 36 patients at a dose of 50 million IU weekly for 3 months and monthly for 9 months. Patients were evaluated every 3 months on the basis of their clinical and analytical data and the cystoscopic findings. RESULTS: Twenty-six patients completed treatment and were evaluable. The follow up and disease-free period was 25.70 months. Recurrence was observed in 38.4% of the patients and tumor progression in 3.8%. CONCLUSIONS: Alpha 2b interferon is useful in the prevention of tumor recurrence. Its utility is similar to that of other drugs currently used.

CONTROLLED TERM: Check Tags: Female; Human; Male
Aged
*Bladder Neoplasms: PC, prevention & control

English Abstract

***Interferon Alfa-2b: TU, therapeutic use**

Middle Aged

CAS REGISTRY NO.: 99210-65-8 (Interferon Alfa-2b)

L63 ANSWER 7 OF 79 MEDLINE on STN
ACCESSION NUMBER: 1998199189 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9538388
TITLE: Retinoids and metastatic renal cell carcinoma.
AUTHOR: Paule B; Brion N
CORPORATE SOURCE: Service de Rhumatologie, Centre Hospitalier de Bicetre, Le Kremlin-Bicetre.
SOURCE: Annales de medecine interne, (1997) 148 (7) 496-501. Ref: 51
Journal code: 0171744. ISSN: 0003-410X.
PUB. COUNTRY: France
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199804
ENTRY DATE: Entered STN: 19980430
Last Updated on STN: 20000303
Entered Medline: 19980422

ABSTRACT:

The treatment of metastatic renal cell carcinoma remains unsatisfactory. Several therapeutic trials with retinoids and r interferon alpha (r IFN alpha) suggest a synergic antiproliferative effect between retinoid acid and r IFN alpha. Pharmacokinetic data and the mechanism of antiproliferative effects of retinoids are discussed. The induction of growth arrest is related to the expression of specific retinoid receptors. Further investigations are required in order to target the patient population which requires this therapy.

CONTROLLED TERM: Check Tags: Human
Antineoplastic Agents: PD, pharmacology
*Antineoplastic Agents: TU, therapeutic use
***Carcinoma, Renal Cell: DT, drug therapy**
*Carcinoma, Renal Cell: SC, secondary
Drug Synergism
Drug Therapy, Combination
Interferon Type I, Recombinant: PD, pharmacology
*Interferon Type I, Recombinant: TU, therapeutic use
***Kidney Neoplasms: DT, drug therapy**
*Kidney Neoplasms: PA, pathology
Retinoids: PD, pharmacology
*Retinoids: TU, therapeutic use
CHEMICAL NAME: 0 (Antineoplastic Agents); 0 (Interferon Type I, Recombinant); 0 (Retinoids)

L63 ANSWER 8 OF 79 MEDLINE on STN
ACCESSION NUMBER: 97252935 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9122733
TITLE: Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
AUTHOR: Legha S S
CORPORATE SOURCE: Department of Melanoma/Sarcoma, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
SOURCE: Seminars in oncology, (1997 Feb) 24 (1 Suppl 4) S39-43. Ref: 25
Journal code: 0420432. ISSN: 0093-7754.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199704
ENTRY DATE: Entered STN: 19970506
Last Updated on STN: 19970506
Entered Medline: 19970422

ABSTRACT:

Biochemotherapy, which uses recombinant interferon alpha (rIFN-alpha) and recombinant interleukin-2 (rIL-2) in combination with chemotherapy is a promising therapy for metastatic malignant melanoma. Various biochemotherapy regimens have produced overall objective response rates of > 50% and durable complete remission (CR) in approximately 10%-of treated patients. One such biochemotherapy regimen, consisting of sequential administration of cisplatin, vinblastine, and dacarbazine (CVD regimen) followed by rIFN-alpha and rIL-2, has produced a response rate of 60% and a CR rate of 20% in the most recent cohort of 62 patients treated at The University of Texas M.D. Anderson Cancer Center. The duration of partial responses with this and similar regimens typically averages 6 to 9 months; however, more than half of the CRs achieved with this regimen have been durable for 3+ to 5+ years. This has raised the possibility of long-term survival in approximately 10% of patients with metastatic melanoma. If confirmed, this will represent a significant advance in the treatment of metastatic melanoma.

CONTROLLED TERM: Check Tags: Human
Antineoplastic Combined Chemotherapy Protocols: AE, adverse effects
*Antineoplastic Combined Chemotherapy Protocols: TU, therapeutic use
Clinical Trials
Cyclophosphamide: AD, administration & dosage
Cyclophosphamide: AE, adverse effects
Dacarbazine: AD, administration & dosage
Dacarbazine: AE, adverse effects
*Interferon-alpha: AD, administration & dosage
Interferon-alpha: AE, adverse effects
*Interleukin-2: AD, administration & dosage
Interleukin-2: AE, adverse effects
*Melanoma: DT, drug therapy
Neoplasm Metastasis
*Skin Neoplasms: DT, drug therapy
Vincristine: AD, administration & dosage
Vincristine: AE, adverse effects
CAS REGISTRY NO.: 4342-03-4 (Dacarbazine); 50-18-0 (Cyclophosphamide); 57-22-7 (Vincristine)
CHEMICAL NAME: 0 (Antineoplastic Combined Chemotherapy Protocols); 0 (CVD protocol); 0 (Interferon-alpha); 0 (Interleukin-2)

L63 ANSWER 9 OF 79 MEDLINE on STN
ACCESSION NUMBER: 97252933 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9122731
TITLE: The role of interferon alfa in the treatment of metastatic melanoma.
AUTHOR: Legha S S
CORPORATE SOURCE: University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
SOURCE: Seminars in oncology, (1997 Feb) 24 (1 Suppl 4) S24-31.
Ref: 35
Journal code: 0420432. ISSN: 0093-7754.
PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW OF REPORTED CASES)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199704
ENTRY DATE: Entered STN: 19970506
Last Updated on STN: 19970506
Entered Medline: 19970422

ABSTRACT:

Recombinant interferon alpha (rIFN-alpha) has shown antitumor activity in metastatic malignant melanoma both as single-agent therapy and in combination with chemotherapeutic agents. As a single agent, rIFN-alpha yields an objective response rate of approximately 15%, which is comparable with other biologic agents, such as recombinant interleukin-2 (rIL-2) and single-agent chemotherapy. The most effective application of rIFN-alpha to the treatment of metastatic melanoma seems to be as a component of drug regimens that combine rIFN-alpha with rIL-2 or with combination chemotherapy regimens. The combination of rIFN-alpha with rIL-2 appears to have greater antitumor activity than either agent alone. Likewise, rIFN-alpha may potentiate the antitumor activity of combination chemotherapy regimens. Chemoimmunotherapy using dual biologic agents is currently the most promising therapy for metastatic melanoma with objective response rates of more than 50%. The greatest success of chemoimmunotherapy is its ability to produce durable complete remission in approximately 10% of treated patients. These regimens produce long-term remissions and offer hope to patients with advanced melanoma.

CONTROLLED TERM: Check Tags: Human
Antineoplastic Combined Chemotherapy Protocols: TU,
therapeutic use

Interferon Alfa-2a: AD, administration & dosage

Interferon Alfa-2a: TU, therapeutic use

Interferon Alfa-2b: AD, administration & dosage

Interferon Alfa-2b: TU, therapeutic use

Interferon-alpha: AD, administration & dosage

*Interferon-alpha: TU, therapeutic use

Interleukin-2: AD, administration & dosage

*Melanoma: DT, drug therapy

Neoplasm Metastasis

Recombinant Proteins: AD, administration & dosage

*Skin Neoplasms: DT, drug therapy

CAS REGISTRY NO.: 76543-88-9 (Interferon Alfa-2a); 99210-65-8 (Interferon Alfa-2b)

CHEMICAL NAME: 0 (Antineoplastic Combined Chemotherapy Protocols); 0 (Interferon-alpha); 0 (Interleukin-2); 0 (Recombinant Proteins)

L63 ANSWER 10 OF 79 MEDLINE on STN

ACCESSION NUMBER: 1998431745 MEDLINE

DOCUMENT NUMBER: PubMed ID: 9759581

TITLE: Adjuvant interferon treatment for melanoma.

AUTHOR: Agarwala S S; Kirkwood J M

CORPORATE SOURCE: University of Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania, USA.

SOURCE: Hematology/oncology clinics of North America, (1998 Aug) 12 (4) 823-33. Ref: 24

Journal code: 8709473. ISSN: 0889-8588.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, TUTORIAL)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199811
ENTRY DATE: Entered STN: 19990106
Last Updated on STN: 19990106
Entered Medline: 19981117

ABSTRACT:

After decades of research, the adjuvant therapy of patients with melanoma has recently shown significant survival and relapse-free interval benefit for the intravenous and subcutaneous administration of maximally tolerable dosages of recombinant IFN alpha 2b in a trial conducted by the ECOG (E1684). Despite the toxicity of this therapy, retrospective analyses of its impact upon quality-of-life using Q-TWiST methods and cost-efficacy analyses all argue for the benefit and utility of this intervention, especially for node-positive patients with resectable melanoma at highest risk of relapse. A confirmatory trial has been completed and will mature in the spring of 1998. The impact of lower dosages of IFN, apparent transiently during and for a period of time following treatment has not been sustained with longer follow-up in a number of trials. Current approaches in Europe and North America focus upon refinement of dose and duration of treatment with IFN and their potential interactions with, and comparison with, active specific immunotherapy with vaccines. A recently emerging area of research is the patient with stage IIA melanoma and the potential role of an abbreviated high-dose regimen of IFN alpha in this patient subset.

CONTROLLED TERM: Check Tags: Female; Human
Adjuvants, Pharmaceutic: AD, administration & dosage
Adult
*Antineoplastic Agents: AD, administration & dosage
Clinical Trials
*Interferon Type II: AD, administration & dosage
*Interferon-alpha: AD, administration & dosage
*Melanoma: DT, drug therapy
Melanoma: PA, pathology
Neoplasm Staging
*Skin Neoplasms: DT, drug therapy
Skin Neoplasms: PA, pathology
CAS REGISTRY NO.: 82115-62-6 (Interferon Type II)
CHEMICAL NAME: 0 (Adjuvants, Pharmaceutic); 0 (Antineoplastic Agents); 0 (Interferon-alpha)

L63 ANSWER 11 OF 79 MEDLINE on STN
ACCESSION NUMBER: 1998308579 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9644709
TITLE: Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma.
AUTHOR: Donnelly S
CORPORATE SOURCE: Clinical Research Services, University of Pittsburgh Cancer Center, PA, USA.
SOURCE: Oncology nursing forum, (1998 Jun) 25 (5) 921-7. Ref: 16
Journal code: 7809033. ISSN: 0190-535X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals; Nursing Journals
ENTRY MONTH: 199809
ENTRY DATE: Entered STN: 19980917
Last Updated on STN: 19980917
Entered Medline: 19980908

ABSTRACT:

PURPOSE/OBJECTIVES: To review results of Eastern Cooperative Oncology Group (ECOG) trial E1684 in the context of nursing issues concerning interferon alfa-2b (IFN alpha-2b) as adjuvant therapy for high-risk melanoma. DATA

SOURCES: Published results of ECOG trial E1684 and additional safety data provided by the trial sponsor. Selection of material was based on information that would expand on published safety results and present patient-management strategies relevant to oncology nurses. DATA SYNTHESIS: High-dose IFN alpha-2b significantly prolonged median relapse-free survival (< 0.01) and overall survival ($p = 0.047$), but side effects required extensive nursing interventions. With appropriate patient management, including dose modifications, 74% of patients who did not relapse received a full course of therapy. CONCLUSIONS: Adjuvant, high-dose IFN alpha-2b can significantly prolong relapse-free and overall survival in patients with high-risk melanoma, but nursing interventions are required to ensure patient compliance. IMPLICATIONS FOR NURSING PRACTICE: Accurate nursing assessment and appropriate interventions can help patients safely complete this effective adjuvant therapy.

CONTROLLED TERM: Check Tags: Female; Human; Male
*Antineoplastic Agents: TU, therapeutic use
Chemotherapy, Adjuvant
Disease-Free Survival
*Interferon Alfa-2b: TU, therapeutic use
*Melanoma: DT, drug therapy
Melanoma: NU, nursing
Middle Aged
Nursing Assessment
Patient Education
CAS REGISTRY NO.: 99210-65-8 (Interferon Alfa-2b)
CHEMICAL NAME: 0 (Antineoplastic Agents)

L63 ANSWER 12 OF 79 MEDLINE on STN
ACCESSION NUMBER: 1998227672 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9568721
TITLE: Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma.
AUTHOR: Krown S E
CORPORATE SOURCE: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.. krowns@mskcc.org
SOURCE: Journal of interferon & cytokine research : official journal of the International Society for Interferon and Cytokine Research, (1998 Apr) 18 (4) 209-14. Ref: 68
Journal code: 9507088. ISSN: 1079-9907.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals; AIDS
ENTRY MONTH: 199806
ENTRY DATE: Entered STN: 19980708
Last Updated on STN: 19980708
Entered Medline: 19980619

ABSTRACT:

This article reviews developments over nearly 15 years in the application of interferon-alpha (IFN-alpha) to the treatment of Kaposi's sarcoma (KS) in patients with acquired immunodeficiency syndrome (AIDS). The initial success of IFN treatment for selected patients with AIDS-associated KS occurred before identification of the human immunodeficiency virus (HIV) and in the absence of any coherent view of KS pathogenesis. A more comprehensive understanding of the biology of both AIDS and KS, together with increased knowledge of the biologic effects of IFN and therapeutic advances in the treatment of HIV infection, have made IFN therapy for KS both more rational and more successful. There is every reason to believe that the current results with IFN for KS can be improved on by capitalizing on recent improvements in HIV therapy and the availability of specific inhibitors of angiogenic cytokines. I sincerely thank

the Milstein family and my colleagues in the International Society for Interferon and Cytokine Research (ISICR) for recognizing this work, which is the product of many collaborations between clinical and basic scientists in my own institution and elsewhere.

CONTROLLED TERM: Check Tags: Human; Support, Non-U.S. Gov't
 *Acquired Immunodeficiency Syndrome: CO, complications
 *Antineoplastic Agents: TU, therapeutic use
 *Antiviral Agents: TU, therapeutic use
 *Interferon-alpha: TU, therapeutic use
 *Sarcoma, Kaposi: DT, drug therapy
 Sarcoma, Kaposi: ET, etiology
 CHEMICAL NAME: 0 (Antineoplastic Agents); 0 (Antiviral Agents); 0 (Interferon-alpha)

L63 ANSWER 13 OF 79 MEDLINE on STN
 ACCESSION NUMBER: 1998142249 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 9481250
 TITLE: Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.
 AUTHOR: Gale D M; Kiley K E
 CORPORATE SOURCE: Lutheran General Hospital, Park Ridge, IL, USA.
 SOURCE: Clinical journal of oncology nursing, (1998 Jan) 2 (1) 5-10. Ref: 28
 Journal code: 9705336. ISSN: 1092-1095.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LANGUAGE: English
 FILE SEGMENT: Nursing Journals
 ENTRY MONTH: 199803
 ENTRY DATE: Entered STN: 19980312
 Last Updated on STN: 19980312
 Entered Medline: 19980305

ABSTRACT:

Malignant melanoma, the least common but most serious form of skin cancer, is increasing at a faster rate than any other form of cancer. Early diagnosis can lead to cures through surgery alone. Patients with deeper primary lesions (greater than 4 mm) or regional lymph node involvement have a high risk of relapse. High-dose alpha interferon-2b is the first agent to significantly affect the relapse-free survival of high-risk patients with melanoma in a large randomized, controlled trial. Knowledge of the stages of malignant melanoma, its treatments, the mechanism of action of interferon, and commonly experienced adverse events will contribute to the nurse's ability to manage the clinical problems patients with melanoma face.

CONTROLLED TERM: Check Tags: Human
 *Antineoplastic Agents: TU, therapeutic use
 Chemotherapy, Adjuvant
 *Interferon Alfa-2b: TU, therapeutic use
 *Melanoma: DT, drug therapy
 Melanoma: PA, pathology
 Neoplasm Metastasis
 Neoplasm Staging
 Prognosis
 *Skin Neoplasms: DT, drug therapy
 Skin Neoplasms: PA, pathology
 CAS REGISTRY NO.: 99210-65-8 (Interferon Alfa-2b)
 CHEMICAL NAME: 0 (Antineoplastic Agents)

L63 ANSWER 14 OF 79 MEDLINE on STN
 ACCESSION NUMBER: 2000008222 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 10540708

TITLE: A case of pulmonary metastasis from renal cell carcinoma with complete response to interferon-alpha and tegafur/uracil (UFT) but possibly UFT-induced liver dysfunction and leukoencephalopathy-like symptoms.

AUTHOR: Suzuki K; Nukui A; Kobayashi M; Sugaya Y; Muraishi O; Morita T; Tokue A

CORPORATE SOURCE: Department of Urology, Jichi Medical School.

SOURCE: Hinyokika kiyo. Acta urologica Japonica, (1999 Sep) 45 (9) 621-4. Ref: 19
Journal code: 0421145. ISSN: 0018-1994.

PUB. COUNTRY: Japan

DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW OF REPORTED CASES)

LANGUAGE: Japanese

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199912

ENTRY DATE: Entered STN: 20000113
Last Updated on STN: 20000113
Entered Medline: 19991221

ABSTRACT:

A 61-year-old man presented with gross hematuria. He underwent left radical nephrectomy under a diagnosis of left renal cell carcinoma without distant metastasis, but bilateral multiple pulmonary metastases appeared 2.5 months after the operation. Though the metastases responded well to combination therapy of interferon-alpha and a 1:4 mixture of tegafur and uracil (UFT), the side effects of liver dysfunction and leukoencephalopathy-like symptoms due to UFT appeared 7 months after the beginning of the chemotherapy. These side effects were improved after the cessation of UFT administration.

CONTROLLED TERM: Check Tags: Human; Male
*Antineoplastic Combined Chemotherapy Protocols: AE, adverse effects
Antineoplastic Combined Chemotherapy Protocols: TU, therapeutic use
*Brain Diseases: CI, chemically induced
***Carcinoma, Renal Cell: DT, drug therapy**
*Carcinoma, Renal Cell: SC, secondary
English Abstract
***Interferon-alpha: AD, administration & dosage**
Kidney Neoplasms: PA, pathology
*Liver Diseases: CI, chemically induced
***Lung Neoplasms: DT, drug therapy**
*Lung Neoplasms: SC, secondary
Middle Aged
Tegafur: AD, administration & dosage
Tegafur: AE, adverse effects
Uracil: AD, administration & dosage
Uracil: AE, adverse effects

CAS REGISTRY NO.: 17902-23-7 (Tegafur); 66-22-8 (Uracil); 74578-38-4 (1-UFT protocol)

CHEMICAL NAME: 0 (Antineoplastic Combined Chemotherapy Protocols); 0 (Interferon-alpha)

L63 ANSWER 15 OF 79 MEDLINE on STN

ACCESSION NUMBER: 1999432316 MEDLINE

DOCUMENT NUMBER: PubMed ID: 10501706

TITLE: [Chemoimmunotherapy in the systemic treatment of advanced renal carcinoma].
Chemoimmuntherapie des fortgeschrittenen Nierenzellkarzinoms.

AUTHOR: Atzpodien J; Buer J; Sel S; Janssen J; Oevermann K

CORPORATE SOURCE: Hamatologie und Onkologie der Medizinischen Hochschule
Hannover.
SOURCE: Der Urologe. Ausg. A, (1999 Sep) 38 (5) 474-8. Ref: 0
Journal code: 1304110. ISSN: 0340-2592.
PUB. COUNTRY: GERMANY: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: German
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199911
ENTRY DATE: Entered STN: 20000113
Last Updated on STN: 20000113
Entered Medline: 19991130

ABSTRACT:

Polychemotherapy and immunomodulating treatment using IL-2 and/or IFN-alpha produce objective responses in a proportion of advanced renal cell carcinoma patients. The goals of an improved cost effectiveness and therapeutic index of interleukin-2 and/or Interferon-alpha in combination with chemotherapeutic agents require the design of risk factor adapted individual therapeutic strategies for the outpatient setting. High dose i. v. IL-2 therapy in metastatic renal cell carcinoma has been proven effective [11]. Other modalities of applying IL-2 have been described [12-14] (Table 1). A cumulative risk-score identified three risk-groups with significant differences in median survival [16]. The SC use of IL-2 and INF-alpha has been established in the treatment of RCC [16, 23]. It appears that combination chemoimmunotherapy including p. o. retinoic acid is far more effective than single agent treatment. Further studies will have to be designed to improve therapeutic index and cost effectiveness in systemic combination therapy in metastatic RCC.

CONTROLLED TERM: Check Tags: Human
*Antineoplastic Combined Chemotherapy Protocols: TU,
therapeutic use
*Carcinoma, Renal Cell: DT, drug therapy
Carcinoma, Renal Cell: MO, mortality
Carcinoma, Renal Cell: PA, pathology
Combined Modality Therapy
English Abstract
*Interferon-alpha: AD, administration & dosage
*Interleukin-2: AD, administration & dosage
*Kidney Neoplasms: DT, drug therapy
Kidney Neoplasms: MO, mortality
Kidney Neoplasms: PA, pathology
Survival Rate
Treatment Outcome
*Tretinoin: AD, administration & dosage
CAS REGISTRY NO.: 302-79-4 (Tretinoin)
CHEMICAL NAME: 0 (Antineoplastic Combined Chemotherapy Protocols); 0
(Interferon-alpha); 0 (Interleukin-2)

FILE 'HOME' ENTERED AT 11:52:47 ON 14 MAY 2004